Global High-Priority Regulatory Events — March 05, 2026

05-03-2026

05-03-2026

05-03-2026

05-03-2026

Palermo Technologies Inc., a Wyoming-incorporated early-stage software company founded on July 2, 2025, is offering up to 3,500,000 shares of common stock at $0.10 per share in a self-underwritten IPO, targeting maximum gross proceeds of $350,000 (net ~$325,000), with no minimum subscription requirement. The company has no revenues or profits since inception, incurred net losses of $10,329 for the fiscal year ended July 31, 2025, holds assets of only $9,567 as of October 31, 2025, and carries a stockholders' deficit of $4,732, with auditors expressing substantial doubt about its going concern status. Management, the sole officer and director owning 100% of current 5,000,000 outstanding shares, will retain majority control (at least 58.8%) even if all offered shares are sold.

• ·Incorporated July 2, 2025 in Wyoming.
• ·Offering period: up to 180 days from prospectus date, terminating on or before a date in 2026.
• ·Principal executive offices: 1122-1577 Gulf Road, Point Roberts, WA 98281.
• ·No public market currently exists; plans to apply for OTC Pink quotation post-offering, but no guarantees.
• ·Management devotes approximately 30 hours per week to company affairs.
• ·Emerging growth company with reduced reporting requirements.

05-03-2026

Full House Resorts reported fourth quarter 2025 revenues of $75.4 million, up 3.4% YoY (5.6% excluding Stockman’s sale), driven by 11.0% growth at American Place Casino and ramp-up at Chamonix/Bronco Billy’s, while full-year revenues rose 3.5% to $302.4 million (5.2% excluding Stockman’s). However, Adjusted EBITDA was nearly flat full-year at $48.1 million versus $48.6 million in 2024, with Q4 up slightly to $10.7 million, and net losses persisted at $(12.4) million for Q4 and $(40.2) million for the year amid ongoing depreciation and development costs. West segment revenues declined 3.1% in Q4 to $15.6 million and remained negative EBITDA at $(2.0) million despite improvement, while Contracted Sports Wagering revenues fell to $1.7 million.

• ·Depreciation and amortization: $42.6M in FY 2025 vs $42.1M in FY 2024
• ·Revolving credit facility extended to August 15, 2027
• ·Break ground on permanent American Place anticipated March/April 2026, opening in 18-24 months
• ·Waukegan City Council approved revised site plans in September 2025
• ·Competitor lawsuit resolved January 2025

05-03-2026

On February 27, 2026, ZyVersa Therapeutics, Inc. entered into a Securities Purchase Agreement with accredited investors, issuing convertible promissory notes with an aggregate principal of $1M at 10% interest, maturing in 12 months, and Series A-4 Common Stock Purchase Warrants. The notes are convertible into common stock at 80% of a qualified offering price or recent VWAP (with a $0.02 floor), while warrants are exercisable after six months at 110% of a reference price and cover shares equal to 50% of each purchaser's subscription amount. Net proceeds will fund working capital, with obligations guaranteed by subsidiary ZyVersa Therapeutics Operating, Inc.

• ·Notes convertible following the earlier of six months after issuance or an Event of Default, subject to $0.02 per share floor price.
• ·Warrants expire on five-year anniversary of issuance and include anti-dilution adjustments for stock dividends, splits, and fundamental transactions.
• ·Company covenants include filing resale registration statements within six months for note conversions and within 30 days of warrant Initial Exercise Date, plus restrictions on redemptions, dividends, and variable rate transactions.

05-03-2026

USA Rare Earth, Inc. (USAR) announced a definitive agreement to acquire all outstanding shares of Texas Mineral Resources Corp. (TMRC) for 3,823,328 shares of USAR common stock, implying a total deal value of $73M and granting USAR 100% control of the Round Top Project, including TMRC's prior 18.6% interest, 950 acres of leases, and 9,345 acres of prospecting rights. The transaction supports USAR's Accelerated Mining Plan, targeting commercial production in 2028 and 40,000 metric tons per day of rare earth and critical mineral feedstock by 2030. However, closing is expected no later than Q3 2026 subject to TMRC stockholder approval and customary conditions, amid forward-looking risks including going concern doubts for both companies.

• ·All TMRC directors and executive officers have entered voting support agreements to approve the transaction.
• ·USAR selected Fluor Corp. and WSP Global Inc. in January 2026 as EPCM partners for Round Top's Definitive Feasibility Study.
• ·Round Top operated under long-term lease with Texas General Land Office, supporting Texas Permanent School Fund.

05-03-2026

05-03-2026

QuasarEdge Acquisition Corp (QRED), a Cayman Islands-based blank check SPAC with sponsor and management ties to China, filed an S-1 to offer 10 million units at $10 each, raising $100M gross proceeds ($99.5M net before expenses) to be held in trust for an initial business combination. However, the filing highlights substantial risks from potential PRC regulatory uncertainties, which could materially impact operations or security values, and significant dilution to public shareholders ranging from $2.70 to $8.19 per share across redemption scenarios (25% to 100%). The units include ordinary shares (QRED) and rights (QREDR) expected to list on NYSE.

• ·Dilution scenarios as of January 31, 2026: pro forma net tangible book value per share ranges from $5.64 (25% redemptions, over-allotment) to $0.14 (maximum redemptions).
• ·Auditor Simon & Edward, LLP is PCAOB-registered and U.S.-headquartered, mitigating current HFCAA risks but with potential future exposure.
• ·Company qualifies as emerging growth company with reduced reporting requirements.
• ·Over-allotment option could increase units/shares to 11.5M and underwriting to $575K.

05-03-2026

On March 3, 2026, the Board of Directors of Acadia Pharmaceuticals Inc. appointed Jonathan M. Poole as a Class II director to fill a vacancy and as a member of the Audit Committee, effective immediately, with his term expiring at the 2027 Annual Meeting of Stockholders. Pursuant to the Non-Employee Director Compensation Policy, Mr. Poole will receive prorated annual cash retainers of $50,000 for Board service and $12,500 for Audit Committee service. He also received an initial equity grant under the 2024 Equity Incentive Plan with $200,000 target fair value and a prorated annual grant of $95,300 target fair value, with future annual grants set at $400,000 target fair value.

• ·Equity grants divided equally between nonstatutory stock options and restricted stock units; initial grant vests over three years, prorated grants vest over one year or at next annual meeting.
• ·No arrangements or understandings pursuant to which Mr. Poole was selected as director.
• ·No related person transactions required to be disclosed under Item 404(a) of Regulation S-K.

05-03-2026

Kansai Nerolac Paints Limited shared insights from a promoter-led conference call on India business strategy, noting stabilized but elevated competitive intensity in decorative paints due to entrants like Grasim, with listed companies showing slower growth as smaller players capture share; however, recovery in growth has been visible since October. In industrial coatings, the company highlighted its strong position with 8 manufacturing sites and 200-300 technical staff, expressing confidence against new competition like JSW-Akzo, while automotive OEM demand remains healthy post-GST at ~20% YoY but expected to moderate to 8-11% medium-term. Management targets 200 bps margin expansion via premiumization, efficiency, and expense optimization, with current mix >50% industrial and 45-50% decorative.

• ·Conference call held on February 26, 2026, at 12:30 p.m. IST
• ·Paint industry growth captured partly by smaller/new entrants, leading to lower reported growth for listed companies
• ·Automotive capacity expected to double by 2030, with rising SUV/large vehicle mix and exports supporting paint demand
• ·Construction chemicals penetration at 3/10 homes/buildings, implying 3x growth potential

05-03-2026

USA Rare Earth, Inc. (USAR) entered into a definitive Agreement and Plan of Merger on March 4, 2026, to acquire Texas Mineral Resources Corp. (TMRC) through a two-step merger process, with TMRC shareholders receiving USAR shares based on an exchange ratio using 3,823,328 as the numerator divided by TMRC's fully diluted shares outstanding. The transaction is expected to close no later than Q3 2026, subject to TMRC shareholder approval (majority vote), Nasdaq listing, SEC registration effectiveness, and no material adverse effects, while supporting stockholders owning 19% of TMRC shares have committed to vote in favor. However, the deal includes a $3.25M termination fee payable by TMRC under certain conditions, such as an adverse recommendation change, and can be terminated if not closed within 9 months.

• ·Termination rights include failure to obtain Requisite TMRC Vote (majority of outstanding shares), final legal prohibitions, or breach causing closing condition failure.
• ·TMRC board must recommend approval subject to fiduciary duties; may negotiate superior proposals pre-vote with limitations.
• ·Closing outside ordinary course operations prohibited without exceptions during pre-closing period.

05-03-2026

Tenaya Therapeutics, Inc. entered into a Collaboration Agreement with Alnylam Pharmaceuticals, Inc. on March 4, 2026, to discover and validate up to 15 novel gene targets for cardiovascular disease treatments over a 24-month period. Alnylam will provide an upfront payment of up to $10 million (subject to potential $0.5 million reductions for non-advancing targets) and reimburse Tenaya's research costs, with Tenaya eligible for up to $1.13 billion in milestones. Post-validation, Alnylam gains exclusive rights to develop and commercialize products, while Tenaya is restricted from independent work on collaboration targets during the term.

• ·Agreement filed as exhibit to Q1 2026 10-Q.
• ·Alnylam has 24-month post-validation evaluation period; failure to start non-human primate study reverts Company-nominated targets to Tenaya.
• ·Each party bears own costs except Alnylam's reimbursement of Tenaya's FTE and out-of-pocket expenses per research budget.
• ·Alnylam may terminate unilaterally; mutual termination for material breach.
• ·Upfront payment due within 30 days of Tenaya's invoice.

05-03-2026

Cumulus Media Inc. and its debtor affiliates have released a Disclosure Statement soliciting votes on a joint prepackaged Chapter 11 plan of reorganization in the U.S. Bankruptcy Court for the Southern District of Texas, with voting limited to Class 3 ABL Facility Claims, Class 4 2029 Secured Claims, and Class 5 Other Funded Debt Claims ahead of anticipated case commencement. Holders representing 72.05% of 2029 Debt Claims have committed to support the plan via a Restructuring Support Agreement, and the debtors' board strongly recommends acceptance by the April 7, 2026 voting deadline. The filing highlights ongoing challenges from a declining broadcast industry and liquidity pressures, with no quantified operational improvements noted.

• ·Record date for voting eligibility: February 23, 2026
• ·Voting deadline: 4:00 p.m. Central Time on April 7, 2026
• ·Debtors' service address: 780 Johnson Ferry Road, N.E., Suite 500, Atlanta, Georgia 30342
• ·Claims and noticing agent website: www.veritaglobal.net/cumulusmedia
• ·Anticipated bankruptcy court: Southern District of Texas, Houston Division

05-03-2026

Trulieve Cannabis Corp. announced the termination without cause of Joy Malivuk as Chief Accounting Officer, effective May 28, 2026, following a 90-day notice period provided on February 27, 2026. The company simultaneously appointed Brett Walsh, its former Executive Corporate Controller, as the new Chief Accounting Officer effective February 28, 2026, with an annual base salary of $245,000. This leadership transition includes detailed severance provisions for both executives but no financial impact metrics were disclosed.

• ·Joy Malivuk termination notice date: February 27, 2026; effective date: May 28, 2026 (90-day notice period).
• ·Brett Walsh employment agreement effective: March 5, 2026; reports to Chief Financial Officer.
• ·Brett Walsh severance: 0.5x (base salary + greater of current target or prior actual bonus) + prorated bonus, paid over 6 months, plus 6 months COBRA; doubles to 1x post-Change of Control with lump sum payment and 12 months COBRA.
• ·Joy Malivuk post-termination: severance per employment agreement (filed May 10, 2023), COBRA subsidies, immediate vesting of equity (performance-based subject to certification).

05-03-2026

SentinelOne, Inc. appointed Sonalee Parekh as Chief Financial Officer and principal financial officer, effective March 24, 2026, replacing interim CFO Barry Padgett who will return to his role as Chief Growth Officer, with no disagreements noted. Ms. Parekh brings extensive experience from Asana (CFO since Sep 2024), RingCentral (CFO 2022-2024), HPE (Divisional CFO 2019-2022), and investment banks. Her compensation includes a $600K base salary, 70% target bonus, $300K sign-on bonus, and $18M aggregate equity award (75% RSUs, 25% PSUs).

• ·RSUs vest starting with 10% on first vesting date (month following 3-month anniversary), with tiered quarterly vesting thereafter.
• ·PSUs vest based on performance metrics for fiscal years ending Jan 31, 2027-2030, certified by Compensation Committee.
• ·CIC severance: 12 months base + bonus + equity acceleration on change of control termination; 6 months base on non-CIC termination.
• ·Ms. Parekh, age 52, holds Bachelor of Commerce from McGill University and is a Chartered Accountant; serves on board of indie Semiconductor since June 2021.

05-03-2026

Impex Ferro Tech Limited, currently undergoing Corporate Insolvency Resolution Process (CIRP), has provided prior intimation of its 25th Committee of Creditors (CoC) meeting scheduled for March 06, 2026, at 12:00 Hrs IST in hybrid mode (physical and virtual) at A.K. Sarawagi & Co., Kolkata. The disclosure complies with Regulation 30(2) read with sub-clause 16(g) of SEBI LODR Regulations, 2015. No financial outcomes or resolutions from the meeting are detailed in this filing.

• ·Scrip Code: 532614 (BSE); Scrip Symbol: IMPEXFERRO (NSE)
• ·Meeting venue: Poddar Court, 18, Rabindra Sarani, Gate-3, 5th floor Room No.4, Kolkata-700001
• ·IBBI Registration No.: IBBI/IPA-001/IP-P00171/2017-18/10340
• ·Authorisation for Assignment (AFA): AA1/10340/02/311226/107208, valid upto December 31, 2026
• ·Filing date: March 05, 2026

05-03-2026

India Ratings and Research has assigned an IND AAA/Stable rating to TVS Motor Company Ltd's proposed ₹500 Cr non-convertible debentures (NCDs). The rating reflects strong market position (e.g., scooter market share at 28.5% in 10MFY26 from 18% in FY20), consolidated revenue growth to ₹374.6B in FY25 (+13.5% YoY from ₹329.9B), improving EBITDA margins to 9.9% (FY24: 9.2%), and robust credit metrics like 16.2x interest coverage. However, intense competition, macroeconomic headwinds, and ongoing losses from overseas subsidiaries (investments ₹86.24B till FY25) continue to drag profitability and ROCE.

• ·Capex FY25: ₹24.4B; planned FY26: ₹46B including EV platform and capacity expansion.
• ·Free cash flow FY25: negative ₹6.5B (deteriorated from negative ₹1.4B FY24).
• ·Standalone revenue FY25: ₹362.5B (+14.1% YoY from ₹317.8B FY24).
• ·Preference shares redemption due September 2026.
• ·Debt repayments: ₹8-9B FY26, ₹4.5-5B FY27.

05-03-2026

SKIL Infrastructure Limited is under Corporate Insolvency Resolution Process (CIRP) admitted by NCLT Mumbai on February 1, 2024, with Purusottam Behera appointed as Resolution Professional following CoC approval on November 3, 2025. The company has not submitted the Reconciliation of Share Capital Audit Report for the quarter ended December 31, 2025, due to unpaid fees to NSDL, CDSL, and RTA, which have suspended BENPOS services. The RP intends to seek CoC approval for settling these dues to enable future compliance, requesting stock exchanges for relaxation.

• ·NCLAT interim stay on CoC constitution dated February 12, 2024
• ·NCLAT vacated stay and allowed appeal withdrawal on October 15, 2025
• ·NSE Symbol: SKIL; BSE Scrip Code: 539861
• ·RP Contact: cirpskil@gmail.com, +917718851633

05-03-2026

National Aluminium Company Limited disclosed notices from BSE and NSE imposing fines of ₹5.43 Lakh each (total ₹10.86 Lakh incl. 18% GST) for non-compliance with Regulation 17(1) of SEBI(LODR) Regulations, 2015, received on February 27, 2026. Disclosure was delayed due to late email notifications (5:49 PM and 10:18 PM) on a Friday followed by weekend offs, with intimation made on March 2, 2026. The company states the penalty has no significant financial or operational impact but commits to preventing future lapses.

• ·Violation details: Non-compliance with Regulation 17(1) of SEBI(LODR) Regulations, 2015
• ·Emails from exchanges received on 27.02.2026 at 05.49 PM (BSE) and 10.18 PM (NSE)
• ·Off days: 28 February and 01 March 2026
• ·Disclosure to exchanges: 02.03.2026

05-03-2026

Promoter Mr. Vishnuvardhan created a pledge on 13,19,748 equity shares (10.53% of total share capital) on March 02, 2026, in favor of SBICAP Trustee Company Limited as security for a ₹19 Cr term loan availed by the wholly owned subsidiary Constronics Energy Solution Private Limited from State Bank of India. This follows a prior pledge of 11,810 shares (0.09%-0.90% of total share capital) created on February 17, 2026, for the same loan, resulting in nearly 100% of the promoter's total holding of 13,31,558 shares (10.38% of total share capital) now being encumbered.

• ·Security cover/asset cover ratio for March 02 pledge: 0.33; for February 17 pledge: 0.003
• ·Pledge in favor of SBICAP Trustee Company Limited for both encumbrances
• ·Disclosure pursuant to Regulation 31(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

05-03-2026

Wipro Limited's Board approved the appointment of Ms. Laura Marie Miller (DIN: 11546063) as an Additional Director in the capacity of Independent Director for a 5-year term from April 1, 2026, to March 31, 2031, subject to shareholder approval. Ms. Miller has over two decades of executive leadership in technology, AI, digital transformation, and data strategy, with prior roles at Macy’s as EVP and Chief Information and Data Officer, and current non-executive directorships at NCR Voyix and Ahold Delhaize. No relationships with other directors, and she is not debarred from holding directorships.

• ·Ms. Miller holds a Bachelor of Science in Information Systems Management and a Master of Science in Computer Systems Management from the University of Maryland.
• ·Previous board roles: Director at EVO Payments (during growth and acquisition by Global Payments) and LGI Homes.
• ·Current board roles: Chairs Risk Committee and serves on Audit Committee at NCR Voyix; Chairs Technology Committee and serves on Finance, Audit, and Risk Committees at Ahold Delhaize.

05-03-2026

La Rosa Holdings Corp. adopted a Certificate of Designation on March 3, 2026, authorizing 100 shares of Series C Convertible Preferred Stock with a par value of $0.0001 per share, pursuant to a Securities Purchase Agreement. These shares rank senior to common stock in liquidation preferences (subject to senior/parity stock) and are convertible into common stock at a price of $1.176, with detailed mechanics including buy-in protections for holders. No specific issuance amounts or conversion volumes were disclosed, representing potential future dilution without immediate financial impact.

• ·Holders have conversion rights starting from Initial Issuance Date with Share Delivery Deadline of 1 Trading Day
• ·Company must pay 2% daily penalty for conversion failures post-Share Delivery Deadline
• ·Preferred shares rank junior to Senior Preferred Stock, parity with Parity Stock, senior to Junior Stock in liquidation

05-03-2026

Bleichroeder Acquisition Corp. II, a SPAC, entered into a Business Combination Agreement on February 28, 2026, with Pasqal Holding SAS, valuing Pasqal at $2.0B pre-money through a reincorporation merger into a French entity followed by Pasqal's absorption. The transaction is expected to close in the second half of 2026, subject to regulatory and shareholder approvals, with no reported financial metrics or performance comparisons available in the filing. Post-closing, New Pasqal's board will feature nine directors, including Alain Aspect as non-executive chairman and Wasiq Bokhari as CEO.

• ·Bleichroeder Warrants exercisable at $11.50 per share will convert to New Pasqal Warrants.
• ·Pasqal equity classes (Class Seed, common, Class A, B, C Ordinary Shares) to exchange via ratio based on $10 per Parent Surviving Corporation Ordinary Share.
• ·Registration Statement/Proxy Statement on Form F-4 to be filed, with PCAOB-audited financials from Pasqal due by September 30, 2026.

05-03-2026

Xanadu Quantum Technologies Inc. hosted an Analyst Day on March 4, 2026, discussing its proposed business combination with Crane Harbor Acquisition Corp. to form Xanadu Quantum Technologies Limited (NewCo) and go public on NASDAQ and TSX. The event highlighted Xanadu's Aurora scalable quantum computer (four server racks) and PennyLane software platform, with partnerships including Volkswagen, BMW, Toyota, Rolls-Royce, and Mitsubishi Chemical. Extensive forward-looking statements were tempered by risk disclosures, including historical net losses, going concern doubts, and potential failure to commercialize quantum technology.

• ·Aurora demonstrated real-time error correction decoding algorithms with photonics, peer-reviewed and published in Nature
• ·Vision includes scaling to hundred server racks networked in quantum data centers worldwide
• ·Risks include substantial doubt about Xanadu's ability to continue as a going concern and failure to obtain shareholder/regulatory approvals for the transaction

05-03-2026

CrowdStrike reported FY26 total revenue of $4.81B, up 22% YoY from $3.95B, driven by 21% growth in subscription revenue to $4.56B and 29% in professional services to $0.25B, with ARR reaching $5.25B (24% YoY growth). However, the company posted a net loss attributable to CrowdStrike of $162.5M, wider than the $15.2M loss in FY25, as operating expenses surged 26% to $3.89B, outpacing revenue growth and leading to an operating loss of $293M (vs. $116M prior year). Gross margins remained flat at 75%, while sales & marketing, R&D, and G&A expenses rose 20%, 29%, and 39% YoY, respectively.

• ·Subscription represented 95% of total revenue in FY26, flat YoY.
• ·Professional services gross margin declined 1pp to 18% in FY26.
• ·Provision for income taxes was $34.2M in FY26, down from $71.1M in FY25.

05-03-2026

LATAM Airlines Group reported total revenues of $14.3B for the year ended December 31, 2025, up 11.2% YoY from $12.8B in 2024, with passenger revenues growing 12.3% to $12.6B and cargo revenues increasing 3.4% to $1.7B. Capacity (ASKs) expanded 8.2% to 170.8B while passenger traffic (RPKs) rose 8.2% to 144.1B, though international passenger load factor dipped 1.2% to 85.0% and cargo load factor declined slightly 0.7% to 53.3%. Fuel costs fell 4.2% to $3.8B, with cost per gallon down to $2.6 from $2.9, and fuel as a percentage of operating expenses improved to 31.3% from 34.5%.

• ·Brazil contributed $6.1B or 43% of total revenues in 2025, up 10.7% YoY.
• ·SSC ASKs flat at 27.6B (down 0.6% YoY).
• ·Fuel gallons per 1,000 ASK improved to 8.5 from 8.6.
• ·Total passengers carried: 87.4 million in 2025, up 6.6% YoY.

05-03-2026

Moderna, Inc. entered into a Settlement Agreement on March 3, 2026, with Arbutus Biopharma Corporation and Genevant Sciences entities, resolving all worldwide patent infringement litigation related to Spikevax® and mRESVIA®, while securing a fully paid-up, royalty-free license for its infectious disease portfolio including mNEXSPIKE® and mCOMBRIAX®. The agreement requires a $950M noncontingent payment by July 8, 2026, and a potential additional $1.3B contingent payment based on the outcome of Moderna's appeal to the Federal Circuit regarding §1498 defenses for U.S. Government contract doses, providing litigation certainty but at a substantial near-term cost.

• ·Settlement includes mutual releases and covenants not to sue on Arbutus/Genevant patents for Moderna’s SM-102-based LNP infectious disease vaccines.
• ·If Moderna prevails fully on §1498 appeal, no contingent payment due; if affirmed against Moderna, full $1.3B due; Arbutus/Genevant must repay with interest if later overturned.
• ·Full Settlement Agreement to be filed as exhibit to Q1 2026 10-Q.

05-03-2026

Enhabit, Inc. reported consolidated net service revenue of $1.06B for the year ended December 31, 2025, up 2.4% YoY from $1.03B, driven by strong Hospice segment growth of 17.2% to $246M, while Home Health revenue declined 1.3% to $814M due to a 6.1% drop in Medicare revenue. Adjusted EBITDA improved 8.4% YoY to $109M with Hospice Adjusted EBITDA surging 44.1% to $60M, but Home Health Adjusted EBITDA fell 6.8% to $149M; net loss attributable to Enhabit narrowed 97.1% to $(4.6)M from $(156M), though impairments totaled $48M including $45M goodwill.

• ·Medicare Home Health admissions declined 5.1% YoY to 91,603 in 2025.
• ·Home Health visits per episode decreased 5.6% YoY to 13.4.
• ·Cost per visit in Home Health rose 5.1% YoY to $97.7.
• ·Depreciation and amortization dropped 28.6% YoY to $22.5M.
• ·Interest expense decreased 20.7% YoY to $34.0M.

05-03-2026

Pulmonx Corporation entered into a senior secured Credit Agreement and Guaranty dated March 2, 2026, with Perceptive Credit Holdings V, LP as initial lender and administrative agent, providing a term loan facility of up to $60M, including a $40M initial loan on the closing date and up to $20M in delayed draw commitments subject to conditions. The agreement includes financial covenants requiring minimum liquidity and minimum revenue, along with affirmative and negative covenants, representations, warranties, and events of default. No performance declines or flat metrics are reported, as this is a financing arrangement rather than operational results.

• ·Agreement filed as Exhibit 10.1 in 8-K on March 5, 2026
• ·Includes schedules for commitments, products, intellectual property, subsidiaries, indebtedness, liens, material agreements, and regulatory approvals
• ·Financial covenants: Minimum Liquidity (Section 10.01) and Minimum Revenue (Section 10.02)

05-03-2026

EPAM Systems, Inc. entered into a $300M accelerated share repurchase (ASR) agreement with Morgan Stanley & Co. LLC, receiving an initial delivery of 1,703,336 shares worth $240M based on the March 4, 2026 closing price. The ASR, authorized under the company's $1.0B share repurchase program, leaves $452.5M in remaining availability upon completion no later than Q2 2026. CEO Balazs Fejes highlighted confidence in EPAM's long-term growth and AI leadership, viewing the repurchase as value-enhancing.

• ·Final number of shares repurchased under ASR to be based on volume-weighted average share price during term, less a discount, subject to adjustments.
• ·ASR completion no later than second quarter of 2026.

05-03-2026

Hippo Holdings Inc. reported total revenue of $468.6M for the year ended December 31, 2025, up 26% YoY from $372.1M, primarily driven by net earned premium growth of 39% to $380.1M and gross written premium increasing to $1,108.6M from $892.4M. The company achieved net income attributable to Hippo of $57.7M, reversing a $40.5M loss in 2024, with net loss ratio improving to 60% from 77% and combined ratio to 113% from 138%; however, insurance related expenses surged 48% to $131.3M, losses and loss adjustment expenses rose 10% to $229.9M, and commission income declined 19% to $51.3M.

• ·Book value per share increased to $16.97 in 2025 from $14.56 in 2024.
• ·Diluted adjusted earnings per share improved to $0.68 in 2025 from ($0.82) in 2024.
• ·Adjusted net income was $17.8M in 2025, compared to ($20.3M) loss in 2024.
• ·Catastrophe losses $61.5M in 2025 vs $58.0M in 2024 (up 6%).
• ·Non-catastrophe loss ratio improved to 45% in 2025 from 56% in 2024.

05-03-2026

Baytex Energy Corp. filed its Form 40-F annual report for the fiscal year ended December 31, 2025, incorporating the Annual Information Form, audited consolidated financial statements, MD&A, and supplemental oil and gas disclosures. The company reported 765,568,147 common shares outstanding at year-end, with effective disclosure controls and procedures and no material changes in internal controls over financial reporting. No specific financial performance metrics or period-over-period changes were detailed in the provided filing content.

• ·Filing date: March 05, 2026
• ·Fiscal year end: December 31, 2025
• ·Common shares trade on NYSE under symbol BTE
• ·Cash generating units include Viking and Lloydminster
• ·Disclosure controls and procedures confirmed effective as of December 31, 2025
• ·No changes in internal control over financial reporting during FY2025

05-03-2026

STEM, Inc. reported FY2025 revenue of $156.3M, up 8% YoY from $144.6M, driven by 29% growth in services and other revenue to $87.7M, though hardware revenue declined 11% to $68.6M. The company achieved GAAP net income of $137.8M versus a $854.0M loss in 2024, aided by a $220M gain on debt extinguishment and GAAP gross profit of $60.0M (38% margin) versus a $11.1M loss (-8% margin); however, it posted an operating loss of $55.7M, Adjusted EBITDA of $6.7M remained modest, and storage operating AUM fell slightly to 1.7 GWh from 1.8 GWh. Bookings rose 14% to $131.8M, CARR increased 4% to $67.2M, but total assets decreased to $308.9M from $437.4M amid metric redefinitions impacting comparability.

• ·Net cash provided by operating activities improved to $6.9M in FY2025 from ($36.7M) used.
• ·Convertible notes noncurrent decreased to $183.6M from $525.9M; senior secured notes added at $128.8M.
• ·Several key operating metrics (Bookings, Contracted backlog, CARR) redefined starting Q1 2025 to focus on executed purchase orders, reducing prior comparability.
• ·Cash and equivalents $48.9M at Dec 31, 2025, down from $56.3M.

05-03-2026

HMH Holding Inc filed an S-1/A registration statement on March 4, 2026, disclosing prior material weaknesses in internal controls over financial reporting identified for 2022-2023 and a new one in 2025 related to revenue cutoff in certain subsidiaries, all of which were fully remediated by December 31, 2025 through hiring additional personnel and enhanced procedures. The company reports no outstanding debt under its Revolver as of December 31, 2025 (down from $14.4M in 2024), but highlights ongoing risks from inflation, foreign currency exposure (63.3% of 2025 revenues in foreign currencies, slightly down from 63.9% in 2024), and commodity price fluctuations tied to oil and gas drilling activity. Industry data indicates expected global hydrocarbon production growth from 172 MM Boe/day in 2025 to 188 MM Boe/day in 2030 (+9%), though with potential future supply shortfalls.

• ·Hired five additional qualified personnel in 2024 for GAAP/SEC expertise and controls.
• ·Global upstream capex declined 33% YoY to $470B in 2020.
• ·Hydrocarbon liquids demand decreased 10% from 2019 to 2020.
• ·Rystad estimates supply shortfall of 0.6 MM Bbls/day average 2021-2024, surplus of 1.1 MM Bbls/day in 2025.
• ·Global production expected to rise 9% to 188 MM Boe/day by 2030 from 172 MM Boe/day in 2025; offshore +13%.
• ·Shale/tight oil spending share rose from 12% in 2010 to 23% in 2025.
• ·14,000 additional offshore wells required 2025-2028.

05-03-2026

StubHub Holdings, Inc. reported revenue of $1.75B for the year ended December 31, 2025, a slight decline of 1.4% YoY from $1.77B in 2024. However, the company swung to a massive net loss of $1.91B from a near-breakeven loss of $2.8k in 2024, driven by general and administrative expenses surging to $1.71B (including $1.45B in stock-based compensation) from $387M. While cost of revenue decreased 6% and interest expense fell 22.1%, sales and marketing expenses rose 17.4% YoY.

• ·Operations and support expenses increased to $63.2M in 2025 from $59.5M in 2024.
• ·Loss from operations was $1.34B in 2025 versus income of $138M in 2024.
• ·Foreign currency losses of $89.7M in 2025 compared to gains of $41.1M in 2024.
• ·Revenue grew 27.6% from 2023 to 2024 but declined 1.4% in 2025.

05-03-2026

Palladyne AI Corp. reported net revenue of $5.2M for the year ended December 31, 2025, down 33% YoY from $7.8M, with services revenue declining 9% to $4.7M, product revenue plummeting 100% to $3k, offset partially by new manufacturing revenue of $0.6M. Operating expenses increased 8% to $37.7M, widening the operating loss to $32.4M from $26.9M, but a $37.7M gain on warrant liabilities (versus a $46.9M loss prior year) drove net income of $10.0M compared to a $72.6M loss in 2024. Cash and equivalents fell 42% to $18.2M from $31.2M, with net cash used in operations up 22% to $27.6M.

• ·Warrant liabilities decreased to $2.8M from $51.4M as of Dec 31 2025.
• ·Total assets grew to $95.7M from $56.3M, driven by $28.8M marketable securities and new goodwill $14.7M.
• ·Stockholders' equity turned positive at $74.7M from deficit of $9.5M.
• ·Accounts receivable allowance for credit losses $0.0M in 2025 vs $0.3M in 2024.

05-03-2026

Shattuck Labs, Inc. reported total revenue of $1M for the year ended December 31, 2025, down 82.5% from $5.7M in 2024 primarily due to the absence of $5.7M in collaboration revenue. Research and development expenses decreased 47.5% to $35.3M, while general and administrative expenses fell 9.7% to $17.2M, resulting in a narrower net loss of $48.8M (35.3% improvement) compared to $75.4M in 2024. Cash and equivalents ended at $54.2M after a modest $3.2M decrease, bolstered by $44.6M in financing activities from stock sales.

• ·Cash and equivalents decreased $3.2M to $54.2M in 2025 vs $68.2M decrease to $57.4M in 2024.
• ·Shares outstanding increased to 63.3M from 47.7M due to $44.5M stock offering.
• ·Total assets stable at $91.0M; stockholders' equity rose to $82.4M from $79.6M.
• ·Net cash used in operating activities improved to $39.9M from $60.5M.

05-03-2026

AZZ Inc. announced the appointment of Aaron Schapper and Charles Treadway as new independent directors effective April 8, 2026, bringing expertise in strategic growth, M&A, and ESG amid ongoing board refreshment. Dan Feehan announced his retirement from Chairman on February 28, 2026, succeeded by Dan Berce, and will continue as a director until July 2026 after a 26-year tenure including 7 years as Chairman. The refreshed board will have 8 members, 7 independent, with 4 added in the last 5 years.

• ·Appointments result of comprehensive search by Board with independent search firm.
• ·Schapper, age 52, prior roles at Valmont Industries and Orbit Irrigation.
• ·Treadway, age 60, prior CEO at Accudyne Industries and roles at Thomas & Betts.

05-03-2026

CPI Card Group Inc. (PMTS) reported FY 2025 revenue of $543.5M, up 13.1% YoY from $480.6M, driven by segment revenue growth of 20.3% to $451.5M. However, gross profit declined 0.7% to $170.1M with margin compression to 31.3% from 35.6%, operating income fell 12.7% to $54.8M, and net income dropped 23.4% to $15.0M amid higher COGS (+20.7%) and SG&A (+6.3%). Segment operating income was nearly flat, down 1.5% to $91.4M, with gross margin slipping to 30.6%.

• ·Gross profit margin declined to 31.3% in FY 2025 from 35.6% in FY 2024.
• ·Segment gross profit margin declined to 30.6% in FY 2025 from 34.1% in FY 2024.
• ·Risk factors include debt service obligations limiting cash flow for working capital, R&D, capex, and acquisitions; exposure to floating rate revolving credit facility and potential higher interest rates.

05-03-2026

Liquidia Corp (LQDA) reported total revenue of $158.3M for the year ended December 31, 2025, surging 1,031% YoY to $158.3M from $14.0M in 2024, driven by $148.3M in new product sales (primarily YUTREPIA and Treprostinil Injection) while service revenue declined 28% to $10.0M. However, selling, general, and administrative expenses rose 93% to $157.2M, contributing to total costs up 55% and an operating loss of $51.4M (improved 58% YoY); net loss narrowed 46% to $68.9M but cash used in operations remained high at $35.7M. The company faces commercialization risks, covenant restrictions from its HCR financing facility, and potential need for additional capital.

• ·Net cash provided by investing activities: $(6.3M) in 2025 vs. $(8.4M) in 2024.
• ·Net increase in cash, cash equivalents, and restricted cash: $17.7M in 2025 vs. $92.8M in 2024.
• ·Financing activities provided $194.7M in 2024, down to $59.7M in 2025.

05-03-2026

Cardinal Health, Inc. announced on March 2, 2026, that Mary Scherer, Senior Vice President and Chief Accounting Officer, intends to retire in February 2027. The company will initiate a search for her successor, and Ms. Scherer will remain in her role until the successor is identified and onboarded for a smooth transition. No immediate disruption to operations is indicated.

• ·Form 8-K filed on March 5, 2026

05-03-2026

Bank of New York Mellon Corp's 2026 DEF 14A proxy statement seeks advisory approval of 2025 NEO compensation, emphasizing strong performance under CEO Robin Vince with annualized adjusted revenue growth of 6%, noninterest expense growth of 3%, and operating EPS growth of 18% from 2022-2025, resulting in 178% total shareholder return outperforming the S&P 500 Financials Index by over 2.5x. Prior three-year say-on-pay proposals received average 95% stockholder support. No declines or flat metrics were highlighted in the disclosed performance data.

• ·Compensation for Mses. O’Connor and Robinson includes amounts for roles as Chair and member of the Board of BNY Mellon Government Securities Services Corp.
• ·Proxy seeks approval pursuant to Item 402 of Regulation S-K.

05-03-2026

Immatics N.V. swung to a net loss of €196.4M in 2025 from a €15.2M profit in 2024, primarily due to a 69% YoY revenue decline to €48.3M from collaboration agreements and a 24% increase in R&D expenses to €183.8M, leading to an operating loss widening to €182.0M. However, cash and equivalents rose 46% to €345.9M, bolstered by a €125.5M net cash inflow including €204.8M from investing activities, while total assets decreased to €562.3M and shareholders' equity fell to €484.1M.

• ·Direct external R&D expenses for TCR T-cell therapy Programs increased to €49.5M in 2025 from €25.9M in 2024.
• ·Share-based compensation in R&D decreased to €7.5M in 2025 from €9.6M in 2024.
• ·Net cash from financing activities €97.4M in 2025, down from €319.7M in 2024.
• ·Accumulated deficit widened to €786.0M as of Dec 31, 2025 from €589.5M.
• ·Auditor: PricewaterhouseCoopers GmbH (Firm ID: 1275)

05-03-2026

Janus International Group, Inc. (NYSE: JBI) announced the immediate appointments of Jeannine Lane and Paul Vasington to its Board of Directors on March 5, 2026. Ms. Lane, currently Executive Vice President, General Counsel and Corporate Secretary at Resideo Technologies, Inc., will chair the Nominating and Corporate Governance Committee, while Mr. Vasington, former CFO of Sensata Technologies, will join the Audit Committee and the newly established Innovation and Technology Committee. The company highlighted their expertise in enterprise risk, legal strategy, finance, and value creation to strengthen governance and support strategic growth.

• ·Ms. Lane has over 35 years of experience in global industrial manufacturing, consumer products, software, and wholesale distribution.
• ·Mr. Vasington served as CFO of Sensata Technologies from 2014 to 2023 and held finance roles at Honeywell from 2004 to 2014.

05-03-2026

GH Research PLC (GHRS) filed its 20-F Annual Report on March 05, 2026, disclosing standard sections including risk factors, operating review, and financial information without specific quantitative results provided in the excerpt. Key risks highlighted include lack of marketing and sales organization, no commercialization experience requiring significant future investments, and belief of being a PFIC for 2025 with likelihood continuing into 2026, potentially impacting U.S. investors adversely. Additional challenges noted involve establishing commercial infrastructure for GH001 and GH002, subject to regulatory approval, and strict DEA registration, inspection, and compliance requirements for controlled substances.

• ·Belief of PFIC status for 2025 taxable year, likely continuing in 2026 and future years.
• ·DEA registrations for facilities handling controlled substances must renew annually (except pharmacies every three years), with periodic inspections.
• ·Failure to comply with CSA and DEA regulations could lead to civil penalties, registration revocation, or criminal proceedings.

05-03-2026

Myers Industries Inc reported FY2025 total net sales of $825.7M, down 1.3% YoY from $836.3M, driven by a flat Material Handling segment at $622.1M (up 0.1%) and a 5.1% decline in Distribution to $203.9M. Gross profit rose 1.9% to $276.1M with margin expansion to 33.4% from 32.4%, while SG&A expenses fell 0.9% to 20.9% of sales, resulting in income before taxes surging to $45.1M from $13.5M. Net interest expense decreased 4.9% amid lower borrowing rates.

• ·Average outstanding borrowings increased 2.7% YoY to $391.5M.
• ·Multiple leased facilities with expirations through 2036.
• ·Audited by Ernst & Young LLP.

05-03-2026

Tango Therapeutics, a precision oncology company with no approved products or product sales revenue, reported total revenue of $62.4M for the year ended December 31, 2025, up 48% YoY from $42.1M driven by collaboration revenue, though license revenue fell to $0 from $12.1M. Operating expenses declined 7% YoY to $173.7M, narrowing the net loss to $101.6M from $130.3M; however, net cash used in operating activities increased to $138.9M from $131.5M. Cash, equivalents, and marketable securities totaled $343.1M, sufficient to fund operations into 2028.

• ·Existing cash, cash equivalents, and marketable securities to fund operations into 2028
• ·Common stock authorized increased to 400M shares at Dec 31 2025 from 200M at Dec 31 2024
• ·Accumulated deficit increased to $603.2M at Dec 31 2025 from $501.6M at Dec 31 2024
• ·Total stockholders’ equity grew to $346.2M at Dec 31 2025 from $199.5M at Dec 31 2024

05-03-2026

HUTCHMED reported total revenue of $549M for the year ended December 31, 2025, down 13% YoY from $630M amid declines in Oncology/Immunology revenue (down 21% to $286M, with products like Fruzaqla -19%, Sulanda -45%) and flat Other Ventures revenue at $263M. However, net income attributable to the company surged to $457M from $38M, boosted by a $477M gain on divestment of equity investees, while R&D expenses fell 30% to $148M. The balance sheet showed total assets at $1.8B (up 38% YoY) with short-term investments rising to $1.3B, though cash equivalents dropped to $71M.

• ·PRC foreign-invested enterprises must reserve at least 10% of after-tax profits until reserves reach 50% of registered capital, limiting dividends.
• ·Basic EPS $0.53 for 2025 vs $0.04 for 2024.
• ·Total shareholders’ equity $1.3B as of Dec 31, 2025, up 62% YoY.

05-03-2026

Climb Bio, Inc. reported a narrowed net loss of $59.9M for the year ended December 31, 2025, an improvement of 19% YoY from $73.9M, driven by the absence of a $51.7M acquired in-process R&D charge and a 17% decline in total operating expenses to $67.9M. However, R&D expenses surged 226% YoY to $46.7M amid increased investment, net cash used in operating activities more than tripled to $54.4M, and cash and equivalents dropped 59% to $35.7M, contributing to a 23% reduction in total assets to $167.7M.

• ·Common shares outstanding decreased to 47.8M from 67.3M due to exchange for pre-funded warrants.
• ·Accumulated deficit increased to $289.7M from $229.9M.
• ·Stock-based compensation expense rose to $8.1M from $5.6M.

05-03-2026

Invivyd reported product revenue of $53.4M for FY 2025, more than doubling YoY from $25.4M (+110.5%), driven by commercial progress, while R&D expenses plummeted 72% to $38.3M amid cost controls. However, SG&A expenses rose 6% to $66.9M, total operating expenses remained elevated at $109M, and the company posted a net loss of $52.5M (improved from $169.9M prior year). Cash and equivalents surged to $226.7M, bolstered by $215.6M in net financing proceeds, though operating cash burn persisted at $58.1M.

• ·Net cash used in operating activities improved to $(58.1M) from $(170.5M) YoY.
• ·Proceeds from public offering net: $182.5M; ATM offering net: $33.4M in FY2025.
• ·Loan and Security Agreement with Silicon Valley Bank dated April 18, 2025.
• ·Controlled Equity Offering Sales Agreement with Cantor Fitzgerald dated Dec 22, 2023.
• ·Clinical Master Services Agreement with WuXi Biologics dated July 21, 2020.
• ·Diluted EPS: $(0.30) FY2025 vs $(1.43) FY2024.

05-03-2026

Compass Therapeutics, Inc. (CMPX) filed its 10-K annual report on March 05, 2026, highlighting significant commercialization risks, including dependence on third-party payors for coverage and reimbursement, compliance with extensive U.S. federal, state, and foreign laws (e.g., anti-kickback, false claims, GDPR effective May 2018), and the need to establish marketing, sales, and distribution infrastructure. The company has never generated revenue from product sales and may never be profitable, while facing manufacturing risks such as delays, shortages, and potential recalls. Under equity compensation plans, 1.0 million shares of common stock are issuable upon vesting of restricted stock units.

• ·Equity compensation values exclude weighted average exercise price calculation per disclosure.
• ·Risks include post-approval requirements like REMS that could limit promotion, advertising, distribution, or sales.

05-03-2026

Kura Oncology reported total revenue of $67.5M for FY2025, up 25% YoY from $53.9M, driven by first-ever product revenue of $2.1M and 21% growth in collaboration revenue to $65.4M. However, net loss widened 60% YoY to $279M amid R&D expenses surging 48% to $251M and SG&A up 56% to $120M, leading to negative operating cash flow of $64M versus $134M inflow prior year, cash and equivalents dropping to $149M from $225M, and stockholders' equity halving to $174M.

• ·Long-term debt totals $10M, due in 1-3 years.
• ·Total contractual obligations $37M, with $23.967M in operating leases.
• ·Accumulated deficit grew to $1.174B from $895M.
• ·Short-term investments increased to $518M from $503M.

05-03-2026

Bioventus Inc. reported net sales of $568.1M for FY2025, a slight decline of 0.9% YoY from $573.3M, driven by sharp drops in Restorative Therapies (-29.5% U.S., -35.6% International) despite growth in Pain Treatments (+5.7% U.S., +17.0% International) and Surgical Solutions (+7.6% U.S., +7.7% International). Profitability improved markedly with net income of $27.3M versus a $47.0M loss in 2024, Adjusted EBITDA rising 6.8% to $116.3M, gross margin expanding to 68.3%, and operating income reaching 9.5% versus a 2.7% loss. U.S. and International sales both fell slightly by 0.9% and 0.7%, respectively.

• ·Depreciation and amortization declined 25.2% to $5.7M in FY2025.
• ·Income tax benefit narrowed to $1.6M from $5.3M, with effective tax rate at 6.1% versus 10.1%.
• ·Shareholder litigation costs dropped to $51K from $13.8M.
• ·Total contractual obligations amount to $451.6M.

05-03-2026

Jio Financial Services Limited subscribed to and was allotted 14,74,50,000 equity shares of ₹10 each in its joint venture Allianz Jio Reinsurance Limited for ₹147.45 crore, increasing the aggregate investment to ₹150 crore. The transaction is a related party deal conducted on an arm's length basis, with funds to be used for AJRL's business operations. No governmental or regulatory approvals were required.

• ·Investment executed at 2.13 p.m. on March 5, 2026
• ·Related party transaction with no interest from promoters, promoter group, or other group companies
• ·Further to prior disclosure dated September 9, 2025
• ·No governmental or regulatory approval required

05-03-2026

MediWound Ltd.'s 20-F annual report includes a detailed description of burn wound classification by total body surface area (TBSA), noting that an adult's palm burn equates to 1% TBSA, the average hospitalized patient has burns covering 9% TBSA, and burns exceeding 15-20% TBSA typically require hospitalization. The report outlines burn degrees from superficial first-degree (self-healing) to fourth-degree (extending to muscle/bone, requiring debridement and extensive treatment), highlighting the role of debridement, autografting for full-thickness burns, and factors like patient age, burn location, and comorbidities in treatment decisions. No financial metrics or period-over-period comparisons are present in the provided excerpt.

• ·Superficial partial-thickness burns may heal after eschar removal, while deep partial-thickness burns risk progressing to full-thickness without timely debridement.
• ·Full-thickness (third-degree) burns require debridement and autografting using patient's own skin.
• ·Fourth-degree burns are rare and extend to muscle or bone.

05-03-2026

Lakeland Financial Corp (LKFN) filed its DEF 14A proxy statement on March 5, 2026, for the annual shareholder meeting on April 14, 2026, at 3:30 p.m. ET, held virtually. Proposals include the election of 13 director nominees, non-binding approval of executive officer compensation, and ratification of Crowe LLP as independent auditors for the year ending December 31, 2026, with the board recommending a FOR vote on all items.

• ·Shareholders can request proxy materials by March 31, 2026, via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com.
• ·Virtual meeting access: www.virtualshareholdermeeting.com/LKFN2026.

05-03-2026

For the year ended December 31, 2025, Distribution Solutions Group reported consolidated revenue of $1.98B, up 9.8% YoY from $1.80B, with strong growth in Gexpro Services (+12.7% to $497M) and Canada Branch Division (+77.1% to $221M), while Lawson (+2.6% to $481M) and TestEquity (+1.6% to $783M) showed modest increases. Operating income improved to $78.3M (4.0% margin) from $56.0M (3.1%), and net income swung to a profit of $8.3M from a $7.3M loss; however, adjusted EBITDA was essentially flat at $175.2M (vs. $175.3M) and gross margin declined slightly to 33.4% from 34.0%.

• ·Lawson end markets: Automotive 31%, Manufacturing 14%; Product categories: Aftermarket automotive supplies 21%, Fastening systems 16%.
• ·TestEquity end markets: Electronics manufacturing 31%, Aerospace and defense 20%.
• ·Interest expense stable at ~$55M YoY.
• ·Depreciation and amortization increased to $80.9M from $74.4M.

05-03-2026

Balmer Lawrie & Co. Ltd.'s Board of Directors, at its meeting on 5 March 2026, noted fines imposed by BSE and NSE for non-compliance with Regulations 17(1) and 19(1)/19(2) of SEBI Listing Regulations for the quarter ended 31 December 2025, attributing the lapses to dependency on government appointments by the Ministry of Petroleum & Natural Gas, which are beyond the company's control. The Board clarified no violation of Regulation 19(2) occurred as the NRC Chairperson was an Independent Director throughout the quarter. The company has made representations to stock exchanges seeking waiver of the fines.

• ·Previous intimations dated 27 February 2026 (BSE fines) and 28 February 2026 (NSE fines).
• ·Board meeting commenced at 12:30 p.m. and concluded at 05:45 p.m. on 5 March 2026.
• ·CIN: L15492WB1924GOI004835.
• ·Article 7A of Articles of Association governs government-appointed directors.

05-03-2026

Arvana Inc. (AVNI) filed an S-1 registration statement on March 5, 2026, for its IPO, reporting FY2024 revenue of $67,964, nearly flat but down 0.5% YoY from $68,276 due to hurricanes and vessel repairs that curtailed charter fishing services. Net loss improved significantly by 66% to $447,495 from $1,316,573, driven by a 23.1% reduction in operating expenses to $406,236 and 91% lower other expenses; however, gross profit declined 19.1% to $33,644 amid higher costs of service, total assets fell to $202,176 from $216,549, and working capital deficit stood at $969,980 with expected continued losses.

• ·Acquired Down2Fish Charters LLC on February 3, 2023, contributing to 2023 other expenses.
• ·Charter services curtailed in Q3 2023 and halted in Q4 2023 due to vessel repairs under warranty.
• ·Capital expenditures in 2023 included property and equipment from Down2Fish acquisition.
• ·Expects revenue increase next 12 months as vessels return to service, but higher operating expenses and continued net losses.

05-03-2026

Silence Therapeutics plc reported FY2025 revenue of $0.6M, a 99% YoY decline from $43.3M, driving net loss to $88.6M from $45.3M and operating loss to $91.1M from $63.3M, exacerbated by restructuring charges of $1.3M and foreign currency losses. Cash and equivalents dropped sharply to $11.3M from $121.3M, with total assets falling to $131.4M from $202.6M. However, G&A expenses improved 17% YoY to $22.3M, R&D costs remained nearly flat, and operating cash outflow lessened 8% to $62.3M.

• ·Short-term investments increased to $73.8M from $26.0M as of Dec 31 2025.
• ·Restructuring charges of $1.3M recognized in FY2025.
• ·Net cash outflow from investing activities increased to $48.0M from $22.0M.
• ·Financing cash inflow minimal at $15k in FY2025 vs $142.1M in FY2024.
• ·Loss per share (basic and diluted) $0.63 in FY2025 vs $0.33 in FY2024.

05-03-2026

Aligos Therapeutics reported a sharply reduced net loss of $24.2M for the year ended December 31, 2025, compared to $131.2M in 2024 (-82% YoY), primarily due to a $60.2M gain from the change in fair value of 2023 Common Warrants and slight declines in operating expenses (total OpEx -3% to $90.2M). However, total revenue fell 45% YoY to $2.2M amid a complete drop in collaboration revenue (-100%) and customer revenue decline (-39% to $2.2M), while cash and equivalents decreased to $18.3M from $37.0M with operating cash burn of $82.5M. The company raised $101.6M net via PIPE financing, boosting total assets to $88.5M (+26%) and flipping stockholders' equity to a positive $53.5M from a $29.0M deficit.

• ·Net cash used in investing activities increased to $37.8M in 2025 from $18.3M in 2024, driven by short-term investment purchases.
• ·Stock-based compensation expense declined to $5.0M in 2025 from $8.5M in 2024.
• ·Net loss per share improved to ($2.45) in 2025 from ($20.94) in 2024.
• ·Restricted cash remained flat at $110K.

05-03-2026

First Business Financial Services, Inc. highlighted strong 2025 performance in its proxy statement for the April 24, 2026 Annual Meeting, with core deposit and loan balances growing 11% and 8% YoY over 2024, respectively, total revenue up 10%, and efficiency ratio improving to 58.78%. The company reported over 14% growth in pre-tax pre-provision earnings, EPS, and tangible book value per share, alongside a robust ROATCE of 15.3%, all exceeding strategic targets. Five-year TSR through December 31, 2025 reached 235%, outperforming peers (66% median), Russell 2000 (73%), and S&P 500 Banks (125%).

• ·2026 Annual Meeting virtually on April 24, 2026 at 10:00 a.m. CDT via www.meetnow.global/M6YH2SP
• ·Proposals: Elect three Class I directors to serve until 2029 Annual Meeting; approve 2026 Equity Incentive Plan; non-binding advisory vote on compensation
• ·Leadership transition: Dave Seiler to assume CEO role in May 2026 following Corey Chambas retirement (announced May 2025)
• ·Peer group: publicly traded banks with assets between $1.75B and $7.0B

05-03-2026

Delta Air Lines announces key leadership changes, including Peter Carter's promotion to President, Dan Janki's appointment as Chief Operating Officer (previously CFO), Erik Snell's move to Chief Financial Officer, Ranjan Goswami's naming as Chief Marketing and Product Officer, and Alain Bellemare adding Chairman of Delta TechOps to his role as EVP and President – International. These changes follow the retirement of John Laughter, longtime EVP Chief of Operations and President of Delta TechOps, effective April 30, 2026, after over 30 years, and Alicia Tillman's departure as Chief Marketing Officer for external opportunities. CEO Ed Bastian emphasized the moves strengthen the executive team and reflect Delta's deep talent bench to drive long-term growth.

• ·All new appointees (Carter, Janki, Snell, Goswami) report directly to CEO Ed Bastian.
• ·John Laughter's career started as an aircraft liaison engineer in TechOps.

05-03-2026

flyExclusive, Inc. reported FY2025 revenue of $375.9M, up 14.9% YoY from $327.3M, with strong growth in fractional ownership (+66.1% to $37.7M) and maintenance, repair, and overhaul (+48.2% to $10.6M), while jet club and charter rose 10.2%. However, the company recorded a net loss of $67.1M (improved 33.9% from $101.5M), attributable net loss of $17.6M (down 16.5% from $21.1M), with total costs and expenses up 3.2% and average aircraft on certificate declining to 92 from 101. Adjusted EBITDA improved to -$7.0M from -$56.2M and Adjusted EBITDAR turned positive at $12.4M from -$36.4M, though cash and equivalents fell to $29.3M from $31.7M.

• ·Cash provided by operating activities: $6.7M in FY2025 vs used $10.9M in FY2024
• ·Net cash from investing activities: $108.9M in FY2025 vs used $7.9M in FY2024
• ·Total liabilities: $524.3M as of Dec 31 2025 (down from $550.0M)
• ·Redeemable noncontrolling interest: $213.4M as of Dec 31 2025 (up from $159.5M)
• ·Stockholders' deficit: $325.6M as of Dec 31 2025 (worsened from $210.1M)

05-03-2026

Sysco Corporation announced that Executive VP and CFO Kenny Cheung will step down effective March 6, 2026, to join a Fortune 10 company, with Brandon Sewell appointed as Interim CFO; Cheung will remain until April 17, 2026, to ensure a smooth transition. The company highlighted Cheung's contributions to finance organization improvements and ROIC discipline, while praising Sewell's deep experience leading U.S. finance, supply chain, and merchandising. Sysco reaffirmed FY2026 adjusted EPS guidance at the high end of $4.50-$4.60, sales growth of 3%-5%, Q3 2026 consensus adjusted EPS of $0.94, and USFS local case growth of at least 2.5% YoY.

• ·Sysco generated sales of more than $81B in FY2025 ended June 28, 2025.
• ·Sewell joined Sysco in 2014 with 12 years tenure, holds degrees from Brigham Young University and Duke Fuqua.

05-03-2026

Reviva Pharmaceuticals Holdings, Inc. amended its Amended and Restated Certificate of Incorporation to implement a one-for-20 reverse stock split of its Common Stock, effective 12:01 a.m. Eastern Time on March 9, 2026. The Reverse Split reclassifies every 20 shares of Old Common Stock into 1 share of New Common Stock, with no reduction in authorized shares, and applies to convertible securities or rights. The amendment was duly adopted by the Board of Directors and stockholders per Delaware General Corporation Law, with fractional shares rounded up to the nearest whole share.

• ·Reverse Split executed on March 4, 2026, and filed on March 5, 2026.
• ·Old Common Stock certificates automatically represent New Common Stock post-Effective Time, subject to fractional adjustment.
• ·Reverse Split applies to securities or rights convertible into, exchangeable for, or exercisable for Old Common Stock.

05-03-2026

Okta, Inc. reported total revenue of $2.9B for the year ended January 31, 2026, up 12% YoY from $2.6B in 2025, primarily driven by 12% subscription revenue growth to $2.9B, while professional services revenue grew 18% to $64M. Gross profit increased 13% to $2.3B with gross margin expanding to 77%, leading to operating income of $149M and net income of $235M, a sharp turnaround from a $74M operating loss and $28M net income in 2025. However, R&D expenses declined slightly by 1% to $639M, sales and marketing rose 5% to $1.0B, and G&A remained flat at $448M.

• ·Subscription revenue represented 98% of total revenue in FY2026, unchanged from FY2025.
• ·Total cost of revenue increased 7% YoY to $661M in FY2026.
• ·Stock-based compensation expense decreased to $544M in FY2026 from $565M in FY2025.
• ·Restructuring and other charges fell to $4M in FY2026 from $11M in FY2025.

05-03-2026

McKesson Corporation announced that Executive Vice President and CFO Britt Vitalone will retire after a 20-year career, including over eight years as CFO, with Kenny Cheung succeeding him effective May 29, 2026. Vitalone will remain as a strategic advisor to support the transition and the planned separation of McKesson’s Medical Surgical Solutions into an independent company. The announcement highlights Vitalone's contributions to financial performance and capital allocation amid the company's strong third quarter results with record revenue and adjusted operating profit.

• ·Filing date: March 5, 2026
• ·Vitalone's tenure: 20 years at McKesson, more than 8 years as CFO
• ·Cheung previously served as EVP and CFO at Sysco

05-03-2026

Acorn Energy, Inc. reported FY2025 revenues of $11.5M, up 4.5% YoY from $11.0M, driven by OmniMetrix with gross profit margin improving to 77% from 73%; operating income rose slightly 2.7% to $2.0M. However, net income attributable to stockholders fell sharply 60% to $2.5M from $6.3M due to a lower deferred tax benefit ($0.5M vs $4.4M), resulting in diluted EPS declining to $0.99 from $2.51; the Critical Power (CP) segment revenues dropped 33% to $0.7M (6% of total) from $1.1M (10%), and total hardware revenues decreased 8% to $5.9M.

• ·R&D expense increased 8% YoY to $1.1M from $1.0M.
• ·SG&A expense rose 13.5% YoY to $5.7M from $5.1M.
• ·Deferred income tax benefit $0.5M in FY2025 vs $4.4M in FY2024.
• ·Lease obligations: $41k (2026), $42k (2027), $33k (2028).
• ·Stock option grants: 2,200 options at $17.50 (2025) and $17.89 exercise prices.

05-03-2026

CorMedix Inc. reported FY2025 total revenue of $311,709, up 617% YoY from $43,472, driven by DefenCath product sales of $258,813 (up from $43,472) and new Melinta Portfolio sales of $45,531, alongside contract revenue of $7,365. The company achieved a dramatic turnaround to net income of $163,055 from a $17,930 loss, with operating income of $150,141 versus a prior-year loss of $22,356 and gross profit of $275,748 (up 585%). However, total operating expenses increased 101% to $125,607, with G&A up 128% to $68,220 and selling/marketing up 32% to $38,054, while a $6,501 unfavorable change in contingent consideration partially offset other income.

• ·Agreement and Plan of Merger with Melinta Therapeutics, LLC dated August 7, 2025
• ·Accrued returns allowance of $18.3M as of December 31, 2025, including for Melinta Portfolio
• ·Company achieved cumulative pre-tax income over the most recent three-year period as of September 30, 2025, supporting realizability of certain deferred tax assets

05-03-2026

Sirius XM Radio LLC completed a cash tender offer for any and all of its outstanding $1B 3.125% Senior Notes due 2026, with $498.9M (49.89%) validly tendered at $994.64 per $1,000 principal, excluding $70.6M subject to guaranteed delivery procedures. The repurchase is funded partly by $1.25B of newly issued 5.875% senior notes due 2032, which closed on March 4, 2026. Remaining untendered notes will be redeemed or defeased using proceeds and cash on hand.

• ·Notes commenced tender offer on February 26, 2026; expired March 4, 2026 at 5:00 p.m. NYC time
• ·Settlement payment for valid tenders expected March 5, 2026; guaranteed delivery payment expected March 9, 2026
• ·Notes callable at 100.000% of principal plus accrued interest; mature September 1, 2026
• ·CUSIP Numbers: 82967NBL1, U82764AU2, 82967NBN7

05-03-2026

On February 27, 2026, Valerie O. Murray, President of Beacon Trust Company and Executive Vice President and Chief Wealth Management Officer of Provident Bank (subsidiaries of Provident Financial Services, Inc.), announced her resignation effective May 22, 2026, to pursue other opportunities, with no disagreement on company matters. Under the Separation Agreement, she will be on garden leave from March 27 to May 22, 2026, continuing to receive base salary and benefits, and is entitled to a $1.2M lump sum payment subject to conditions including a release of claims. The company expressed appreciation for her leadership and contributions.

• ·Filing date: March 5, 2026
• ·Garden leave period: March 27, 2026 to May 22, 2026
• ·Resignation announcement date: February 27, 2026

05-03-2026

PacBio (NASDAQ: PACB) announced on March 5, 2026, the appointment of Christopher Gibson, Ph.D., co-founder and Chairman of Recursion (NASDAQ: RXRX), to its Board of Directors to strengthen expertise in AI-driven biology and data tools for HiFi sequencing. CEO Christian Henry stated that Gibson's experience scaling AI-native life sciences will support PacBio's vision of integrating sequencing, computation, and data-driven discovery. Gibson expressed enthusiasm for leveraging PacBio's high-quality long-read sequencing datasets with AI analytics to accelerate healthcare advancements.

• ·Filing date: March 05, 2026
• ·PacBio products are for Research Use Only, not for diagnostic procedures

05-03-2026

Gala Global Products Limited received a notice from BSE Limited on February 27, 2026, for non-submission of the corporate governance compliance report under Regulation 27(2) for the quarter ended December 2025, leading to a fine of ₹16,520 (incl. GST). The company promptly paid the fine on March 1, 2026, with no additional financial implications anticipated. This represents a minor compliance lapse with no broader operational impact mentioned.

• ·Scrip Code: 539228
• ·Company website for intimation: https://www.galaglobalhub.com/
• ·DIN: 09851691

05-03-2026

RAND Capital Corp's annual 10-K for the year ended December 31, 2025, reports sharp declines including total assets down 26.6% YoY to $53.2M from $72.5M, net assets down 20.1% to $52.2M, investments at fair value down 31.5% to $48.5M, and net unrealized depreciation of $8.6M versus $2.7M appreciation prior year. While liabilities decreased 85.8% to $1.0M and new investments added $6.6M, portfolio at cost fell 16.2% due to $19.8M in repayments, sales, and liquidations, reducing active portfolio companies from 22 to 20; realized losses totaled $2.0M compared to $11.1M gains in 2024.

• ·Annual expenses total 5.51% of net assets, including 1.53% base management fees and 0.36% incentive fees.
• ·Top holdings at Dec 31, 2025: EFINEA ($5.2M, 10%), Caitec ($5.1M, 9%), First Coast Mulch ($3.9M, 7%).
• ·Stock traded at discounts to NAV throughout most quarters in 2024 and 2025, with premiums up to 29.60% in Q1 2025.

05-03-2026

Classover Holdings, Inc. (KIDZW) filed an 8-K on March 05, 2026, covering Items 3.03 (material events, potentially impairments), 5.03 (charter or bylaws amendments), and 9.01 (financial statements and exhibits), categorized under Charter/Bylaws Amendments as a Material Event. No specific financial metrics, period-over-period comparisons, improvements, declines, or flat performance were disclosed in the provided filing index. The filing size is 562 KB with no quantitative impacts detailed.

• ·CIK: 0002022308
• ·SIC: 8200 - SERVICES-EDUCATIONAL SERVICES
• ·Mailing/Business Address: 8 THE GREEN STE B, DOVER DE 19901
• ·Phone: 530-574-6789
• ·Fiscal Year End: December 31
• ·File/Film Number: 001-42588 / 26724283

05-03-2026

Aditxt, Inc. amended its Certificate of Incorporation to implement a 1-for-8 reverse stock split, effective March 6, 2026, at 4:01 p.m. Eastern Time, whereby every eight shares of old common stock will automatically convert into one share of new common stock. Fractional shares will be rounded up to a whole share, with the amendment duly approved by stockholders pursuant to Delaware General Corporation Law Section 242.

• ·Original Certificate of Incorporation filed with Delaware Secretary of State on September 28, 2017.
• ·Amendment inserts new Subsection (e) into ARTICLE IV, SECTION I.

05-03-2026

Six Flags Entertainment Corporation announced definitive agreements to divest seven parks to EPR Properties for $331M in cash consideration, with the divested parks generating $260M in net revenue and $45M in Adjusted EBITDA from 4.5M guests in FY2025. Proceeds, after taxes and expenses, will pay down debt and slightly improve the leverage ratio while sharpening focus on higher-return remaining parks. No significant guest impact expected during transition, with operations continuing normally through 2026.

• ·Transaction expected to close by end of Q1 or beginning of Q2 2026, subject to closing conditions and third-party approvals.
• ·EPR retains Six Flags brand usage through end of 2026.
• ·Perella Weinberg Partners acted as financial advisor; Weil, Gotshal & Manges LLP as legal counsel to Six Flags.
• ·Parks currently total 26 amusement parks, 15 water parks, and 9 resort properties across 16 states in U.S., Canada, and Mexico, plus one managed in Saudi Arabia.

05-03-2026

AGCO CORP filed an 8-K on March 05, 2026, under Items 5.02 (Director/Officer Departure/Election) and 9.01 (Financial Statements and Exhibits), announcing an officer or director change with an attached press release (EX-99.1). The content details are largely unreadable due to formatting issues, providing no specific names, roles, or financial impacts. No quantitative metrics or period-over-period comparisons are discernible.

• ·Filing Type: 8-K
• ·Subcategory: Director/Officer Departure/Election

05-03-2026

NCR Atleos Corporation commenced a Consent Solicitation on March 5, 2026, from holders of its 9.500% Senior Secured Notes due 2029 to amend the indenture, specifically to ensure the pending merger with The Brink’s Company does not trigger a 'Change of Control' provision. The Merger Agreement was executed on February 26, 2026, and completion of the merger is not conditioned on the success of the Consent Solicitation. The announcement includes extensive forward-looking statement cautions highlighting risks such as regulatory approvals, integration challenges, financing, and potential business disruptions.

• ·Merger Agreement dated February 26, 2026
• ·Company's Annual Report on Form 10-K for year ended December 31, 2025, filed February 27, 2026
• ·Brink’s Annual Report on Form 10-K for year ended December 31, 2025, filed February 26, 2026

05-03-2026

Merlin Labs, the target of Inflection Point Acquisition Corp. IV's proposed business combination, announced the successful completion of its Preliminary Design Review (PDR) for the C-130J autonomy program under a $105M IDIQ contract with U.S. Special Operations Command (USSOCOM), marking a key technical milestone toward production-ready reduced aircrew capability. This approval validates Merlin's integration design and airworthiness approach, enabling transition to the Critical Design stage. Merlin reports over $100M in total awarded contracts from military customers.

• ·Next contract stages include Critical Design Review, system integration, ground testing, and takeoff-to-touchdown flight demonstrations.
• ·Filing references proposed business combination; definitive proxy statement/prospectus filed February 12, 2026.

05-03-2026

World Mobile Group Ltd converted payable notes into 1,277,018 shares of Cuentas Inc. common stock, acquiring approximately 18.5% ownership and becoming the company's largest shareholder, signaling strong confidence in Cuentas' platform. This deepens their strategic alliance, with Cuentas holding 51% ownership in both World Mobile LLC and World Mobile Media Group LLC. The WMTx crypto token ecosystem demonstrates robust momentum, generating over 1.5 billion tokens in average daily trading volume over the last 30 days.

05-03-2026

QuantumScape Corporation appointed Ross Niebergall to its Board of Directors on March 4, 2026, with his term expiring at the next annual stockholder meeting. Dr. Niebergall, an experienced executive in defense sector R&D and technology commercialization, has held senior roles at L3Harris Technologies, RTX Corporation, and others, and currently serves on the board of V2X, Inc. He is eligible for standard non-employee director compensation, including $80,000 annual cash and initial equity awards of 40,973 RSUs vesting over three years and 6,402 pro-rated RSUs.

• ·No committee appointments for Dr. Niebergall at this time.
• ·Initial RSUs vest one-twelfth quarterly over three years starting May 15, 2026; pro-rated RSUs vest on the earlier of one-year anniversary or day before next annual meeting.
• ·No family relationships or material interests under Item 404(a) of Regulation S-K.

05-03-2026

Invech Holdings, Inc. entered into an Equity Financing Agreement and Registration Rights Agreement with GHS Investments, LLC on March 3, 2026, providing access to up to $10M in equity financing upon S-1 effectiveness, through put notices for common stock priced at 80% of the lowest traded price over the prior 10 trading days. Each put ranges from $10,000 to $500,000, limited to 200% of average daily trading volume and a 4.99% beneficial ownership cap, over 24 months or until the full commitment is reached. No historical financial performance data or period-over-period comparisons are provided in the filing.

• ·Puts restricted to at least 10 trading days following a prior closing.
• ·Post-NASDAQ uplisting, purchase price adjusts to 90% of VWAP with $1.00 floor.
• ·Company to file S-1 registration statement for resale of shares.

05-03-2026

WEBTOON Entertainment Inc. (Nasdaq: WBTN) elevated Yongsoo Kim from Chief Strategy Officer and Head of Global WEBTOON to President, effective March 5, 2026, to lead global operations, accelerate innovation, growth, and execution; Kim also joins the Board of Directors and will report to Founder & CEO Junkoo Kim. Under Kim's prior leadership since late 2022, the company achieved its successful 2024 IPO, a 2025 collaboration with The Walt Disney Company, and launched initiatives like Video Episodes and expanded Creator programs. The company reports approximately 160 million monthly active users across its global platforms.

• ·Yongsoo Kim joined WEBTOON Entertainment in late 2022 and led the 2024 IPO.
• ·Prior roles for Yongsoo Kim: Principal at KKR, founding team of Tesla’s Korea operations, Engagement Manager at McKinsey & Company.
• ·Yongsoo Kim holds a Bachelor of Business Administration from Yonsei University and serves as director at LD Carbon.

05-03-2026

The National Company Law Tribunal (NCLT), Bengaluru Bench, sanctioned the Scheme of Amalgamation of Shilpa Therapeutics Private Limited (wholly owned loss-making subsidiary) with Shilpa Medicare Limited (profit-making listed parent) on February 27, 2026, with an appointed date of April 1, 2023. The scheme was approved by requisite majorities in relevant creditor meetings, with no objections received from regulators or stakeholders. However, both companies have outstanding undisputed statutory dues (Transferor: ₹61.17 L; Transferee: ₹3.59 Cr) and MSME dues (Transferor: ₹25.60 L; Transferee: ₹53.13 L), which require settlement.

• ·Board of Directors approved the scheme on June 21, 2023.
• ·First Motion order dated May 2, 2024; Second Motion petition filed August 26, 2024.
• ·Scheme effective upon filing certified NCLT order with Registrar of Companies.

05-03-2026

Promoter and Managing Director Amit Goenka has informed of the release of pledge on 1,000,000 equity shares (4.19% of total share capital) previously encumbered in favor of Catalyst Trusteeship Limited. Post-release, his remaining pledged shares stand at 44,97,928, representing 18.84% of the total share capital, down from 54,97,928 shares prior to the release. Other promoters and promoter group members hold no encumbered shares as of the reporting date.

• ·Pledge released pursuant to part repayment of loan.
• ·Other promoters and promoter group have 0% shares encumbered.
• ·Scrip Code: 544296; ISIN: INE0DQN01013.

05-03-2026

Pinterest, Inc. filed an 8-K on March 5, 2026, disclosing under Item 1.01 entry into a material definitive agreement, Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, Item 3.02 unregistered sales of equity securities, and Item 9.01 financial statements and exhibits. No specific transaction details, dollar values, strategic context, or financial impacts are provided in the filing summary. This is a multi-item filing with no disclosed positive or negative metrics.

05-03-2026

Mazagon Dock Shipbuilders Limited clarified a Business Today news report claiming its shares climbed 6% amid rumors of a ₹99,000 crore defense deal, confirming that CNC negotiations with the Government are completed and the proposal is awaiting approval from the competent authority. This updates prior disclosures dated 25.08.2025, 10.09.2025, and 09.01.2026. The company stated it is unaware of any other undisclosed material information explaining the share movement.

• ·Prior disclosures on negotiations: 25.08.2025, 10.09.2025, 09.01.2026
• ·BSE query email dated 05 March 2026
• ·No regulatory/legal proceedings applicable

05-03-2026

Decoy Therapeutics Inc., originally incorporated as Flex Pharma, Inc. on February 26, 2014, amended its Certificate of Incorporation to authorize 110M total shares (100M Common Stock and 10M Preferred Stock, each with $0.0001 par value) and effected a 1-for-12 reverse stock split without changing authorized share totals. The reverse split consolidates every 12 old shares into 1 new share effective 5:00 p.m. ET on March 6, 2026, with cash payments in lieu of fractional shares based on the Nasdaq closing price. No performance metrics or financial changes are reported.

05-03-2026

On March 4, 2026, Match Group, Inc. informed Hesam Hosseini, its Chief Operating Officer and Chief Executive Officer of Evergreen & Emerging Brands, that the COO role is being eliminated effective June 2, 2026, leading to his departure from the company after over 15 years of service. The announcement follows discussions between Mr. Hosseini and the company. It was signed by Sean Edgett, Chief Legal Officer and Secretary, on March 5, 2026.

• ·Event reported date: March 4, 2026
• ·Filing date: March 5, 2026
• ·Company address: 8750 North Central Expressway, Suite 1400, Dallas, TX 75231
• ·Telephone: (214) 576-9352

05-03-2026

Textron Inc. filed its 2026 DEF 14A Proxy Statement on March 5, 2026, for the annual shareholder meeting on April 29, 2026, soliciting votes for the election of directors, ratification of the independent registered public accounting firm, and an advisory vote on executive compensation. The proxy includes corporate governance highlights, director independence details, security ownership information, audit committee report, and comprehensive executive compensation discussion and analysis covering fiscal years 2021 through 2025, with no specific performance metrics or changes highlighted in the provided content.

• ·Annual shareholder meeting scheduled for April 29, 2026, held virtually at www.virtualshareholdermeeting.com/TXT2026.
• ·Fiscal year end: January 3.
• ·Proxy materials reference compensation data for Principal Executive Officer (PEO) and Non-PEO Named Executive Officers (NEOs) across fiscal years 2021-2025, including elements like stock awards, options, pension changes, and fair value adjustments.

05-03-2026

NATIONAL RESEARCH CORP reported FY2025 revenue of $137.4M, down 4% YoY from $143.1M, with operating income declining 36% to $22.6M due to a 22% rise in SG&A expenses to $54.8M and higher interest costs, resulting in net income of $11.6M versus $24.8M in 2024. However, Total Recurring Contract Value increased 8% to $144.1M, Adjusted EBITDA held steady at $40.2M (29.2% margin), and cash from operations was $26.5M. Shareholders' equity fell to $14.0M amid $20.7M in treasury stock repurchases and increased notes payable to $79.0M.

• ·Dividends declared $0.52 per common share in FY2025 ($11.8M total).
• ·Capital expenditures $10.7M in FY2025, down from $15.4M in FY2024.
• ·Purchase of 1,340,224 treasury shares for $20.7M in FY2025.
• ·Notes payable borrowings $47.7M and payments $31.4M in FY2025.
• ·Non-recurring executive compensation $6.6M added back for adjusted net income.
• ·Allowance for doubtful accounts $80K as of Dec 31 2025.

05-03-2026

Nokia reported solid 2025 performance with net sales growing 3.5% YoY to EUR 19,889M from EUR 19,220M in 2024, alongside comparable operating profit and strong free cash flow in line with expectations, and total shareholder return reaching 197.49% (rebased to 100 at Dec 2020). However, net sales remained below the 2022 peak of EUR 23,761M after declines in 2023 and 2024, reflecting ongoing challenges. Leadership transitioned with Justin Hotard joining as President and CEO on April 1, 2025, receiving EUR 7.3M in actual remuneration versus EUR 4.0M for Pekka Lundmark in 2024.

• ·2026 STI for CEO based on comparable operating profit in constant currency and free cash flow, with Board discretion on health & safety and workforce composition.
• ·2026 LTI metrics: relative TSR (50%), cumulative EPS (40%), GHG emission reduction (10%).
• ·Former CEO Pekka Lundmark continued as Advisor until December 31, 2025; notice period paid out until February 9, 2026.
• ·2022 LTI awards to Pekka Lundmark and GLT members fully lapsed.

05-03-2026

Greif, Inc. and subsidiaries (Greif Packaging LLC, Greif International Holding B.V., Greif Beheer B.V.) entered into a Third Amended & Restated Credit Agreement on February 27, 2026, amending and restating the prior Second Amended & Restated Credit Agreement dated March 1, 2022, which provided an initial aggregate principal amount of $2.415B. The new agreement refinances existing loans under updated terms, with the Term A-2 Loans to be repaid in full concurrently with the closing of a CoBank Credit Agreement. No changes in facility sizes or negative impacts on liquidity were disclosed.

• ·SEC 8-K filing date: March 05, 2026
• ·CUSIP numbers: Deal 39762JAX2, Term A-1 Loan 39762JBA1, Global Revolving Credit Facility 39762JAY0, U.S. Revolving Credit Facility 39762JAZ7
• ·Prior agreement date: March 1, 2022
• ·Term A-2 Facility termination and full repayment on Restatement Effective Date concurrent with CoBank Credit Agreement closing

05-03-2026

Global Crossing Airlines Group Inc. reported total revenue growth of 10.1% YoY to $246.3M for the year ended December 31, 2025, driven by ACMI revenue surging 42.8% to $175.8M, while Charter revenue declined sharply 34.8% to $62.3M and total Charter block hours fell 39.6%. Operating income improved to a positive $8.9M from a $1.1M loss, with operating expenses up only 5.6% to $237.4M despite rises in salaries (18.8%) and maintenance (44.7%), but the company recorded a net loss of $2.6M (improved from $11.4M) amid higher interest expense (28.5%). Cash from operations rose significantly to $28.1M, supporting total assets of $203.1M up from $166.7M.

• ·Cash and cash equivalents increased to $16.7M from $12.3M as of Dec 31, 2025.
• ·Stockholders’ deficit remained relatively flat at approximately $29.5M.
• ·Total block hours grew 16.5% to 33,564.
• ·Aircraft rent expense nearly flat at $57.4M (-0.4%).
• ·Loss per share improved to $(0.05) from $(0.19).

05-03-2026

OneIM Acquisition Corp., a blank check company, announced on March 5, 2026, that commencing March 6, 2026, holders of its units (OIMAU) may elect to separately trade Class A Ordinary Shares (OIM) and Warrants (OIMAW) on the Nasdaq Global Market. Each unit consists of one Class A ordinary share, par value $0.0001, and one-sixth of one redeemable warrant exercisable for one share at $11.50. Units not separated will continue trading under OIMAU, with no fractional warrants issued upon separation.

• ·Transfer agent: Continental Stock Transfer & Trust Company
• ·Company address: 11th Floor, 390 Park Avenue, New York, NY 10022
• ·Phone: (646) 222-9570
• ·EIN: 98-1883783
• ·Cayman Islands incorporation

05-03-2026

For the three months ended January 30, 2026 (Q1 FY2026), Toro Co reported net sales of $1,036.3M, up 4.1% YoY from $995.0M, with net earnings rising 28.6% to $67.9M driven by higher operating earnings ($87.1M, +12.0%) and other income. However, gross profit remained essentially flat at $336.5M (+0.3%), operating cash flow was modest at $26.1M after improving from a negative $48.6M YoY, and a $210.3M acquisition significantly increased investing outflows and goodwill to $592.1M.

• ·Professional segment external net sales $809.4M; Residential $206.0M; Other $20.9M.
• ·Goodwill increased to $592.1M from $449.8M YoY due to acquisition.
• ·Stockholders’ equity declined to $1,419.2M from $1,467.6M YoY.
• ·Weighted-average basic shares outstanding decreased to 98.0M from 101.3M YoY.
• ·Other segment reported pre-tax loss of $49.7M.

05-03-2026

Capstone Companies, Inc. (CAPC) secured $250,000 in working capital funding on March 4, 2026, via an unsecured promissory note from eBliss Global, Inc., bearing 7% simple annual interest due in a lump sum on March 4, 2027. The note includes a 90-day 'no shop' provision granting eBliss exclusive rights to discuss potential mergers, acquisitions, or joint ventures for the first 60 days, with a special committee of independent directors formed to oversee talks. No agreements or commitments exist, and the company emphasizes the exploratory nature with no assurance of any transaction.

• ·Note dated March 3, 2026
• ·90-day 'no shop' period starting around March 4, 2026, with 60-day exclusivity for superior proposals thereafter
• ·eBliss anticipates e-bike production start at Utica, New York factory in 2026

05-03-2026

Starlink AI Acquisition Corp (OTAI) filed an S-1/A registration statement on March 5, 2026, for an IPO of 10,000,000 units at $10 each, with net proceeds of $100M (or $115M if over-allotment exercised) to be held in a trust account for an initial business combination. The sponsor will purchase 171,600 private units for $1.716M, resulting in 12,821,600 ordinary shares outstanding post-offering, with initial shareholders owning 20%. No operational financials or period comparisons are provided, as this is a pre-business combination SPAC filing.

• ·Founder shares purchased for $0.0145 per share; up to 375,000 subject to forfeiture if over-allotment not exercised.
• ·Rights entitle holder to one-eighth ordinary share upon business combination; must hold multiples of eight.
• ·Transfer restrictions (lock-up) on founder shares and private units until 180 days post-initial business combination or earlier triggers.
• ·Initial shareholders waive redemption rights and will vote in favor of business combination.

05-03-2026

Carter Bankshares, Inc. reported net interest income growth of 14.3% YoY to $130.8M in 2025 from $114.5M in 2024, with net interest margin expanding to 2.82% from 2.57% and average earning assets rising to $4.64B. Loan portfolio averaged $3.76B, up from $3.56B, driven by commercial real estate and construction loans. However, noninterest expenses increased 6.4% to $117.1M, outpacing 4.8% growth in noninterest income to $22.4M, while insurance commissions declined 26.0% and total liquidity sources fell to $1.23B from $1.39B.

• ·Highly Liquid Assets to Uninsured Deposits declined to 59.8% in 2025 from 66.8% in 2024.
• ·Federal Home Loan Bank Borrowings decreased to $110.9M average in 2025 from $222.7M in 2024.
• ·Pretax Net Interest Income sensitivity: +200 bps change results in -1.0% impact in 2025.

05-03-2026

Stratasys Ltd. reported FY2025 revenues of $551.1M, down 3.8% YoY from $572.5M in FY2024, with slight declines across all regions (Americas -3.7%, EMEA -3.3%, Asia Pacific -4.3%) and gross margin contracting to 41.2% from 44.9%. However, GAAP net loss narrowed 13.3% to $104.3M from $120.3M, operating loss margin improved to -13.2% from -15.0%, Adjusted EBITDA rose to $28.5M from $26.0M, and cash position strengthened to $95.4M from $71.1M. Non-GAAP net income improved to $12.7M from $4.2M.

• ·Non-GAAP net income FY2025: $12.7M (up from $4.2M in FY2024)
• ·Net cash provided by operating activities FY2025: $15.1M (up from $7.8M)
• ·Net cash used in investing activities FY2025: $112.2M (vs $14.8M used in FY2024)
• ·Weighted average diluted shares FY2025: 81,602K (up from 70,858K)
• ·R&D as % of revenues FY2025: 14.0% (down from 17.3%)
• ·New U.S. headquarters in Minnetonka, MN: 183,519 sq ft
• ·Israeli headquarters in Rehovot: 284,713 sq ft

05-03-2026

Uwharrie Capital Corp reported net income attributable to common shareholders of $10.8M for 2025, up 15.5% YoY from $9.3M, driven by net interest income growth of 8.1% to $38.9M and noninterest income up 15.7% to $11.3M; total assets expanded 6.0% to $1.20B with loans held for investment up 3.5% to $690M. However, certain noninterest income streams declined, including interchange fees down 8.3% to $1.1M and other banking fees down 9.8% to $0.9M, while noninterest expenses rose 7.4% to $34.8M. EPS basic increased 18.3% YoY to $1.49.

• ·Provision for credit losses increased to $726K in 2025 from $528K in 2024.
• ·Allowance for credit losses on loans: $6.4M (2025) vs $5.8M (2024).
• ·Accumulated other comprehensive loss improved to $(16.6M) from $(24.7M) YoY.

05-03-2026

Home BancShares, Inc. (HOMB) reported record 2025 financial results, including total loans of $15.7B, stockholders' equity of $4.3B, net income of $475M (ROAA 2.10%), and diluted EPS of $2.41. The company announced the acquisition of Mountain Commerce Bancorp, Inc. (MCBI) on December 8, 2025, expected to close in Q2 2026, providing entry into Tennessee markets including Knoxville, Nashville, and Johnson City. West Texas operations have improved post-Happy State Bank acquisition, with no ongoing legal expenses, while total shareholder return since 2006 turned a $1,000 investment into $24,581.

• ·Net Interest Margin: 4.51%
• ·Efficiency Ratio: 40.88%
• ·Tangible Book Value per Share (non-GAAP): $14.60
• ·Dividends per Share: $0.805
• ·Shareholders’ Meeting: April 16, 2026
• ·MCBI acquisition expected to be immediately triple accretive

05-03-2026

ParkOhio Holdings Corp reported net sales of $1,599.1 million for 2025, down 3% YoY from $1,656.2 million, with declines across all segments: Supply Technologies -3%, Assembly Components -4.5%, and Engineered Products -2.2%. Operating income fell 23% to $66.3 million, driven by sharp drops in Engineered Products operating income to $6.6 million (1.4% margin from 3.7%) and asset impairment charges of $8.9 million; however, Supply Technologies held steady at 9.7% operating margin and gross margin remained flat at 17.0%. Income attributable to common shareholders declined 41% to $24.8 million ($1.77 diluted EPS), though operating cash flow improved to $42.3 million.

• ·Cash provided by operating activities increased to $42.3M in 2025 from $35.0M in 2024.
• ·Gross debt rose slightly to $635.7M in 2025 from $628.7M in 2024, but net debt as % of capitalization improved to 58% from 60%.
• ·Restructuring and other special charges increased 31% YoY to $6.4M in 2025.
• ·Decrease in cash and cash equivalents was $8.3M in 2025 vs $1.7M in 2024.

05-03-2026

Solitario Resources Corp. reported a narrowed net loss of $3.8M for 2025 compared to $5.4M in 2024, driven by lower exploration expenses (-31% YoY to $2.8M) and G&A (-17% YoY to $1.6M), while total operating expenses declined 27% YoY to $4.4M. Total assets grew 9% YoY to $25.0M, supported by short-term investments surging 68% to $7.6M, however marketable equity securities dropped 78% to $0.3M and cash remained flat at $0.08M. Shareholders' equity increased 10% YoY to $24.7M amid share issuances, though operating cash use improved modestly to $3.6M from $5.1M.

• ·Shares issued via ATM net: 1,007k shares for $0.73M in 2025 vs 1,802k for $1.22M in 2024.
• ·Private placement: 7.1M shares for $4.4M in 2025.
• ·Net cash provided by financing: $5.3M in 2025 vs $1.3M in 2024.
• ·Investing cash used $1.8M in 2025 (driven by $3.1M net purchase of short-term investments) vs provided $3.9M in 2024.

05-03-2026

Galaxy Enterprises Inc. (GLEI), a real estate agents and managers firm, filed an S-1/A on March 5, 2026, to register 3,920,000 shares of common stock for resale by 40 selling shareholders at prevailing or negotiated prices between $0.01 and $1.00, with no proceeds to the company. The company has 4,170,000 shares issued and outstanding held by 37 stockholders, trading on the OTC Markets Pink Limited Market under 'GLEI', but warns of no active liquid market, penny stock restrictions limiting sales, and $10,000 annual compliance costs that could force cessation of operations if unabsorbable.

• ·Shares acquired by selling shareholders in private placement exempt under Regulation D on June 7, 2021
• ·Fiscal year end: July 31
• ·No dilution to existing shareholders from this offering
• ·No authorized preferred stock, warrants, options, or convertible securities
• ·Company has never declared or paid cash dividends and does not anticipate doing so
• ·Par value of common stock: $0.0001 per share

05-03-2026

L.B. Foster's net sales rose 1.7% YoY to $540M in 2025 from $531M in 2024, bolstered by 14.9% growth in the Infrastructure segment to $234M, while the Rail segment declined 6.5% to $306M. Gross profit fell 3.6% to $114M with margin contracting 110 bps to 21.1%, and operating income edged up 6.7% to $22M; however, net income plummeted 83% to $7.5M from $43M due to a $38M swing to tax expense. Operating cash flow improved significantly to $36M from $23M.

• ·Diluted EPS declined to $0.69 from $3.89 YoY.
• ·Total assets decreased to $330M from $334M.
• ·Outstanding borrowings on revolving credit facility: $42M; letters of credit: $0.9M as of Dec 2025.
• ·Critical audit matter identified on revenue recognition for long-term contracts using input method.
• ·Shares outstanding decreased to 10.1M from 10.6M due to treasury stock purchases.

05-03-2026

Quest Water Global, Inc. (QWTR) reported a significantly larger net loss of $291,413 for the three months ended September 30, 2025, compared to $137,329 in the prior year (112% YoY increase), driven by new marketing expenses and higher management fees. For the nine months ended September 30, 2025, the net loss edged up 3.4% YoY to $630,907 from $610,054, while total expenses rose modestly to $630,907. Stockholders' deficit widened to $2.94M from $2.26M YoY amid continued cash burn from operations funded by related party advances.

• ·Management fees for nine months ended Sep 30, 2025: $401,250 (up from $371,250 YoY)
• ·Stock-based compensation: $99,200 in Q3 2025 (nine months total includes prior periods)
• ·Cash and equivalents end of nine months: $9 (down from $12 YoY)
• ·Computer equipment fully depreciated to $0 net book value as of Sep 30, 2025

05-03-2026

Intrepid Potash, Inc. reported total sales of $298.3M for 2025, up 17.2% YoY from $254.7M, with gross margin surging 88.5% to $54.8M from $29.1M and net income turning positive at $11.2M versus a $212.8M loss in 2024. Potash sales volumes increased 20.4% to 289K tons while Trio® volumes rose 19.3% to 303K tons with higher prices ($367/ton vs $311); however, Potash average price declined 6.4% to $353/ton and cash flows from operations fell 23.1% to $55.8M from $72.5M.

• ·Total assets increased to $632.2M from $594.5M; stockholders' equity rose to $491.4M from $474.4M.
• ·Potash production volumes declined slightly to 280K tons from 295K tons.
• ·Trio® production volumes increased to 273K tons from 251K tons.

05-03-2026

Ardagh Metal Packaging S.A. (AMBP) reported FY2025 revenue of $5.5B, up 12% YoY from $4.9B, with gross profit rising 8% to $681M and operating profit increasing 21% to $244M, driven by 91% of revenues from stable Europe/North America markets and over 80% backed by multi-year contracts. However, net finance expenses surged 25% to $240M due to higher Senior Facilities interest ($158M, +13%), leading to profit before tax declining to $4M from $10M and a slim $11M net profit versus a $3M loss in 2024. The company highlighted its $1.8B growth investment plan (2021-2024) and sustainability targets approved in 2022.

• ·Sales, general and administration expenses increased slightly to $299M from $288M YoY.
• ·Intangible amortization decreased to $138M from $140M YoY.
• ·Income tax credit of $7M in 2025 vs charge of $13M in 2024.

05-03-2026

TriSalus Life Sciences reported strong revenue growth of 53.4% YoY to $45.2M for the year ended December 31, 2025, with gross profit up 50.8% to $38.2M and R&D expenses down 15.4% to $15.0M, improving operating loss by 25.5% to $(26.9M). However, sales and marketing expenses rose 11.1% to $28.7M, G&A increased 19.4% to $21.5M, and net loss widened 30.6% to $39.2M amid higher interest expense (up 79.4%) and unfavorable changes in fair value liabilities. Cash and equivalents grew to $20.4M from $8.5M, bolstered by $30.8M in financing activities, though net cash used in operations remained negative at $18.0M (improved from $40.8M).

• ·Common shares outstanding increased to 49,997,836 from 31,279,264 YoY due to sales, conversions, and exercises.
• ·Total liabilities rose to $69.2M from $49.9M, driven by long-term debt up to $33.0M and warrant/SEPA liabilities to $12.9M.
• ·Net cash provided by financing activities totaled $30.8M, including $22.0M from common stock issuance and $10.0M from debt.
• ·Stock-based compensation expense increased to $9.8M from $5.4M.
• ·Cash paid for interest rose to $3.7M from $1.8M.

05-03-2026

NCS Multistage Holdings, Inc. reported total revenues of $183.6M for the year ended December 31, 2025, up 13.0% YoY from $162.6M, driven by strong U.S. growth of 33.5% but tempered by modest 4.7% growth in Canada. Net income rose 219.9% to $26.0M, boosted by a $9.2M tax benefit, while operating income increased 143.7% to $10.5M; however, services gross margin declined to 45.0% from 48.7%, and other countries services revenues fell 31.1% YoY.

• ·Net cash provided by operating activities increased to $22.2M in 2025 from $12.7M in 2024.
• ·U.S. services revenues surged 87.8% YoY to $18.0M.
• ·Product sales revenues grew 13.1% YoY to $127.9M, with Other Countries up 126.1%.
• ·Provision for litigation of $0.9M in 2025.
• ·Filing date: March 05, 2026 for year ended December 31, 2025.

05-03-2026

Camp4 Therapeutics' revenue surged 436% YoY to $3.5M in 2025 from $0.65M, driven by research and collaboration agreements, while R&D expenses remained flat at approximately $38.2M-$38.8M. However, net loss widened 55% to $80.4M from $51.8M primarily due to a $29.8M unfavorable change in fair value of derivative tranche liability, despite improved operating cash use to $29.6M from $45.6M and a strengthened cash position of $109.5M. Stockholders' equity declined to $47.7M from $63.1M amid significant share issuance.

• ·Derivative tranche liability recorded at $44.8M as of Dec 31, 2025.
• ·Issuance of 31.7M common shares in private placement and registered direct offering in 2025, net proceeds $57.3M.
• ·Initial public offering in 2024 converted preferred stock and raised net $72.4M.
• ·Net loss per share improved to ($2.65) from ($11.04) due to increased shares outstanding.
• ·Impairment of right-of-use asset $0.5M in 2025.

05-03-2026

Evommune, Inc. (EVMN) reported FY2025 revenue growth of 86% YoY to $13M from $7M, primarily from license revenue, while completing an IPO with $157M net proceeds and converting all convertible preferred stock, boosting total assets to $225M and cash equivalents to $44.1M. However, operating expenses increased 22% YoY to $94.1M driven by 15% higher R&D ($74M) and 57% higher G&A ($20M), resulting in a widened net loss of $68.9M (up 3% YoY) and increased operating cash use to $76.4M. EVO301 R&D expenses declined sharply to $7.1M from $19.7M, while EVO756 R&D rose to $35.2M.

• ·Convertible preferred stock fully converted to common stock upon IPO, eliminating $257M non-cash liability.
• ·Stockholders' equity swung from ($144.2M) deficit in 2024 to $205.6M surplus in 2025.
• ·Property and equipment, net declined to $0.99M from $1.33M.
• ·Weighted average shares outstanding increased to 6.14M from 1.51M, reducing basic/diluted loss per share to ($11.22) from ($45.29).

05-03-2026

Cedar Realty Trust, Inc. reported a net loss of $1.9M for the year ended December 31, 2025, compared to a $4.5M profit in 2024, primarily due to a 14.1% decline in revenues to $29.7M, higher impairment charges of $5.8M (up 442.8%), and a reduction in properties owned from 16 to 12. However, Same-Property NOI grew slightly to $17.1M from $16.8M with flat occupancy at 92.4%, FFO increased to $19.3M (per share $1.41 from $0.52), and AFFO turned positive at $1.0M; the company also repurchased 4,244 shares of Series C Preferred Stock for $69K in October 2025.

• ·Same-Property occupancy flat at 92.4% (end of 2025 and 2024).
• ·Aggregate gross leasable area declined to 1,943,176 sq ft from 2,352,528 sq ft.
• ·Cash flows from operating activities down to $8.0M from $9.5M; financing activities outflow increased to $52.7M from $20.3M.
• ·Total liabilities slightly up to $158.8M from $160.7M despite property sales.
• ·Preferred stock equity down to $76.2M from $139.8M.

05-03-2026

Hawthorn Bancshares, Inc. (HWBK) filed its 10-K annual report on March 5, 2026, covering the fiscal year ended December 31, 2025, with comparative data for 2024 and 2023 across banking and fiduciary/trust segments. The filing discloses detailed loan portfolio segments including commercial financial/agricultural, real estate construction (residential and commercial), real estate mortgages (residential and commercial), and installment/consumer loans, along with securities holdings, property/equipment, derivatives, and subordinated notes. No specific numerical financial metrics such as revenue growth, declines, or balance sheet totals are provided in the extracted XBRL tags.

• ·Filing covers periods: FY2025 (Jan 1 - Dec 31, 2025), FY2024, FY2023, with some Q4 2025 data.
• ·Loan classifications include Pass, Watch, Special Mention, Substandard, Doubtful; nonperforming and past due receivables tracked by segment.
• ·Securities categories: US Treasury, US Government Agencies/Sponsored Enterprises, States/Political Subdivisions, Mortgage-Backed, Other Debt, Equity.
• ·Trusts issued: Exchange Statutory Trust Two (Mar 17, 2005), Exchange Statutory Trust One (Mar 17, 2004).
• ·Shelf registration referenced as of July 2, 2025; 2025 Repurchase Plan authorized June 5, 2025.

05-03-2026

BCP Investment Corp (BCIC) reported total assets of $523.6M as of December 31, 2025, up 15.4% YoY from $453.6M, driven by portfolio fair value growth to $501.0M (+23.7% YoY) bolstered by the $153.4M LRFC Acquisition; net asset value rose 17.2% YoY to $209.2M. However, total investment income declined slightly 2.0% YoY to $61.2M, with core investment income dropping 12.7% YoY to $54.3M amid lower interest and CLO income, while net expenses decreased 6.2% YoY to $36.0M. Unrealized gains on investments improved to $6.5M from $1.0M in 2024.

• ·Non-controlled/non-affiliated investments fair value: $409.7M (Dec 31, 2025) vs $327.6M (Dec 31, 2024), +25.1% YoY
• ·Total liabilities increased to $314.5M (+14.3% YoY) from $275.1M, with new debt issuances including $72.6M 2030 Notes
• ·Realized losses on investments: $21.4M in 2025 vs $29.4M in 2024

05-03-2026

A.K.A. Brands Holding Corp. reported net sales growth of 4.4% YoY to $600.2M for FY 2025, with gross margin stable at 57% and net cash from operating activities surging to $16.4M from $0.7M. However, net loss widened 21% YoY to $31.4M, Adjusted EBITDA declined 15% to $19.7M (3% margin from 4%), and free cash flow remained negative at $0.6M despite improvement from -$10.9M.

• ·Distribution center relocation costs: $4.6M in FY2025 (up from $2.1M in FY2024)
• ·Non-routine legal matters: $6.6M in FY2025 (up from $4.5M in FY2024)
• ·Goodwill impairment: $0 in FY2025 (vs $68.5M in FY2023)
• ·Purchases of property and equipment: $17.1M in FY2025 (up from $11.6M in FY2024)

05-03-2026

Keysight Technologies reported Q1 FY2026 revenue of $1.6B, up 23% YoY driven by 25% growth in products and 19% in services; however, operating income rose only 14% to $248M due to cost increases outpacing revenue in areas like cost of products (+30%) and SG&A (+24%), resulting in margin compression to 15.5% from 16.8%. Net income surged 66% to $281M primarily from an $83M tax benefit versus prior $30M expense, boosting diluted EPS to $1.63 from $0.97. Operating cash flow improved 17% to $441M, while the company repurchased $87M in shares.

• ·Tax provision was a benefit of $83M vs $30M expense YoY due to discrete items.
• ·Interest expense increased to $29M from $20M YoY.
• ·Acquired business for $1.564B total consideration on Oct 15, 2025, with $711M goodwill.
• ·Small acquisition of $16M in current quarter cash flows.
• ·Total assets $11.481B as of Jan 31, 2026, up from $11.301B at Oct 31, 2025.

05-03-2026

RTX Corporation announced that director James A. Winnefeld Jr. resigned effective March 5, 2026, with no dispute or disagreement regarding company operations, policies, or practices. As a result, the Board size will decrease from 11 to 10 members.

05-03-2026

Amalgamated Financial Corp. (AMAL) reported total assets of $8.5B as of December 31, 2025, up from $8.3B in 2024, with net interest income growing 5.4% YoY to $297.8M on higher loan volumes (+$25.2M interest income) and total interest income up 5.2% to $422.2M at a 5.09% yield. However, non-interest income declined 6.9% YoY to $30.9M amid losses on securities sales and equity investments, while non-interest expenses rose 7.9% to $172.2M driven by higher compensation, professional fees, and technology costs; nonperforming assets also edged up slightly to $28.7M or 0.32% of assets.

• ·Average total loans grew to $4,720M in 2025 from $4,479M in 2024 (+5.4% YoY).
• ·Nonaccrual loans in commercial portfolio rose to $22.1M from $16.0M YoY.
• ·Allowance for credit losses on loans to total loans declined to 1.16% from 1.29% YoY.
• ·Service charges on deposit accounts dropped sharply to $17.5M from $32.2M YoY.

05-03-2026

Applied Optoelectronics, Inc. (AAOI) entered into a design-build agreement dated February 13, 2026, with LCC3 Solution Inc. for the construction of a Manufacturing Cleanroom at 1111 Gillingham Lane, Sugar Land, TX 77478. The agreement outlines responsibilities for design, construction, testing, and commissioning, with Dr. Fred Chang as AAOI's authorized representative and Mingzheng (Miles) Yang for the design-builder. No financial terms such as contract sum or schedule details are specified in the filing.

• ·Agreement effective as of February 13, 2026; SEC 8-K filed March 05, 2026.
• ·Project location: 1111 Gillingham Lane, Sugar Land, TX 77478.
• ·AAOI address: 13139 Jess Pirtle Blvd., Sugar Land, TX 77478.
• ·LCC3 Solution Inc. address: 7165 Colleyville Blvd. Suite 101, Colleyville, TX 76034.
• ·Dispute resolution includes meet-and-confer and arbitration per Exhibit N.

05-03-2026

EyePoint Pharmaceuticals reported total revenues of $31.4M for FY 2025, down 28% YoY from $43.3M, with product sales declining 50% to $1.6M and license/collaboration revenues dropping 57% to $16.7M, though royalty income surged 708% to $13.0M. Operating expenses rose 45% to $274.8M, primarily due to a 66% increase in R&D to $221.0M, resulting in a net loss of $232.0M, up 77% from $130.9M in FY 2024. Cash and equivalents stood at $101.8M as of Dec 31, 2025, with net cash used in operations worsening to $240.1M and stockholders' equity declining to $306.1M.

• ·Marketable securities decreased to $204.3M from $271.2M as of Dec 31, 2025.
• ·Total current assets down to $328.7M from $383.3M.
• ·Stock-based compensation expense $27.9M in FY 2025 vs $36.7M in FY 2024.
• ·Issuance of common stock net of costs: 13.7M shares raising $172.9M in FY 2025.

05-03-2026

Texas Roadhouse, Inc. (Nasdaq: TXRH) appointed Lisa Ingram, CEO and Chair of White Castle System, Inc., to its Board of Directors on March 5, 2026. Ms. Ingram, who has led White Castle since 2015, oversees 340 restaurants in 14 states and 6 manufacturing plants supplying consumer products nationwide. Jerry Morgan, Texas Roadhouse CEO, highlighted her restaurant industry expertise and people-first leadership approach.

• ·Lisa Ingram is a fourth-generation family member leading the 105-year-old White Castle brand, considered the nation's first fast-food hamburger chain.
• ·Lisa Ingram holds a Bachelor of Business Administration from Southern Methodist University and an MBA from Ohio State University.
• ·Lisa Ingram serves as Chair of the Board of OhioHealth and on the board of M/I Homes (NYSE: MHO).
• ·Texas Roadhouse first opened in 1993.

05-03-2026

CIMG Inc. entered into an Amended and Restated Equity Transfer Agreement on February 27, 2026, to acquire 100% of Daren Business Technology Limited (100 ordinary shares) from Shelei Jiang for zero cash consideration, with closing expected by March 31, 2026, subject to customary conditions. Post-closing, the Company may issue up to 74,487,896 common shares to seller designees Dundas Technology Limited and Kellyview Investment Limited by April 10, 2026, contingent on stockholder approval and audited revenue targets through September 30, 2029; unmet targets result in forfeiture, but full issuance would cause significant dilution with no assurance of approval.

• ·Acquisition amends and restates prior Equity Transfer Agreement dated February 11, 2026.
• ·Award Shares subject to Nasdaq Listing Rule 5635 stockholder approval and transfer restrictions with leak-out tied to RMB-denominated revenue targets.
• ·Shares, if issued, rely on Regulation S and Section 4(a)(2) exemptions as restricted securities.
• ·Filed as Exhibit 10.1: full A&R Equity Transfer Agreement.

05-03-2026

Athena Technology Acquisition Corp. II deposited $497.74 into its trust account on March 4, 2026, to extend the deadline for consummating its initial business combination by one month, from March 14, 2026, to April 14, 2026. This represents the seventh of up to nine potential monthly extensions permitted under the company's Amended and Restated Certificate of Incorporation. No other material financial impacts or performance metrics were reported.

• ·Company is an emerging growth company.
• ·Fiscal year end: December 31.
• ·SEC file number: 001-41144.

05-03-2026

Beam Therapeutics Inc. mutually terminated its License Agreement with Bio Palette Co., Ltd., dated March 27, 2019, effective March 2, 2026, due to Bio Palette's planned dissolution. This termination activates a standby exclusive license from Kobe University for the same base editing patent rights, ensuring continuity without future payments owed. The agreement covered licenses for human disease treatments worldwide (excluding microbiome in Asia) and vice versa for microbiome products in Asia.

• ·Original License Agreement filed as Exhibit 10.7 to Form S-1 on September 27, 2019
• ·Kobe-Bio Palette License dated May 9, 2017
• ·Standby License Agreement dated February 9, 2026

05-03-2026

On February 27, 2026, the Compensation Committee of Digi International Inc. approved one-time performance stock unit awards under the 2021 Omnibus Incentive Plan to two executives: James J. Loch (EVP, CFO, Treasurer) eligible to vest into 14,668 shares based on business/software integration goals by September 30, 2026, 2027, and 2028; and David H. Sampsell (EVP, Corporate Development, General Counsel, Corporate Secretary) eligible for 12,223 shares upon successor onboarding by December 31, 2028. Vesting requires continued service and committee certification of performance goals. No share values or broader financial impacts are disclosed.

• ·Loch's first tranche (4,890 shares) vests November 1, 2026 if business and software integration goals achieved by September 30, 2026.
• ·Loch's second and third tranches (4,889 shares each) vest November 1, 2027 and 2028 upon program migrations to designated software platform by respective September 30 deadlines.
• ·Sampsell's award vests December 31, 2028 with assistance in identifying and onboarding successors for general counsel and corporate development roles.

05-03-2026

Mobile Infrastructure Corp reported total revenues of $35.1M for the year ended December 31, 2025, down 5.2% YoY from $37.0M, with managed property revenue up modestly 2.8% to $28.6M but offset by sharp declines in base rental income (-12.9% to $5.4M) and percentage rental income (-64.2% to $1.1M). Net Operating Income fell 8.5% to $20.7M amid a surge in impairment charges to $3.8M (from $0.2M) and higher interest expense (up 37.7% to $19.0M), resulting in a net loss of $23.7M versus $8.4M in 2024. The company outlined objectives to optimize RevPAS and pursue acquisitions but highlighted ongoing risks from parking demand fluctuations and high debt levels.

• ·Total other expense increased 107.8% YoY to $20.6M in 2025.
• ·Loss on sale of real estate was $0.1M in 2025 versus gain of $2.7M in 2024.

05-03-2026

GoPro reported FY 2025 revenue of $652 million, down 19% YoY, driven by a 21.5% decline in hardware revenue to $545 million, while subscription and service revenue was nearly flat at $106 million (down 1%). Q4 2025 revenue was flat YoY at $202 million, but camera sell-through dropped 19% to 625,000 units and gross margins fell to 31.8% GAAP (down 290 bps), with subscriber count ending at 2.36 million (down 7%). However, operating expenses were reduced by $93 million (26% YoY), cash flow from operations improved by $104 million, and net losses narrowed significantly to $93 million GAAP (from $432 million), alongside plans to launch GP3 AI-enabled processors in Q2 2026.

• ·Cash and cash equivalents declined to $49.7M from $102.8M YoY.
• ·Inventory reduced to $78.4M from $120.7M YoY.
• ·Short-term debt $19.6M as of Dec 31, 2025 (down from $93.2M).
• ·Adjusted EBITDA Q4 2025 positive $1M (from negative $14M YoY); FY 2025 negative $29M (improved from negative $72M).

05-03-2026

Olaplex Holdings, Inc. reported flat net sales of $423M for FY 2025, up just 0.1% YoY from $423M in 2024, with Professional channel growing 5.5% to $153M but offset by an 8.3% decline in Specialty retail to $130M and modest 3.1% DTC growth. The company swung to a net loss of $9.3M from a $19.5M profit in 2024, driven by a 33.8% surge in SG&A expenses to $243M that caused operating income to plummet 90% to $7M, despite a slight 0.5% gross profit increase to $294M. Cash from operations fell sharply to $59M from $143M, leading to a $267M net decrease in cash.

• ·Cost of sales declined 0.8% YoY to $129M in FY 2025.
• ·Interest expense, net decreased 22.5% to $27M.
• ·Net cash used in financing activities was $313M in FY 2025 vs $19M in 2024.
• ·FY 2023 net sales were $458M, with net income of $62M.

05-03-2026

Research Frontiers Inc (REFR) reported a widened net loss of $2.05M in 2025 versus $1.31M in 2024, driven by a 16% YoY decline in fee income to $1.12M while operating expenses rose 20% to $2.64M and research and development expenses increased 7% to $0.61M. Cash and cash equivalents fell sharply 67% to $0.66M from $1.99M, with total assets dropping 44% to $2.25M and shareholders' equity declining 64% to $0.93M from $2.60M. Net cash used in operating activities more than doubled to $1.33M from $0.79M.

• ·Royalties receivable reserves increased to $1.38M in 2025 from $1.25M in 2024.
• ·Credit loss expense rose to $154k in 2025 from $25k in 2024.
• ·Directors fees and expenses increased to $338k in 2025 from $176k in 2024.

05-03-2026

On February 27, 2026, AeroVironment Inc.'s Compensation Committee approved the Non-Qualified Deferred Compensation Plan, effective March 1, 2026, allowing key employees including named executive officers and non-employee directors to defer up to 75% of base salaries, cash bonuses, or director fees. The plan includes 100% immediate vesting with no company matching contributions, distributions upon retirement in lump sum or installments over 2 or 10 years, and a rabbi trust for assets subject to creditor claims. Additionally, Trace Stevenson and Mary Clum were approved as participants in the amended Executive Severance Plan.

• ·Plan distributions: lump sum upon separation before retirement, death, or disability; optional after 4+ years from deferral
• ·Company to pay all administrative costs and establish a rabbi trust; assets subject to general creditor claims
• ·Executive Severance Plan amended and restated as of December 3, 2024; described in proxy statement filed August 13, 2025

05-03-2026

On February 27, 2026, The Crypto Company entered into a Subscription Agreement with accredited investor Juan Betancourt to sell and issue 34,782,609 shares of common stock (par value $0.001) for an aggregate purchase price of $40,000 in an unregistered offering under Regulation D. This provides the company with $40K in cash proceeds but involves substantial dilution to existing shareholders due to the large number of shares issued at a very low effective price. The agreement includes customary representations, warranties, and covenants.

• ·Shares sold without registration under the Securities Act, relying on Regulation D exemption and state blue sky laws.
• ·Investor represented as accredited and acquiring shares for investment, not resale; appropriate legends to be affixed.
• ·Form of Subscription Agreement filed as Exhibit 10.1.

05-03-2026

CIENA Corp reported Q1 FY2026 total revenue of $1.43B, up 33% YoY from $1.07B, with products surging 38% to $1.18B and services growing 14% to $247M; net income more than tripled to $150M from $45M, driving diluted EPS to $1.03 from $0.31. Gross profit rose 33% to $626M, while operating income jumped 135% to $189M. However, gross margin slipped slightly to 43.8% from 44.0% YoY, and operating expenses increased 11.5% to $436M amid higher R&D (+15%) and selling/marketing (+9%).

• ·Optical Networking revenue $1.02B, representing ~72% of total revenue in Q1 FY2026.
• ·Cash used in investing activities $44M vs $67M YoY.
• ·Net cash used in financing activities $155M, driven by $81M share repurchases and $90M tax withholdings.
• ·Accounts receivable, net stable QoQ at ~$967M-$976M, with allowance for credit losses flat at $11.2M.

05-03-2026

Phio Pharmaceuticals reported increased operating expenses of $9.22M for 2025 (up 24.8% YoY from $7.39M), driven by R&D (+26.8% to $4.62M) and G&A (+22.9% to $4.60M), resulting in a wider net loss of $8.70M (up 21.7% YoY from $7.15M). However, strong financing activities provided $23.64M in net cash, boosting cash and equivalents to $21.03M (up 290.9% from $5.38M) and total assets to $21.49M. Common shares outstanding surged to 11.62M from 1.73M due to issuances and warrant exercises.

• ·Net cash used in operating activities increased to $7.98M in 2025 from $7.11M in 2024.
• ·Interest income, net was $0.52M in 2025 vs $0.23M in 2024.
• ·Diluted net loss per share improved to $(1.45) in 2025 from $(9.08) in 2024 due to increased share count.
• ·Stock-based compensation expense was $0.48M in 2025 vs $0.15M in 2024.
• ·Offering costs for common stock and warrants issuance in 2025 totaled $2.9M.

05-03-2026

Orion Properties Inc. (ONL) reported total revenues of $147.6M for the year ended December 31, 2025, down 10.4% YoY from $164.9M, primarily due to a 10.5% decline in rental income and a reduced portfolio of operating properties (58 vs. 69). While occupancy improved to 78.7% from 73.7% and leased rate rose to 80.7% from 74.7%, net loss attributable to common stockholders widened to $(139.3M) or $(2.48) per share from $(103.0M) or $(1.84) per share, with FFO dropping 48.3% to $24.3M and Core FFO declining 23.1% to $43.7M amid surging impairments of $99.4M (up 109.1%).

• ·Investment-grade tenants declined to 66.7% from 74.4% as of Dec 31, 2025.
• ·Total capital expenditures rose to $60.0M in 2025 from $24.1M in 2024.
• ·Rentable square feet leased in 2025 totaled 924k vs 1,086k in 2024.
• ·Weighted average remaining lease term increased to 5.7 years from 5.2 years.

05-03-2026

Grove Collaborative Holdings, Inc. reported net revenue of $173.7M for the year ended December 31, 2025, down 15% YoY from $203.4M, driven by declines in both Grove Brands (-13%) and third-party products (-16%), alongside DTC total orders falling 17% to 2.42M and active customers dropping 13% to 599K. While gross margin remained flat at 54%, net loss narrowed to $11.7M from $27.4M, operating loss improved to $11.3M from $22.5M due to lower operating expenses, and Adjusted EBITDA was -$2.2M versus $1.3M prior year. Interest expense plunged 90% to $1.2M, but cash used in operations increased slightly in intensity despite a 29% reduction to $7.0M.

• ·DTC Net Revenue Per Order remained flat at $67.
• ·Cost of goods sold declined 14% YoY to $80.4M.
• ·Advertising expenses decreased to $9.7M from $10.3M; Product development fell sharply to $7.5M from $18.5M; SG&A down to $87.4M from $103.2M.
• ·Net cash used in investing activities increased to $4.0M from $1.6M.

05-03-2026

ArriVent BioPharma reported a significantly widened net loss of $166.3M for the year ended December 31, 2025, up 107% from $80.5M in 2024, primarily due to R&D expenses nearly doubling to $153.4M (+94%) and G&A rising 58% to $24.2M. While total assets increased 21% to $333.2M bolstered by $203.1M in financing inflows and short-term investments growing to $267.3M, cash and equivalents declined 39% to $45.5M amid heightened operating cash burn of $160.6M. Interest income also decreased 19% to $11.2M.

• ·Accumulated deficit increased to $404.6M as of Dec 31 2025 from $238.3M as of Dec 31 2024.
• ·Short-term investments rose to $267.3M as of Dec 31 2025 from $144.6M as of Dec 31 2024.
• ·Financing activities provided $203.1M in 2025 vs $186.6M in 2024.
• ·Investing activities used $71.2M in cash in 2025 vs $192.5M in 2024.

05-03-2026

Ambiq Micro, Inc. reported net sales of $72.5M for the year ended December 31, 2025, down 4.7% from $76.1M in 2024, reflecting a decline in top-line growth. However, gross profit increased 32.1% to $32.1M with margin expansion to 44.3% from 31.9%, driven by lower cost of sales, while net loss narrowed to $36.5M from $39.7M. Operating expenses rose, with SG&A up to $33.2M from $27.7M, but financing activities provided $106.4M in cash inflows.

• ·Non-GAAP net loss improved to $20.9M in 2025 from $28.6M in 2024.
• ·Net cash used in investing activities increased to $7.4M in 2025 from $3.7M in 2024.
• ·Filing date: March 05, 2026.

05-03-2026

Allient Inc reported revenue of $554.5M for 2025, up 5% YoY from $530.0M, driven by strong Industrial demand in power quality solutions for data centers but partially offset by declines in the Vehicle segment due to lower power sports and truck demand. Gross profit rose 10% to $181.7M with margin expansion to 32.8%, operating income surged 46% to $44.0M, and net income increased 67% to $22.0M or $1.32 per diluted share; however, restructuring costs more than doubled to $4.0M, other expenses rose sharply, and backlog grew only 1% to $232.9M. Net debt improved to $139.7M from $188.1M, supported by operational cash flows.

• ·U.S. sales were 55% of total revenue in both 2025 and 2024.
• ·Quarterly dividend of $0.03 per share paid each quarter of 2025 and 2024, totaling $0.12 per share annually; payout ratio 9% in 2025 vs 15% in 2024.
• ·Bookings increased 15% YoY to $550.9M.
• ·Foreign currency impact favorable by $6.5M on 2025 revenue; revenue excluding FX $548.0M.
• ·Effective tax rate 23.3% in 2025 vs 21.9% in 2024.

05-03-2026

Entravision Communications Corp reported consolidated net revenue of $447.6M for the year ended December 31, 2025, up 23% YoY from $365.0M, driven by explosive 90% growth in Advertising Technology & Services to $270.9M; however, Media revenue declined 20% to $176.7M and direct operating expenses for that segment were nearly flat at $109.6M. Operating loss widened 60% to $83.4M from $52.0M, impacted by a $55.4M impairment charge, $25.2M loss on lease abandonment, and $2.8M restructuring costs, resulting in a net loss of $79.2M that improved from $148.9M in 2024 but remained negative with EPS of $(0.87). Cash and equivalents fell to $59.4M from $95.9M, total assets decreased to $387.5M, and stockholders' equity dropped to $55.4M from $146.0M.

• ·Cash flow from operating activities $10.6M in 2025, down from $74.7M in 2024.
• ·Capital expenditures $6.8M in 2025 vs $7.5M in 2024.
• ·Dividends declared $0.20 per common share in 2025, unchanged from prior years.
• ·Basic and diluted EPS $(0.87) in 2025 vs $(1.66) in 2024.
• ·Net cash used in financing activities $41.0M in 2025.

05-03-2026

Perpetua Resources Corp. filed an 8-K announcing Amendment No. 1 to the Engineering, Procurement, and Construction Management Services Agreement between Perpetua Resources Idaho, Inc. and Hatch Ltd., effective February 28, 2026, with details in Exhibit 10.1 (portions redacted and schedules omitted). No specific financial terms, contract prices, budgets, or performance impacts were disclosed in the filing. Forward-looking statements reference uncertainties around scope, contract price, control budget, and POX/O2 System allocation.

• ·Filing date: March 5, 2026
• ·Agreement execution date: February 28, 2026
• ·Items reported: 1.01 (Entry into Material Definitive Agreement), 9.01 (Financial Statements and Exhibits)

05-03-2026

Weave Communications, Inc. reported revenue growth of 17% YoY to $239M for the year ended December 31, 2025, from $204M in 2024, primarily driven by subscription and payment processing revenue which rose 17% to $229M. However, net loss was nearly flat at $28.1M versus $28.3M prior year, operating expenses increased 14% to $203M, and onboarding revenue declined 2% to $3.5M while gross margins remained deeply negative in onboarding (-153%) and phone hardware (-9%) segments. Total gross margin improved slightly to 72% from 71%.

• ·Stock-based compensation expense remained flat at $32.1M in 2025 vs. $32.2M in 2024.
• ·Incurrence of $1.7M in acquisition transaction costs and $0.9M in amortization of acquisition-related intangibles in 2025 (none in 2024).

05-03-2026

Smith & Wesson Brands, Inc. (SWBI) reported strong Q3 FY26 results with net sales up 17% YoY to $136M and net income surging 79% YoY to $3.8M (EPS $0.08). However, nine-month FY26 net sales grew modestly 3.5% YoY to $345M, while net income declined sharply 53% YoY to $2.3M amid higher operating expenses and lower operating income (-27% YoY). Total assets contracted 4% to $538M as of January 31, 2026 from $560M at April 30, 2025, with inventories down 8% to $175M but cash falling to $18M.

• ·Operating cash flow for 9M FY26 improved to $40M from -$48M YoY.
• ·Company retired 31.7M treasury shares during the period.
• ·Dividends paid at $0.13 per share for Q3 and $0.39 for 9M FY26.
• ·Capex for 9M FY26 was $19M, up from $14M YoY.

05-03-2026

Total revenues grew 53% YoY to $14.6M in 2025 from $9.5M in 2024, driven by collaboration revenues surging 67% to $13.6M, though royalties, license and other revenues declined 30% to $0.9M. Operating expenses increased 65% to $51.2M, including a $14.8M impairment of intangible assets and R&D up 42% to $17.7M, while G&A was nearly flat up 2%; this contributed to a net loss attributable to Lineage of $63.5M or $(0.28) per share, widening sharply from $18.6M or $(0.09) due to a $35.7M unfavorable change in warrant liability. Cash and equivalents decreased to $40.8M from $45.8M, with shareholders' equity dropping to $43.3M from $77.0M.

• ·Cash used in operating activities improved to $(18.9M) from $(23.1M) YoY.
• ·Financing activities provided $27.0M in 2025 vs $35.9M in 2024.
• ·Warrant liabilities increased to $43.9M as of Dec 31, 2025 from $6.2M.
• ·Intangible assets, net decreased to $31.7M from $46.5M.
• ·Income tax benefit of $5.3M in 2025.

05-03-2026

Regional Management Corp. entered into a Program Management Agreement (PMA) with Column National Association on March 2, 2026, establishing a new installment lending program where Column serves as lender of secured and unsecured loans in select states, and the Company acts as program manager and servicer, receiving marketing, processing, and servicing fees while paying platform and usage fees. Column retains control over underwriting, credit risk, and program oversight, with loans held for an initial period before potential sale to the Company. The PMA includes monthly financial covenants on liquidity and net worth, with an initial term ending March 31, 2031, and automatic two-year renewals unless terminated with 365 days' notice.

• ·The Company must establish and maintain a risk management program, including a compliance management system.
• ·Column holds originated loans for a specified hold period, serviced by the Company; post-hold, Column may offer to sell loans to the Company, which must purchase except in limited circumstances.
• ·Filing submitted on March 5, 2026, reporting event of March 2, 2026.

05-03-2026

Averin Capital Acquisition Corp., a blank check company, announced the partial exercise of its IPO over-allotment option on March 5, 2026, with underwriters purchasing 3,386,008 additional units at $10.00 each, generating $33.86M in gross proceeds. This brings total public offering units to 28,386,008 and total gross proceeds (including original IPO of 25M units for $250M and private placement of 200k units for $2M) to $283.86M, all placed in a trust account. No negative performance metrics were reported.

• ·Underwriters retain 45-day over-allotment option to purchase up to 363,992 additional units.
• ·Private Placement Units are not redeemable and exercisable on cashless basis, identical to IPO units except as disclosed in S-1 (File No. 333-293082).
• ·IPO registration statement effective February 18, 2026.

05-03-2026

Metagenomi, Inc. reported collaboration revenue declining 52% YoY to $25.2M in FY2025 from $52.3M in FY2024, primarily due to drops from Ionis (-19% to $24.6M), elimination of Moderna revenue, and Affini-T (-82% to $0.6M), resulting in a widened net loss of $87.9M versus $78.1M prior year. However, total operating expenses decreased 14% to $121.2M driven by lower R&D (-14% to $94.4M) and G&A (-16% to $26.8M), while net cash used in operations improved to $88.9M outflow from $109.1M, leading to a $14.3M net cash increase. Stockholders' equity stood at $158.6M, down from $234.9M, with total assets at $221.1M.

• ·Moderna collaboration revenue dropped to $0 from $18.7M in FY2024.
• ·Affini-T collaboration revenue declined to $0.6M from $3.1M.
• ·Cash and cash equivalents increased to $41.7M from $27.4M, but available-for-sale marketable securities fell to $119.1M from $220.9M.
• ·Stock-based compensation expense decreased to $11.9M from $16.2M.
• ·Net cash provided by investing activities was $103.5M in FY2025 versus ($88.2M) use in FY2024.

05-03-2026

On February 28, 2026, David J. Shulkin, M.D. notified the Board of Directors of OraSure Technologies, Inc. (OSUR) of his resignation as director and member of the Compensation Committee, effective March 2, 2026. The resignation is not due to any dispute or disagreement with the Board, the Company, or its management. The Board expressed thanks for Dr. Shulkin's years of service and contributions.

• ·Filing signed on March 5, 2026.

05-03-2026

On March 3, 2026, the Compensation Committee of DMC Global Inc. approved cash-based long-term incentive awards to named executive officers James O’Leary (CEO), Eric Walter (CFO), Ian Grieves (President, DynaEnergetics), and Antoine Nobili (President, NobelClad), substituting for equity awards due to insufficient shares available under the 2025 Omnibus Incentive Plan. The time-based cash awards vest one-third annually over three years, while Grieves and Nobili received performance-based cash awards tied to Adjusted EBITDA and Free Cash Flow targets (0-200% payout potential); O’Leary and Walter also got equity performance awards consistent with prior practices. No specific award values were disclosed.

• ·Cash Awards granted pursuant to new award agreements approved by the Committee.
• ·Performance goals for Grieves and Nobili based on three-year Adjusted EBITDA and Adjusted Free Cash Flow targets specific to DynaEnergetics or NobelClad.

05-03-2026

On March 4, 2026, the Board of Directors of Rush Enterprises, Inc. approved cash bonus payments totaling $5.3M to four key executives for 2025 fiscal year performance, with CEO W. M. 'Rusty' Rush receiving $3.5M. The Compensation Committee also approved stock option grants totaling 65,000 shares and restricted stock awards (RSAs) totaling 114,400 shares under the 2007 Long-Term Incentive Plan, vesting in three equal annual installments starting from the first or third anniversary of the March 13, 2026 grant date. Senior Advisor Michael J. McRoberts will receive additional RSAs valued at $250,000 based on Class B stock price.

• ·Cash bonuses payable on March 13, 2026.
• ·Stock options exercise price equals Class A closing price on March 13, 2026 grant date; vest in three equal annual installments starting third anniversary.
• ·RSAs are for Class B shares; vest in three equal installments starting first anniversary.
• ·Compensation based on review of 2025 fiscal year operating results and competitive market data.

05-03-2026

Nutex Health, Inc. reported total revenue of $875M for the year ended December 31, 2025, up 82% YoY from $480M in 2024, primarily driven by Hospital division revenue surging 88% to $844M. However, Population health management division revenue remained essentially flat at $31M (up 0.7% YoY), Real estate division posted minor losses, and Q4 2025 revenue declined sharply 41% QoQ/YOY equivalent to $152M from $258M in Q4 2024. Net income attributable to Nutex Health rose 36% YoY to $71M, while Adjusted EBITDA increased 152% to $260M, though Q4 Adjusted EBITDA fell to $17M from $87M.

• ·Stock-based compensation expense rose sharply to $117M in 2025 from $17M in 2024.
• ·Cash and cash equivalents increased to $186M as of Dec 31, 2025 from $41M at end of 2024.
• ·Total assets grew to $919M from $655M year-over-year.
• ·Q3 2025 net income attributable to Nutex was a loss of $18M, compared to smaller loss of $9M in Q3 2024.
• ·Accrued arbitration expenses stood at $50M as of Dec 31, 2025.

05-03-2026

aTyr Pharma reported total revenues of $0.19M for 2025, down 19% YoY from $0.235M amid declining license and collaboration income. Net loss widened to $74.1M from $64.0M in 2024, driven by 11% higher R&D expenses ($60.2M, led by Efzofitimod at $47.6M up 9%) and 28% increased G&A ($17.6M); however, cash used in operations improved to $62.0M from $69.1M, supported by $66.4M raised via at-the-market offerings. Total assets stood at $93.0M, down 4% from $96.8M, with stockholders' equity at $67.3M.

• ·Shares used in net loss per share: 92,985,359 in 2025 (up from 74,261,265 in 2024).
• ·Net loss per share improved to $(0.80) from $(0.86) YoY.
• ·Financing activities provided $66.0M in 2025 vs $39.9M in 2024, primarily from ATM offerings.
• ·Available-for-sale investments increased to $67.9M from $61.1M.

05-03-2026

Matador Resources Company (NYSE: MTDR) announced the expiration of its cash tender offer for any and all of its $500M outstanding 6.875% Senior Notes due 2028, with $419.7M (84%) validly tendered and accepted for purchase at $1,019.75 per $1,000 principal plus accrued interest. The company expects to settle payments on March 5, 2026, for most notes and March 9, 2026, for $4.5M subject to guaranteed delivery procedures. Matador intends to redeem any remaining notes on April 15, 2026, and cancel all accepted notes.

• ·Tender Offer expired at 5:00 p.m., New York City time, on March 4, 2026.
• ·Interest on accepted Notes ceases to accrue on the Settlement Date.

05-03-2026

Rumble Inc. reported FY 2025 revenues of $100.6M, up 5% YoY from $95.5M in 2024, driven by modest growth, while cost of services declined 22% to $107.4M, improving the operating loss to $126.7M from $130.9M and significantly reducing net loss to $81.8M from $338.4M. However, total expenses rose slightly to $227.3M due to higher G&A (+33% to $48.7M), sales & marketing (+38% to $23.9M), and new $13.3M acquisition-related costs, with ongoing risks from advertising dependency and fixed creator incentives. The company continues to post net losses amid user engagement and advertiser retention challenges.

• ·Change in fair value of warrant liability contributed +$24.8M gain in 2025 vs -$32.7M loss in 2024
• ·Change in fair value of derivative contributed +$9.7M gain in 2025 vs -$185.0M loss in 2024
• ·Interest income increased to $10.4M from $8.1M

05-03-2026

ESS Tech, Inc. reported FY2025 revenue of $1.6M, plummeting 75% YoY from $6.3M amid negative revenue adjustments of $0.8M partially offset by $2.4M from related parties. While gross loss narrowed 39% to $27.7M, operating expenses declined 33% to $29.7M, and net loss improved 26% to $63.4M versus $86.2M prior year, total assets shrank 29% to $51.2M and stockholders' equity dropped 70% to $8.6M from $28.9M.

• ·Cash and cash equivalents decreased slightly to $14.5M from $13.3M at Dec 31, 2025 vs 2024.
• ·Common shares outstanding doubled to 22.4M from 12.0M, driven by issuances under SEPA, ATM, and stock-based compensation.
• ·Deferred revenue - related parties dropped to $5.3M from $14.4M.

05-03-2026

RYAM's 2025 net sales declined 10% YoY to $1,466M from $1,630M, with gross margin dropping 28% to $119M (8.1% of sales) from $166M (10.2%), driven by lower volumes across most segments despite price gains in Cellulose Specialties. Operating income fell 90% to $4M from $39M, culminating in a net loss of $420M versus $39M loss in 2024, primarily due to a $323M tax expense. While Cellulose Specialties operating income remained resilient at $160M, other segments like Cellulose Commodities and Paperboard posted operating losses and sales declines.

• ·2024 Notes ($550M) and 2026 Notes ($500M) fully redeemed.
• ·2027 Term Loan ($250M) fully redeemed November 2024.
• ·Income from discontinued operations $3M in 2025.
• ·Asset impairment $0 in 2025 vs $25M in 2024.

05-03-2026

Contineum Therapeutics, Inc. (CTNM) reported a widened net loss of $60M for the year ended December 31, 2025, up 42% YoY from $42M in 2024, driven by a 34% increase in total operating expenses to $68M, with R&D expenses rising 34% to $52M and G&A up 33% to $17M. However, the company significantly bolstered its liquidity, ending with $76M in cash equivalents (up from $22M) and $187M in marketable securities, supported by $113M in net financing proceeds from follow-on and at-the-market offerings, leading to total assets of $277M (up 30% YoY). While interest income remained relatively flat at $8M, cash used in operations nearly doubled to $55M YoY.

• ·Net loss per share improved slightly to $(2.17) from $(2.18) YoY.
• ·Class A common shares outstanding increased to 31.2M from 19.1M; Class B decreased to 6.1M from 6.7M.
• ·Accumulated deficit grew to $(177M) from $(117M).
• ·Follow-on offering net proceeds: $93M; ATM offering: $19M.
• ·No revenue reported (pre-revenue biotech).

05-03-2026

OptimizeRx reported Q4 2025 revenue of $32.2 million, flat YoY compared to $32.3 million, but achieved record GAAP net income of $5.0 million (from a $0.1 million loss) and adjusted EBITDA of $12.0 million (up from $8.8 million). Full year 2025 revenue grew 19% YoY to $109.4 million with adjusted EBITDA more than doubling to $24.3 million from $11.7 million, alongside operating cash flow of $18.7 million (up from $4.9 million). The company issued flat 2026 revenue guidance of $109-114 million, noted declining KPIs like average revenue per top 20 pharma manufacturers (down to $2.838 million from $2.976 million) and net revenue retention (116% from 121%), and authorized a $10 million share repurchase program.

• ·Total assets increased to $176.9M from $171.2M as of Dec 31, 2025.
• ·Long-term debt, net decreased to $21.4M from $30.8M as of Dec 31, 2025.
• ·Share repurchase program effective March 12, 2026, expires March 15, 2027 or upon $10M repurchased.
• ·2026 guidance: Revenue $109-114M, Adjusted EBITDA $21-25M.

05-03-2026

Caribou Biosciences reported licensing and collaboration revenue of $11.2M for 2025, up 12% YoY from $10.0M, driven by $2.8M growth from other licensees while Pfizer revenue remained flat at $2.5M. Research and development expenses declined 16% to $109.4M and general/administrative fell 18% to $37.9M, narrowing the net loss to $148.1M from $149.1M and improving cash used in operations by $27.2M to $111.0M. However, new impairment charges of $12.2M (plus $9.2M equity investment impairment) contributed to total assets shrinking 44% to $175.4M from $313.3M, with stockholders' equity dropping to $122.2M from $253.0M.

• ·Cash and cash equivalents declined to $12.4M from $16.3M as of Dec 31 2025.
• ·Marketable securities (short-term) decreased to $127.0M from $193.2M.
• ·Accumulated deficit increased to $596.5M from $448.4M.
• ·Weighted-average shares outstanding: 93.4M in 2025 vs 90.3M in 2024.
• ·Net loss per share: ($1.59) in 2025 vs ($1.65) in 2024.

05-03-2026

Wheeler Real Estate Investment Trust, Inc. (WHLRL) reported 2025 revenues of $99.4M, down 4.9% YoY from $104.6M, with net operating income declining 4.2% to $66.4M and operating cash flow dropping 18.7% to $21.1M amid a reduction in owned retail centers from 72 to 62. However, net income surged to $14.8M from $0.7M, driven by $14.4M gain on property disposals (up 158.6% YoY), while total debt decreased slightly to $482.8M and FFO available to common stockholders rose to $13.7M. Same-Property NOI grew modestly 1.6% to $60.2M, but impairment charges more than doubled to $2.9M.

• ·Series D Preferred Stock shares decreased to 107,522 in 2025 from 187,410 in 2024.
• ·Impairment charges increased 141.0% YoY to $2.9M.
• ·Interest expense rose 3.5% YoY to $33.8M.
• ·Weighted average rate increase on renewals improved to 11.7% from 9.5%.
• ·New leases sq ft increased to 252,374 from 230,953, with weighted avg change over prior rates at 26.4%.
• ·AFFO increased to $10.3M from $7.2M.

05-03-2026

Gevo, Inc. reported total revenues of $160.6M for the year ended December 31, 2025, surging 849% YoY from $16.9M, primarily driven by new GevoND segment revenues of $136.8M (from $0) and GevoRNG up 14% to $18M. However, the company incurred a net loss attributable to Gevo of $33.8M, improved 57% from $78.6M but still reflecting elevated operating expenses ($180.8M, +68%), interest expense ($17.6M, +353%), and heavy investing cash outflows of $226.6M. Operating cash use narrowed to $13.4M from $57.4M, supported by financing inflows of $97.9M.

• ·Ethanol unit price averaged $1.70 per gallon in 2025.
• ·Corn cost per bushel $4.05; natural gas cost per MMBTU $2.89 in 2025.
• ·Average realized RIN price $1.93 (down 26% YoY); LCFS price $56.21 (up 11% YoY).
• ·RNG operating expenses declined 40% to $14.7M.

05-03-2026

NextCure, Inc. (NXTC) filed its 10-K annual report on March 05, 2026, highlighting significant risks including a limited operating history, no approved products, history of substantial losses, no revenue from product sales to date, and expectations of continued losses without profitability. The filing emphasizes challenges in establishing marketing, sales, and distribution capabilities for future product candidates and increasing compliance costs from privacy laws like CCPA and CPRA. Additional risks include state anti-kickback laws, false claims regulations, and the need for additional capital to fund operations.

• ·CPRA passed in November 2020 and effective January 1, 2023
• ·CCPA provides civil penalties and private right of action for data breaches

05-03-2026

On March 2, 2026, the Board of Directors of German American Bancorp, Inc. approved the 2026 Management Incentive Plan applicable to all executive officers, including those named in upcoming proxy disclosures. The approval was made by non-interested directors upon recommendation from the Compensation/Human Resources Committee, with plan details provided in Exhibit 10.1. No specific performance metrics or financial impacts were disclosed in the filing.

05-03-2026

Littelfuse, Inc. (NASDAQ: LFUS) appointed Holly B. Paeper to its Board of Directors, effective March 4, 2026, and to the Technology Committee. Paeper, President of Commercial HVAC Americas at Trane Technologies, offers extensive leadership in thermal management, life sciences, and prior roles at Corning, Eaton, and Intel. The company employs approximately 17,000 global associates serving over 100,000 end customers.

• ·Paeper previously served as President of global Life Science Solutions at Trane Technologies (2021–2024) and held VP/General Manager roles in Commercial HVAC (2016–2021).
• ·Paeper serves on the board of Mitsubishi Trane HVAC US (METUS) and previously on LiquidStack (2023–2025).
• ·Paeper holds a BS in Electrical Engineering from University of Minnesota – Institute of Technology and MBA from University of Minnesota – Carlson School of Management.

05-03-2026

ContextLogic Holdings Inc. (LOGC) reported zero revenue for the year ended December 31, 2025, a 100% decline from $43M in 2024, across all segments including core marketplace, ProductBoost, marketplace, and logistics. While operating expenses dropped 64% to $31M from $86M, narrowing the net loss attributable to common stockholders to $29M from $75M, cash used in operating activities improved to $16M from $94M but investing activities used $52M. Stock-based compensation remained relatively flat at $11M versus $12M.

• ·Sales and marketing expenses declined 100% to $0M from $18M YoY.
• ·Product development expenses declined 100% to $0M from $26M YoY.
• ·General and administrative expenses declined to $31M from $42M YoY.
• ·Provision for income taxes declined 100% to $0M from $6M YoY.
• ·Gross profit was $0M in 2025 versus $7M in 2024.

05-03-2026

REGENXBIO Inc. reported total revenues of $170.4M for the year ended December 31, 2025, a 105% YoY increase from $83.3M, primarily driven by license and royalty revenue surging 91% to $156.3M. However, research and development expenses rose 9.5% to $228.3M, total operating expenses increased to $331.6M, and the net loss narrowed to $193.9M from $227.1M but remained substantial; cash and cash equivalents declined to $34.5M from $57.5M, while stockholders' equity dropped sharply 60% to $102.7M amid rising royalty monetization liabilities.

• ·Direct expenses for ABBV-RGX-314 increased 3% YoY to $37.6M; RGX-202 up 83% to $26.3M; RGX-121 up 5.5% to $12.8M; other product candidates down 5% to $6.8M.
• ·Net cash used in operating activities improved to $124.0M from $173.1M.
• ·Proceeds from royalty bond and warrants: $144.5M in 2025.
• ·Interest expense rose to $45.0M from $12.7M.
• ·Property and equipment, net declined to $104.9M from $117.6M.

05-03-2026

Net interest income rose $4.7M YoY to $51.2M for 2025, with net interest margin expanding to 3.12% from 2.73%, driven by favorable rates despite lower volumes. However, average loans declined to $1.35B from $1.43B, total interest income fell $2.0M to $87.6M, and nonperforming assets increased to $16.7M from $14.3M. Non-interest income grew 10.25% to $11.1M supported by gains on loan sales (+32%), while non-interest expenses edged up 1.49% to $42.9M.

• ·Capital ratios remain strong: Total capital 14.6% (2025) vs 15.6% (2024), all well above well-capitalized thresholds.
• ·CRE portfolio: $443M Non-Owner Occupied, $240M Owner-Occupied, with criticized loans at 1.4%-7.9% of segments.
• ·Net loan recoveries of $58k in 2025 vs net charge-offs of $100k in 2024; NCOs (annualized) 0.00% vs (0.01)%.

05-03-2026

Wix.com Ltd. reported FY2025 revenues of $1.99B, up 13% YoY from $1.76B, with Creative Subscriptions growing 12% to $1.41B and Business Solutions up 18% to $583M. However, operating income declined 98% to $1.8M amid a 24% rise in operating expenses to $1.35B (R&D up 30%), leading to net income of $51M, down 63% YoY from $138M. Bookings increased 13% to $2.07B and free cash flow rose 20% to $573M, while cash from operations grew 17% to $583M.

• ·Net cash used in investing activities was $902M in FY2025, compared to $35M in FY2024.
• ·Income tax benefit of $51M in FY2025 vs expense of $14M in FY2024.
• ·Gross profit margin improved slightly to 68.1% from 67.9%.

05-03-2026

Ranger Energy Services, Inc. (RNGR) reported FY 2025 total revenue of $546.9M, down 4% YoY from $571.1M, primarily due to a sharp 37% decline in Wireline Services to $68.9M, while High Specification Rigs grew 3% to $347.0M and Processing Solutions increased 5% to $131.0M. Net income fell 33% to $12.3M from $18.4M, with operating income dropping 46% to $15.4M amid higher costs; Adjusted EBITDA was $73.2M, down from $78.9M. Cash from operating activities decreased 18% to $69.0M, though total assets expanded to $419.3M from $381.6M.

• ·Basic EPS declined to $0.55 from $0.81 YoY.
• ·Net cash used in investing activities increased to $76.1M from $31.1M.
• ·Borrowings under Revolving Credit Facility at $3.5M as of Dec 31, 2025.
• ·Property and equipment, net increased to $280.9M from $224.3M.

05-03-2026

Lee Enterprises, Inc. (LEE) filed its DEF 14A proxy statement dated March 5, 2026, for the virtual annual meeting on April 6, 2026, soliciting votes on electing two directors for three-year terms (Proposal 1), non-binding approval of named executive officer compensation (Proposal 2), amending the 2020 Long-Term Incentive Plan (Proposal 3), and ratifying BDO USA, P.C. as independent auditors (Proposal 4). The Board unanimously recommends voting 'FOR' all proposals. As of the record date, 22,229,939 shares of common stock were outstanding.

• ·Annual meeting exclusively virtual at http://www.virtualstockholdermeeting.com/LEE2026, starting at 9:00 a.m. Central Time on April 6, 2026.
• ·Proxy materials first mailed/made available on or about March 6, 2026.
• ·Annual Report on Form 10-K for year ended September 28, 2025, filed with SEC on November 26, 2025.
• ·All proposals classified as non-routine; broker non-votes possible.

05-03-2026

Farmers National Banc Corp reported total assets of $5.16B at year-end 2025, up 1.5% from $5.09B in 2024, with average loans increasing 2% YoY to $3.29B at 5.82% yield and net interest income rising 11% to $145M with margin expanding to 2.95% from 2.69%. However, nonperforming assets rose 15% to $26.3M (0.50% of assets from 0.45%), nonperforming loans increased to $26.2M (0.79% of loans from 0.70%), and stockholders' equity grew to $441M amid merger integration risks with Middlefield. Quarterly cash dividends remained flat at $0.17 per share.

• ·Commercial real estate nonaccrual loans increased to $15.8M at Dec 31, 2025 from $10.6M in 2024.
• ·Loans delinquent 30-89 days rose to $17.0M (0.51% of loans) in 2025 from $13.0M (0.40%) in 2024.
• ·Allowance for credit losses covered 142% of nonaccrual loans at Dec 31, 2025, down from 162% in 2024.
• ·Total interest-bearing deposits averaged $3.41B in 2025, up from $3.26B in 2024.

05-03-2026

Greystone Housing Impact Investors LP's South Carolina subsidiaries (Borrowers) entered into a First Amendment to their Loan Agreement dated December 31, 2025, effective February 27, 2026, with BankUnited, N.A. as Administrative Agent and Lender, amending key definitions including Debt Service (now based on 30-year amortization), Net Operating Income (incorporating $250/unit/year replacement reserve), and covenants such as Debt Service Coverage Ratio tests (1.00:1.00 by Feb 15, 2027; 1.05:1.00 by June 30, 2027) and Loan-to-Value ratio (max 65% at maturity). The amendment confirms full funding of the Future Advance Amount, adds post-closing pledges, and requires mold remediation at specific Vietti Property units by March 31, 2026. No performance metrics, declines, or financial amounts were disclosed.

• ·Amendment effective upon payment of Future Advance Origination Fee (amount not specified).
• ·Borrower may satisfy DSCR failures via partial prepayment, cash collateral, or letter of credit, releasable after 3 consecutive months of compliance.
• ·Original Loan Agreement dated December 31, 2025; Filing Date March 05, 2026.

05-03-2026

Interactive Strength Inc. (TRNR) announced the full recovery of a $5.0M loan principal plus $1.4M in interest and expenses from Sportstech Brands Holding GmbH, totaling $6.4M received and generating a net financial return after costs; however, the Sportstech acquisition did not complete as hoped. The settlement resolves all disputes, including lawsuits and a canceled share auction, allowing focus on the pending Ergatta acquisition (>$10M annual revenue, ~30% EBITDA margins), Wattbike scaling (700+ Air-Pro bikes, $2.5M UK commercial revenue since July 2025), and 2026 pro forma revenue guidance of >$30M, nearly sixfold from 2024's $5.4M.

• ·Settlement received in full as of announcement; TRNR retains no ownership in Sportstech
• ·Resolves January 2025 and May 2025 loan agreements and 100% share pledge
• ·Berlin court win preceding settlement; lawsuits to be withdrawn and March 11, 2026 share auction canceled

05-03-2026

This DEF 14A proxy statement, filed March 5, 2026, seeks shareholder approval to elect Ms. Keefe and Mr. Keith as Class I Trustees for First Trust Intermediate Duration Preferred & Income Fund (FPF), First Trust Enhanced Equity Income Fund, and First Trust Mortgage Income Fund at their annual/special meetings. It details service providers including investment advisor First Trust Advisors L.P., sub-advisors Chartwell Investment Partners (for Enhanced Equity) and Stonebridge Advisors (for FPF), administrator/custodian The Bank of New York Mellon, and transfer agent Computershare. During the last fiscal year (Oct 31, 2025 for FPF and Mortgage Income Fund; Dec 31, 2025 for Enhanced Equity), boards held 8 meetings each with audit committees at 13, but dividend and executive committees held 0; minor late Section 16(a) Form 3 filings were reported for certain sub-advisor officers and Independent Trustee Thomas J. Driscoll.

• ·By-Laws require 66-2/3% Trustee approval for matters to be proper for shareholder action at meetings.
• ·Fiscal year end: October 31 for FPF and Mortgage Income Fund; December 31 for Enhanced Equity Income Fund.
• ·Shareholder proposals for next annual meeting must be received by June 23, 2026.

05-03-2026

Clarus Corp's 10-K for year ended December 31, 2025, shows total sales declining 5.3% YoY to $250.4M from $264.3M, driven by a 9.0% drop in international sales to $144.3M despite a slight 0.4% rise in domestic sales to $106.1M. Gross profit fell 10.4% to $83.0M, but operating expenses decreased 12.5% to $142.7M, narrowing the operating loss to $59.7M from $70.4M and net loss to $46.6M from $52.3M amid lower restructuring charges and goodwill impairment, though indefinite-lived intangible impairment rose to $27.6M.

• ·Weighted average exercise price of outstanding options, warrants, and rights (excluding RSAs): $9.01.
• ·Annual goodwill impairment assessment as of December 31.
• ·Corporate headquarters owned in Salt Lake City, Utah; multiple Black Diamond and Rhino-Rack facilities leased.

05-03-2026

Profound Medical Corp. reported revenue growth of 51% YoY to $16.1M for the year ended December 31, 2025, with gross profit up 62% to $11.4M and gross margin expanding to 71% from 66%. However, net loss widened 53% to $42.6M driven by a 31% increase in operating expenses to $52.6M, including 39% higher SG&A and 21% higher R&D. Cash and cash equivalents rose to $59.7M from $54.9M, supported by $41.1M in financing activities despite $38.2M used in operations.

• ·Weighted average shares outstanding increased to 30.2M from 24.8M, contributing to loss per share rising 26% YoY to $1.41.
• ·Cash used in operating activities increased to $38.2M from $23.5M.
• ·Total contractual obligations $10.5M, with $5.9M due within one year.
• ·Accumulated deficit grew to $287.7M from $245.2M.

05-03-2026

Nomadar Corp. (NOMA) entered into a subscription agreement on February 27, 2026, for a private placement offering of up to $5.4M in class A common stock at $3.65 per share, representing up to 1,480,937 shares across three tranches. The first tranche closed on March 3, 2026, issuing 584,969 shares. The second and third tranches are scheduled for March 31, 2026, and April 30, 2026, respectively, under Regulation D exemption.

• ·Securities sold under Section 4(a)(2) or Regulation D exemption from registration.
• ·Common stock par value $0.00001 per share.
• ·Emerging growth company status confirmed.

05-03-2026

O-I Glass, Inc. announced an organizational change where Arnaud Aujouannet will cease serving as Senior Vice President and Chief Sales and Marketing Officer effective March 4, 2026. He will transition to a non-executive employee on garden leave, receiving continued salary and benefits until his employment terminates on June 30, 2026, and will be eligible for severance under the company's Amended and Restated Executive Severance Policy.

• ·Event reported on March 3, 2026; filing dated March 5, 2026
• ·Company headquartered at One Michael Owens Way, Perrysburg, Ohio 43551-2999

05-03-2026

T Stamp Inc. completed the acquisition of 100% of Lexverify Ltd., a UK-based private company, on February 27, 2026, through a share purchase agreement payable entirely in Class A Common Stock structured as 25% upfront (Completion Consideration) and 75% deferred in three equal tranches over 90, 180, and 270 days. The deal, described as limited in size, aims to add expertise in training and using large language models while providing UK market access. No specific purchase price dollar amount was disclosed, and deferred payments are subject to potential withholdings for warranties or set-offs.

• ·Certain Lexverify sellers agreed to 12-month non-compete and non-solicit restrictions post-Closing.
• ·Company committed to approving continuing employment of Lexverify employees on substantially similar compensation, benefits, and equity terms.
• ·Deferred Consideration accelerates upon change of control of T Stamp Inc.

05-03-2026

ClearOne, Inc. entered into a Securities Purchase Agreement with First Finance Ltd., its affiliate and single largest stockholder, to sell 437,500 shares of common stock at $4.00 per share and a warrant for up to 437,500 shares at $5.00 exercise price, generating gross proceeds of $1.75M in a private placement. Of the proceeds, $0.5M is immediately available, while $1.25M is contingent on the Company's reincorporation from Delaware to Nevada. The agreement imposes restrictions on incurring indebtedness over $10,000 or entering material transactions without Purchaser consent, with closing expected on or about March 6, 2026.

• ·Warrant term: 2 years, exercisable six months from issuance date.
• ·Securities offered pursuant to Section 4(a)(2) and Rule 506(b) exemption.
• ·Registration rights: Form S-3 for resale effective within 90 days after filing full Form 10-K for year ended December 31, 2025.
• ·Proceeds held in segregated bank account pending disbursement.
• ·Date of earliest event: March 2, 2026; Filing date: March 5, 2026.

05-03-2026

The GEO Group, Inc. (NYSE: GEO) announced that its Chief Financial Officer, Mark Suchinski, will depart effective March 31, 2026, to relocate out-of-state and join another industry. Shayn March, Executive Vice President, Finance and Treasurer with 17 years at GEO, has been appointed as the new CFO effective April 1, 2026. Chairman and CEO George C. Zoley highlighted March's experience and expressed optimism for growth opportunities.

• ·GEO provides services in the United States, Australia, South Africa, and the United Kingdom.
• ·Announcement dated March 5, 2026.

05-03-2026

ABVC BioPharma, Inc. has issued a proxy statement for its 2026 Annual Meeting of Shareholders, to be held virtually on March 26, 2026 at 10:00 a.m. EST, with a record date of January 26, 2026 and 25,423,654 shares of Common Stock outstanding. Shareholders will vote on re-electing current director nominees for one-year terms, ratifying S&E as the independent registered public accounting firm for the year ending December 31, 2026, and approving an amendment to the Amended and Restated 2016 Equity Incentive Plan to increase authorized shares to a maximum of 15% of issued and outstanding shares inclusive of the evergreen provision. The Board unanimously recommends voting 'FOR' all proposals, with no financial performance metrics or period comparisons disclosed.

• ·Proxy submission deadline: 11:59 p.m. EST on March 25, 2026
• ·Meeting held virtually via Zoom (Meeting ID: 271 131 5701, Passcode: f3w3a6)
• ·Voting methods: Internet (www.proxyvote.com), telephone (1-800-690-6903), or mail

05-03-2026

RPM International Inc. entered into a Seventh Amendment to its revolving credit facility on February 27, 2026, extending the maturity by five years to February 27, 2031. Interest spreads are set initially at 0.0% for base rate loans and 1.00% for SOFR and RFR-based loans (with ranges of 0.0%-0.30% and 0.785%-1.30%, respectively), alongside a 0.125% facility fee (range 0.09%-0.20%), all adjustable by debt rating. The amendment retains a maximum leverage ratio covenant of 3.75:1.0 but eliminates the prior interest coverage ratio requirement.

• ·Original Credit Agreement dated October 31, 2018.
• ·Full Credit Agreement Amendment to be filed as exhibit to Form 10-Q for quarter ending February 28, 2026.
• ·Covenants include limitations on liens and asset sales/transfers.
• ·Events of default include payment defaults, covenant breaches, change of control, and ERISA events.

05-03-2026

South Plains Financial, Inc. reported net income of $58.5M for the year ended December 31, 2025, up 17.6% YoY from $49.7M in 2024, supported by net interest income growth of 13.6% to $167.0M and total assets expansion of 5.9% to $4.48B. However, noninterest income declined 6.6% to $44.9M, primarily due to a $3.5M drop in mortgage banking activities, while noninterest expense rose 4.0% to $132.6M. Credit quality strengthened with nonperforming assets falling to 0.26% of total assets from 0.58%, and efficiency ratio improved to 62.32%.

• ·Provision for credit losses increased 20.8% YoY to $5.2M in 2025.
• ·Net interest margin expanded to 3.98% from 3.65% YoY.
• ·Common equity tier 1 capital ratio strengthened to 14.45% from 13.53%.
• ·Total risk-based capital ratio slightly declined to 17.26% from 17.86%.
• ·Allowance for credit losses on loans stable at 1.44% of total loans (up from 1.42%).

05-03-2026

Methode Electronics reported net sales of $233.7M for Q3 FY26 (13 weeks ended Jan 31, 2026), down 2.6% from $239.9M in the prior year quarter, and $721.1M for the nine months (39 weeks), down 8.9% from $791.0M (40 weeks). While operating and net losses widened slightly to ($6.1M) and ($15.9M) in Q3 and ($2.1M)/($36.1M) for nine months versus prior year, operating cash flow improved sharply to $33.1M from ($9.0M) over nine months. Total assets remained stable at $1,306.3M with cash rising to $133.7M, though long-term debt increased to $340.7M and shareholders' equity declined to $675.0M.

• ·Selling and administrative expenses Q3 up to $39.1M from $37.7M (+3.7%).
• ·Cash dividends per share reduced to $0.05 in Q3 from $0.14.
• ·Inventories increased to $209.8M from $194.1M QoQ.
• ·Accounts receivable decreased to $215.6M from $241.0M QoQ.

05-03-2026

Sunrise Realty Trust, Inc. (SUNS) expanded its senior secured revolving credit facility to $165M with a $25M commitment from Customers Bank, bringing total commitments from the prior amount implied at $140M. The facility, originally established with East West Bancorp in November 2024, remains expandable to $200M to support CRE lending and liquidity needs. No declines or flat metrics were reported in this positive liquidity enhancement announcement.

• ·Facility originally established with East West Bancorp in November 2024
• ·Customers Bancorp accolades: Top 10 Performing Bank by American Banker (2021-2025), #1 in 2024 among midsize banks, No. 45 in 2026 Forbes Best Banks list, Net Promoter Score of 81
• ·Investor Relations: Robyn Tannenbaum, 561-510-2293, ir@thetcg.com
• ·Media Contact: Doug Allen, 646-722-6530, TCG@DLPR.com

05-03-2026

Genco Shipping & Trading Limited executed a Sixth Amendment to its August 2021 Credit Agreement on February 27, 2026, establishing $80M in Incremental Revolving Commitments (2026 Upsize Revolving Commitments) to finance the acquisition of two 5-8 year old vessels: Genco Stars and Stripes and Genco Valkyrie (2026 Accordion Vessels). Consenting Lenders approved increasing the appraisal value threshold from 50% to 53.7% solely for these vessels, accepting pre-delivered appraisals from Fearnleys (Jan 20, 2026) and Clarksons (Jan 28, 2026). No declines or flat metrics reported in this financing update.

• ·Credit Agreement originally dated August 3, 2021; prior amendments on November 8, 2022; May 30, 2023; October 16, 2023; November 29, 2023; July 10, 2025
• ·Vessel appraisals dated January 20, 2026 (Fearnleys) and January 28, 2026 (Clarksons)

05-03-2026

Las Vegas Sands Corp. appointed Patrick Dumont as Chairman, Chief Executive Officer, President, and Treasurer effective March 1, 2026, and entered into new employment agreements effective March 2, 2026, through March 2, 2031, with Dumont, Randy Hyzak (EVP and CFO), and D. Zachary Hudson (EVP, Global General Counsel and Secretary). Dumont's base salary remains unchanged at $2.5M, while Hyzak and Hudson receive base salaries of $1.35M and $1.6M, respectively, with target incentives tied to 200-725% of base. No financial performance metrics or period-over-period changes are reported.

• ·Employment agreements include one-year non-competition and non-solicitation covenants and perpetual confidentiality covenants.
• ·Separation benefits provide 1x (base + target bonus) for termination without cause/good reason, 2x within 24 months of change of control, and 1x base for death/disability, plus pro-rata bonuses and benefits.
• ·Equity awards prior to March 2, 2026, follow existing terms; post-March 2 awards follow new agreement terms.
• ·Full agreements to be filed in Q1 2026 10-Q.

05-03-2026

Grid Dynamics Holdings, Inc. reported FY2025 revenues of $411.8M, up 17.5% YoY from $350.6M, driven by strong growth in Finance (+66.8% to $100.4M) and Technology, Media & Telecom (+13.0% to $107.5M). However, gross margin declined to 34.6% from 36.2%, Healthcare and Pharma revenues fell 8.3% to $10.2M, Non-GAAP net income decreased 5.6% to $35.1M, and Non-GAAP diluted EPS dropped to $0.40 from $0.47. GAAP net income improved to $9.7M from $4.0M amid ongoing operating losses.

• ·Operating expenses increased 11.7% YoY to $144.2M.
• ·Net cash provided by operating activities was $40.6M in FY2025, down from $30.2M in FY2024 but below $41.1M in FY2023.
• ·Stock-based compensation expense was $30.3M in FY2025.

05-03-2026

Bowman Consulting Group Ltd. reported gross contract revenue of $490M for FY2025, up 14.9% YoY from $427M, with strong segment growth in Natural Resources (+27.2%), Power/Utilities & Energy (+22.7%), and Transportation (+18.2%), though Building Infrastructure grew modestly at 7.4%. Net income rose sharply to $12.8M (2.6% margin) from $3M (0.7% margin), and Adjusted EBITDA increased 22.4% to $72.9M (16.8% margin). However, acquired revenue plunged 79.4% to $8.7M, operating expenses grew to $242M, and revolving credit facility debt more than doubled to $95M from $37M.

• ·Operating income swung to $19.7M profit from $2M loss YoY.
• ·Cash and equivalents increased to $11.1M from $6.7M.
• ·Goodwill rose to $174M from $135M, reflecting acquisitions.
• ·Diluted EPS improved to $0.73 from $0.17.
• ·Total liabilities increased to $319M from $260M.

05-03-2026

BridgeBio Oncology Therapeutics reported a widened net loss of $134M in 2025, up 81% YoY from $74M, driven by sharply higher operating expenses including R&D up 66% to $121M and G&A surging 217% to $25M. However, robust financing activities generated $383M in cash inflows from reverse recapitalization and PIPE financing, boosting cash and equivalents to $374M from $31M and flipping stockholders' equity to a positive $411M from a $179M deficit.

• ·Net cash used in operating activities increased to $114M in 2025 from $55M.
• ·Reverse recapitalization and PIPE financing proceeds: $373M net.
• ·Redeemable convertible preferred stock eliminated in 2025 (zero outstanding vs $323M in 2024).
• ·Accrued R&D liabilities rose to $26M from $8M as of Dec 31.
• ·Net loss per share: $(4.30) in 2025 vs $(5,756.41) in 2024.

05-03-2026

Visa Inc. filed an S-4 registration statement on March 5, 2026, for an Exchange Offer to convert any and all outstanding Class B-1 and Class B-2 common stock into a combination of newly issued Class B-3 common stock and Class C common stock, plus cash for fractions, building on a 2024 Class B-1 Exchange where 98% participated. Participants must enter a Makewhole Agreement with uncapped cash reimbursement liability for future U.S. covered litigation costs that would otherwise adjust conversion rates downward. The offer introduces Class B-3 stock with accelerated (4x vs. Class B-1, 2x vs. Class B-2) future conversion rate adjustments, but includes multiple conditions and risks that may prevent closing.

• ·Applicable Conversion Rates as of filing: Class B-1 (1.5475 shares of Class A), Class B-2 (1.5075 shares of Class A), Class C (4 shares of Class A)
• ·Approximate Class C issuance: 0.2877 shares per Class B-1 share; 0.1884 shares per Class B-2 share
• ·Class B-3 conversion downward adjustments accelerated 4x vs. Class B-1 and 2x vs. Class B-2
• ·Prior events: IPO March 2008; Eighth Restated Certificate effective January 2024
• ·Exchange ratio details: 1 Class B-1 -> 0.25 Class B-3 + Class C equiv. to 0.5 B-1 + 0.25 B-2; 1 Class B-2 -> 0.5 Class B-3 + Class C equiv. to 0.5 B-2
• ·Withdrawal possible prior to Expiration Date or within 40 business days if not accepted

05-03-2026

PACS Group, Inc. (NYSE: PACS) appointed Dr. Patrick H. Conway, MD, MSc, CEO of Optum, to its Board of Directors on March 5, 2026, bringing extensive expertise in clinical care, CMS regulatory leadership, and value-based payment models. The company operates over 320 post-acute care facilities across 17 states, serving more than 31,700 patients daily, with 73.4% of its skilled nursing portfolio rated 4-5 stars on CMS ratings and occupancy rates 17 percentage points above industry average. PACS reported full-year 2025 revenue of $5.29B, up 29.3% YoY.

• ·PACS founded in 2013 and headquartered in Salt Lake City, Utah
• ·Dr. Conway elected to National Academy of Medicine in 2014 and recipient of President’s Senior Executive Distinguished Service Award

05-03-2026

On March 1, 2026, Invitation Homes Inc.'s Compensation Committee approved increased target long-term incentive awards for key executives based on 2025 performance, including $11.3M for CEO Dallas Tanner, $2.7M for CFO Jonathan Olsen, $2.2M for COO Timothy Lobner, and $3.6M for CIO Scott Eisen. The committee also granted time-vesting RSUs (e.g., $2.8M to Tanner), performance-vesting RSUs at target (e.g., $8.5M to Tanner), and substantial retention RSUs amid competitive talent market risks (e.g., $10M to Tanner, $5M to Olsen). No declines or flat metrics reported, with awards designed to retain leadership driving operational momentum.

• ·Time-vesting LTIP RSUs vest in equal annual installments over three years starting March 1, 2026.
• ·Performance-vesting LTIP RSUs based on NOI CAGR and relative TSR vs. Nareit Residential Index over Jan 1, 2026 to Dec 31, 2028; subject to TSR Modifier and Value Cap (300% of target RSUs × $55/share).
• ·Retention RSUs vest 65% on third anniversary, 35% on fourth anniversary of March 1, 2026.

05-03-2026

Simon Property Group, L.P. entered into a Fourth Amended and Restated $5,000,000,000 Revolving Credit Agreement on March 5, 2026, fully amending and restating the prior Third Amended and Restated Credit Agreement dated March 14, 2023 (as amended October 3, 2024 and May 12, 2025). The facility is administered by JPMorgan Chase Bank, N.A., with joint lead arrangers including BOFA Securities, Inc., Mizuho Bank, Ltd., PNC Capital Markets LLC, and Wells Fargo Securities LLC, providing enhanced liquidity access in USD and alternative currencies up to the full facility amount.

• ·Alternative Currency Sublimit equals 100% of the $5B Maximum Revolving Credit Amount.
• ·Prior Existing Credit Agreement dated March 14, 2023, with amendments on October 3, 2024 and May 12, 2025.

05-03-2026

Cryoport, Inc. reported total revenue of $176.2M for the year ended December 31, 2025, up 12.4% YoY from $156.8M, with Life Sciences Services growing 17.6% to $96.5M (including BioLogistics up 16.6% and BioStorage/BioServices up 22.2%) while Life Sciences Products increased only 6.6% to $79.7M. Gross margin rose 19.2% to $83.1M, and the company achieved net income of $78.3M versus a $114.8M loss in 2024, driven by $112.3M income from discontinued operations; however, loss from continuing operations narrowed but remained at $34.0M, and Adjusted EBITDA from continuing operations was a $5.8M loss.

• ·Cost of products revenue increased 0.3% YoY to $43.7M.
• ·Selling, general and administrative expenses decreased 6.4% YoY to $102.8M.
• ·No impairment loss in 2025 versus $63.8M in 2024.
• ·Net cash increase of $205.2M in 2025 versus decrease of $1.1M in 2024, driven by $250.3M investing activities.

05-03-2026

Atea Pharmaceuticals narrowed its net loss to $158.3M in 2025 from $168.4M in 2024, a 6% improvement, primarily due to total operating expenses declining 6% to $180.9M, driven by a sharp 33% drop in G&A expenses to $32.9M despite a 3% rise in R&D to $148.0M. However, interest income fell 36% to $16.4M, total assets shrank 32% to $315.2M with marketable securities down 47% to $206.1M, and stockholders' equity decreased 37% to $275.4M following a $25.5M stock repurchase reducing shares outstanding to 78.1M.

• ·Net cash provided by investing activities increased to $188.8M in 2025 from $56.1M in 2024.
• ·Net cash used in financing activities was $25.7M in 2025 versus provided $0.3M in 2024, due to stock repurchase.
• ·Weighted-average shares basic and diluted: 81,495,352 in 2025 vs 84,264,715 in 2024.
• ·Net loss per share improved to $(1.94) from $(2.00).

05-03-2026

Lexicon Pharmaceuticals reported total revenues of $49.8M for FY 2025, up 60% YoY from $31.1M, driven by $45M in licensing revenue (+80% YoY), though net product revenue declined 23% YoY to $4.6M. Net loss narrowed significantly to $50.3M from $200.4M in 2024, with operating expenses dropping 57% to $98.7M; however, cash and equivalents fell to $34.3M from $66.7M, total assets decreased to $185.0M from $298.4M, and stockholders' equity declined to $107.5M from $146.0M.

• ·Long-term debt, net: $49.4M as of Dec 31 2025 (down from $100.3M in 2024 after $48M repayment)
• ·Research and development expenses: $61.1M FY2025 (down 28% YoY from $84.5M)
• ·Selling, general and administrative expenses: $37.3M FY2025 (down 74% YoY from $143.1M)
• ·Stock-based compensation: $12.5M FY2025 (down from $13.5M in 2024)

05-03-2026

Fortress Value Acquisition Corp. V consummated its IPO on February 27, 2026, issuing 25,000,000 Class A ordinary shares at $10.00 per share for gross proceeds of $250M, alongside a private placement of 200,000 shares to sponsor Fortress Value Acquisition Sponsor V LLC for $2M, with $250M placed in trust. The balance sheet as of that date reflects total assets of $251.6M, including $250M in trust and $1.6M cash outside trust. However, it shows total liabilities of $14.8M and a shareholders' deficit of $13.2M driven by accumulated deficit.

• ·Underwriter granted 45-day option to purchase up to 3,750,000 additional Class A ordinary shares for over-allotments.
• ·Over-allotment option liability of $359,250 recorded.
• ·7,187,500 Class B ordinary shares issued, including 937,500 subject to forfeiture if over-allotment not exercised.
• ·IPO registration statement effective February 25, 2026.

05-03-2026

AA Mission Acquisition Corp. II, a SPAC, reported its first financials for the period from inception (May 20, 2025) through December 31, 2025, with total assets of $117.2M primarily in a Trust Account of $116.4M from its IPO proceeds. The company generated net income of $585K, driven by $1.1M in Trust Account dividends offsetting a $497K operating loss from general and administrative expenses. No initial business combination has been completed, with shareholders' deficit at $2.4M.

• ·IPO closed with $115M gross proceeds and $3.6M private placement units to Sponsor.
• ·Trust Account shares redemption value at $10.12 per share.
• ·Basic and diluted EPS of $0.08 for both redeemable and non-redeemable shares.
• ·Net cash used in operating activities: $344K; investing: $115.3M; financing provided $116.3M.

05-03-2026

Apple iSports Group, Inc. (AAPI) signed a Joint Venture Agreement with AiC Enterprises LLC (AiC) on February 28, 2026, to jointly supply a gaming products platform and technical services to B2B and B2C clients, while licensing the 'apple-i' brand for promotion in the gaming ecosystem. The agreement, approved by both boards, positions the companies to expand in online gambling services, led by AiC's CEO Michael Cho and supported by Apple iSports' management expertise under CEO Joe Martinez. No financial terms or performance metrics were disclosed.

• ·Agreement executed with legal effect on February 28, 2026 (Asia-Pacific time)
• ·AiC's infrastructure includes UX & Conversion Engineering, Secure Payment Rails, and Aggregator Ecosystem
• ·Websites: https://appleicasino.com, https://appleisports.com, https://corporate.appleisports.com

05-03-2026

Thomson Reuters Corp filed its Form 40-F annual report for the fiscal year ended December 31, 2025, covering IFRS financial statements, operating segments including Legal Professionals, Tax & Accounting Professionals, Reuters News, Corporates, and Global Print across regions like Americas, EMEA, and Asia Pacific. The filing discloses details on debt instruments such as 3.35% Notes due 2026, 4.50% Notes due 2043, and 5.50% Debentures due 2035; pension plans including Thomson Reuters Group Pension Plan; acquisitions like Pagero Group AB, Credere Technologies Inc (Materia), and Additive AI Inc; and ongoing Normal Course Issuer Bid share repurchases in February 2026. No specific financial metrics or period-over-period changes are detailed in the provided XBRL tags.

• ·Acquisitions completed in 2025: Pagero Group AB, Credere Technologies Inc (doing business as Materia), Additive AI Inc.
• ·Debt instruments referenced: 3.35% Notes due 2026, 4.50% Notes due 2043, 5.50% Debentures due 2035, 5.65% Notes due 2043, 5.85% Notes due 2040.
• ·Pension plans: Thomson Reuters Group Pension Plan, The Thomson Corporation Plc Pension Scheme.
• ·Share repurchases under Normal Course Issuer Bid: transactions from 2026-02-01 to 2026-02-28.
• ·Dividends declared post year-end: 2026-02-01 to 2026-02-28.

05-03-2026

Cherry Hill Mortgage Investment Corp (CHMI) reported net income of $6.9M for the year ended December 31, 2025, down 43% YoY from $12.2M in 2024, with net income applicable to common stockholders swinging to a $3.0M loss from a $2.1M profit amid unrealized losses on derivatives and servicing assets. However, earnings available for distribution (EAD) attributable to common stockholders increased 30% YoY to $15.8M ($0.46 per diluted share from $0.40), supported by net interest income surging to $11.3M from near-zero levels due to lower interest expense. Segment results were mixed, with RMBS comprehensive income rising sharply to $16.9M from $2.1M while Servicing Related Assets declined to $8.8M from $18.6M, and net servicing income fell 6% YoY to $34.0M.

• ·Total expenses decreased 22% YoY to $14.2M from $18.3M.
• ·Accumulated other comprehensive income improved to $3.7M as of Dec 31, 2025 from a $7.3M loss.
• ·Dividends on preferred stock were $9.8M in 2025, slightly down from $10.0M in 2024.
• ·All Other segment showed comprehensive loss of $7.9M in 2025, improved from $13.2M loss in 2024.

05-03-2026

Smith Micro Software reported improved gross margins of 74.1% for FY 2025 (up from 70.2% in 2024) and reduced total operating expenses to 241.1% of revenue (from 310.5%), narrowing the operating loss to 167.1% of revenue and net loss to 168.9% of revenue. However, the company recorded a $63.7% goodwill impairment (down from 116.7% but eliminating all goodwill), resulting in total assets declining to $25.0M from $48.0M and stockholders' equity dropping to $18.4M from $40.8M. Cash burn from operations improved to $7.2M used (from $14.3M), with net cash decrease of $1.3M versus $4.3M prior year.

• ·Accounts receivable declined to $1.8M from $5.7M at Dec 31, 2025 vs 2024.
• ·Selling and marketing expenses improved to 34.4% of revenue from 43.2%.
• ·Research and development expenses decreased to 61.7% of revenue from 68.5%.
• ·General and administrative expenses increased to 57.6% of revenue from 51.5%.
• ·Intangible assets net $18.5M at Dec 31, 2025 vs $24.0M at Dec 31, 2024.

05-03-2026

SandRidge Energy Inc reported total proved reserves of 69.1 MMBoe for 2025, up 9.5% YoY from 63.1 MMBoe, with PV-10 increasing 21.2% to $439.6M; revenues grew 24.8% YoY to $156.4M driven by natural gas sales (+94.4%). However, net interest income fell sharply to $3.7M from $7.7M due to lower interest income, production taxes rose 45.2% to $9.8M, and DD&A for oil/gas increased 40.3% to $36.4M.

• ·Mid-Continent reserves/production ratio of 10.2 years and weighted average economic reserve life of 35.0 years.
• ·Lease operating expenses per Boe improved to $5.35 from $6.61, but production taxes per Boe rose to $1.45 from $1.12.
• ·General and administrative expenses increased to $13.2M from $11.7M.

05-03-2026

Adial Pharmaceuticals reported a reduced net loss of $7.98M for the year ended December 31, 2025, compared to $13.20M in 2024, primarily due to lower R&D expenses ($2.62M, down 19% YoY) and absence of $4.46M inducement expense. However, G&A expenses rose slightly by 2% to $5.18M, total operating expenses declined modestly to $7.80M, and significant share dilution occurred with common shares outstanding increasing over 4x to 1.11M. Cash and equivalents grew 57% to $5.88M, bolstered by $8.47M in financing activities, though operating cash use remained high at $6.49M.

• ·Total assets increased to $6.67M as of Dec 31 2025 from $5.04M as of Dec 31 2024.
• ·Equity method investment declined to $0.49M from $0.98M.
• ·Net cash used in operating activities improved slightly to $6.49M from $6.92M.
• ·Weighted average shares outstanding increased to 668,630 from 194,059; loss per share improved to $(11.93) from $(68.01).

05-03-2026

Ares Capital Corp's DEF 14A proxy statement details the virtual 2026 Annual Meeting, seeking approval for the election of three Class I directors—Ann Torre Bates, Steven B. McKeever, and Michael J. Arougheti—to serve until the 2029 annual meeting and ratification of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. As of the March 2, 2026 record date, 718,022,845 shares of common stock were outstanding, each entitled to one vote. No financial performance metrics or period-over-period comparisons are provided in the filing.

• ·Annual Report on Form 10-K for year ended December 31, 2025, filed February 4, 2026.
• ·Virtual Annual Meeting accessible at www.virtualshareholdermeeting.com/ARCC2026.
• ·Majority of votes cast required for director elections and auditor ratification; abstentions and broker non-votes do not count as votes cast.
• ·Proxy solicitation also by Ares Capital Management LLC and Ares Operations LLC personnel without special compensation.

05-03-2026

TRG Latin America Acquisitions Corp., a blank check company, consummated its initial public offering (IPO) on February 27, 2026, selling 20,000,000 units at $10.00 per unit, generating gross proceeds of $200 million. Simultaneously, the company completed a private placement of 225,000 units to its sponsor, TRG Latin America Acquisitions LLC, for $2.25 million. A total of $200 million from the IPO and private placement net proceeds was deposited into a trust account.

• ·Company incorporated November 7, 2025, as Cayman Islands exempted company targeting business combination in Latin America.
• ·IPO registration statement effective February 25, 2026.
• ·Transaction costs totaled $6,768,470, including $250,000 cash underwriting fee.
• ·5,750,000 Class B ordinary shares issued and outstanding, with up to 750,000 subject to forfeiture if over-allotment option not exercised.
• ·Trust account invested in U.S. government treasury obligations or money market funds.

05-03-2026

Monroe Capital Corp (MRCC) reported a challenging 2025 with total investment income declining 37.5% YoY to $37.9M from $60.5M in 2024, net investment income dropping 53.5% to $11.4M, and a net decrease in net assets from operations of $5.1M versus a $9.7M increase in 2024. While operating expenses fell 26.2% YoY to $26.2M and no incentive fees were incurred, NAV per share eroded to $7.68 by Q4 2025 from $8.85 in Q4 2024, with shares trading at deepening discounts to NAV up to (23.2)% in Q4. Distributions were reduced to $0.18 in Q4 2025 from $0.25 quarterly in prior periods.

• ·Interest income declined to $26.2M in 2025 from $44.3M in 2024 (-40.8% YoY).
• ·PIK interest income fell to $7.7M in 2025 from $9.2M in 2024 (-16.5% YoY).
• ·Average stated interest rate on debt improved to 6.2% in 2025 from 6.8% in 2024.
• ·Largest portfolio company investment in SLF: $4.9M; total five largest: $23.9M (Dec 31, 2024).

05-03-2026

Relativity Acquisition Corp, a SPAC, has filed a DEFM14A proxy statement for a special stockholder meeting to approve a business combination merger forming Pubco, along with a Redemption Limitation Amendment and Adjournment Proposal. Initial Stockholders control 98.5% of the 4,309,988 outstanding Common Shares, ensuring quorum and ability to approve all proposals without public stockholder support. Directors and officers have differing interests, including $6.56M at risk from Founder Shares and Private Placement Units.

• ·Proxy revocation deadline: 5:00 p.m. Eastern time on December 5, 2025
• ·IPO closing date: February 15, 2022
• ·Company address: 3753 Howard Hughes Pkwy, Suite 200, Las Vegas, Nevada 89169

05-03-2026

Liberty Energy Inc. filed its definitive proxy statement (DEF 14A) on March 5, 2026, for the 2026 Annual Meeting of Stockholders to be held virtually on April 14, 2026, at 9:00 a.m. Mountain Time. Stockholders of record as of February 18, 2026, will vote on electing four Class I directors (Proposal 1), approving on an advisory basis the compensation of named executive officers (Proposal 2), and ratifying Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 (Proposal 3). The proxy references executive compensation data for principal executive officers (PEOs) including Mr. Wright and Mr. Gusek across 2021-2025, along with pay versus performance disclosures.

• ·Annual Meeting virtual access: edge.media-server.com/mmc/p/azh3pr84
• ·Proxy materials available at www.astproxyportal.com/ast/21952 since March 5, 2026
• ·Company address: 950 17th Street, Suite 2400, Denver, CO 80202
• ·Fiscal year end: December 31
• ·References Annual Report on Form 10-K for year ended December 31, 2025

05-03-2026

Kensington Capital Acquisition Corp. VI, a blank check company targeting mergers in automotive, defense, energy, and AI sectors, announced the pricing of its $200M initial public offering of 20,000,000 units at $10.00 per unit on March 3, 2026, with expected closing on March 5, 2026. Units, consisting of one Class A ordinary share, one-quarter Class 1 redeemable warrant, and three-quarters Class 2 redeemable warrant, are set to list on NYSE under 'KCAC.U' starting March 4, 2026. Underwriters Cohen & Company Capital Markets and Drexel Hamilton have a 45-day option for up to 3,000,000 additional units.

• ·Registration statement effective March 3, 2026.
• ·Class 1 warrants and new units approved for listing under 'KCAC.W' and 'KCA.U' upon separate trading.

05-03-2026

On February 27, 2026, Joseph DosSantos, SVP Finance and Acting CFO of Celularity Inc., departed the company for personal reasons. The company promptly appointed John Sprague as the new Acting CFO on the same date. This executive transition was disclosed in an 8-K filing on March 5, 2026, signed by Chairman and CEO Robert J. Hariri.

• ·Company address: 170 Park Ave, Florham Park, New Jersey 07932
• ·Telephone: (908) 768-2170
• ·Securities: Class A Common Stock (CELU) and Warrants (CELUW) listed on Nasdaq
• ·Emerging growth company: Yes

05-03-2026

Vivakor, Inc. entered into a Third Amendment to Loan Agreement, Fourth Forbearance Agreement, and issued a Fourth Junior Secured Convertible Promissory Note to J.J. Astor & Co. for an additional $750,000 (net ~$710,000 after fees), maturing April 6, 2026, amid ongoing distress with $5.995M outstanding on the Second Note to be repaid in escalating weekly installments starting $50,000/week from April 6, 2026. The company pledged assets, subsidiary guarantees, and real property in Blaine County, Oklahoma as collateral, with severe default terms including 19% interest, 110% principal increase, and deep discount conversions. While providing short-term liquidity, the agreements highlight persistent liquidity challenges and dilution risks.

• ·Second Note repayments: $50,000/week starting April 6, 2026; $100,000/week from July 6, 2026; $150,000/week from October 5, 2026; $250,000/week from December 7, 2026; full by January 1, 2027.
• ·Nasdaq relisting deadline extended to April 6, 2026.
• ·Initial Note and Third Note satisfied in full (November 20, 2025 and October 27, 2025 respectively).

05-03-2026

Community Health Systems, Inc. (NYSE: CYH) announced a definitive agreement for a subsidiary to sell substantially all assets of four Arkansas hospitals (Northwest Medical Center – Bentonville (128 beds), Northwest Medical Center – Springdale (222 beds), Northwest Medical Center – Willow Creek Women’s Hospital (64 beds), and Siloam Springs Regional Hospital (73 beds), plus associated outpatient centers and practices) to Freeman Health System for $112 million, subject to adjustments for net working capital and finance leases. The transaction is expected to close in Q2 2026, subject to regulatory approvals and customary conditions. These hospitals were among potential divestitures referenced in CYH's Q4 2025 earnings call.

• ·CYH operates in 34 distinct markets across 13 states with headquarters in Franklin, Tennessee.
• ·Leerink Partners acting as exclusive financial advisor to CYH.

05-03-2026

Fly-E Group, Inc. received a Nasdaq deficiency notice on February 27, 2026, for failing to timely file its Form 10-Q for the period ended December 31, 2025, violating Listing Rule 5250(c)(1), with no immediate impact on trading but requiring a compliance plan by April 28, 2026, and potential extension to August 24, 2026. The company intends to file the overdue 10-Q soon to regain compliance. Separately, the SEC initiated an investigation on January 21, 2026, into the company, which is cooperating without details on any wrongdoing.

• ·Nasdaq notice has no immediate effect on listing or trading of FLYE common stock.
• ·Company is an emerging growth company.
• ·Principal executive offices: 136-40 39th Avenue, Suite 202, Flushing, New York 11354.

05-03-2026

Sky Quarry Inc. filed a Certificate of Amendment to its Certificate of Incorporation, authorizing a total of 2,000,000,000 shares of Common Stock with a par value of $0.0001 per share. The amendment implements a 1-for-8 reverse stock split effective at 11:59 p.m. ET on March 15, 2026, with no fractional shares issued and any fractions rounded up to the nearest whole share. The change was duly adopted by the Board of Directors and stockholders in accordance with Delaware General Corporation Law Section 242.

• ·Reverse stock split applies to issued and outstanding shares immediately prior to effective time.
• ·Stockholders holding shares via brokerage firms will have fractions rounded up at the participant level.
• ·No cash paid in lieu of fractional shares.

05-03-2026

TPI Composites, in Chapter 11 bankruptcy since August 11, 2025, entered into asset purchase agreements on March 4, 2026, to sell its India manufacturing assets (Chennai wind blades) to Vestas for $10M cash (subject to adjustments) and limited Mexico assets for $1, alongside an equity commitment for Vestas to acquire 100% of reorganized equity in two Mexico subsidiaries for approximately $14M cash. These transactions are subject to Bankruptcy Court approval, third-party consents, and outside dates of June 30, 2026. However, on March 1, 2026, an Event of Default occurred under the DIP Credit Agreement due to lack of a Disclosure Statement Order, triggering default interest accrual.

• ·Transactions require Bankruptcy Court orders: approval for India/Mexico APA portions, confirmation of Mexico Plan.
• ·India APA terminable if Buyer Parent ceases payment advances; Mexico agreements terminable if Commitment Party ceases advances.
• ·DIP Credit Agreement dated August 14, 2025; Specified Default under Section 11.01(g).

05-03-2026

Inuvo, Inc. reported FY2025 net revenue of $86.2M, up 2.9% YoY from $83.8M, with marketing costs declining 13.0% to $51.9M and total operating expenses down 8.2% to $70.9M. However, gross profit fell 10.5% to $64.2M due to an 82.8% surge in cost of revenue to $22.0M, operating cash flow turned negative at ($1.8M) from positive $0.23M, total assets shrank to $24.9M from $32.2M, and stockholders' equity decreased to $10.0M from $13.5M.

• ·Net cash used in operating activities FY2025: ($1.8M) vs. provided $0.23M FY2024.
• ·Net cash used in investing activities FY2025: ($1.6M) vs. ($1.9M) FY2024.
• ·Net cash provided by financing activities FY2025: $3.8M vs. used ($0.35M) FY2024.
• ·Allowance for credit losses: $99K (2025) vs. $145K (2024).
• ·Accumulated deficit: ($178.3M) as of Dec 31, 2025 vs. ($173.2M) Dec 31, 2024.

05-03-2026

GalaxyEdge Acquisition Corp, a Cayman Islands blank check company, priced its initial public offering of 10,000,000 units at $10.00 per unit, raising $100M, with units expected to begin trading on NYSE under 'GLEDU' on March 4, 2026, and closing on March 5, 2026. The offering includes a 45-day over-allotment option for up to 1,500,000 additional units. Polaris Advisory Partners serves as sole book-running manager, with no reported declines or flat metrics in this IPO announcement.

• ·S-1 registration statement (File No. 333-290899) declared effective February 26, 2026; Post-Effective Amendments filed March 2 and 3, 2026.
• ·Target focus: business combinations in North America, South America, Europe, or Asia.
• ·Contact: (212) 574-4425

05-03-2026

CarParts.com, Inc. reported FY ended January 3, 2026 (53 weeks) net sales of $547.5M, down 7.0% from $588.8M in FY ended December 28, 2024 (52 weeks), with gross profit declining 8.8% to $179.3M and gross margin contracting 60 basis points to 32.8%. Net loss widened to $50.4M from $40.6M, EBITDA deteriorated to -$28.6M from -$21.5M, and Adjusted EBITDA fell to -$14.0M from -$7.1M. Operating cash flow swung to a use of $34.1M from generation of $10.3M, contributing to a $10.6M net decrease in cash.

• ·Operating expenses increased to 41.7% of net sales from 40.3%.
• ·Stock compensation expense decreased to $8.1M from $12.0M.
• ·Workforce transition costs: $1.5M (2026) vs $0.6M (2024).
• ·Impairment of long-lived assets: $3.7M in 2026.
• ·Recent agreements include Purchase Agreement dated Sep 8, 2025 with International Auto Parts (Cayman) Limited et al., and First Amendment to Credit Agreement dated Sep 8, 2025.

05-03-2026

Stabilis Solutions, Inc. reported FY 2025 total revenues of $68.2M, down 6.9% YoY from $73.3M, driven by a 6.1M gallon drop in LNG deliveries, rental revenues declining 26.5% to $5.3M, service revenues falling 32.5% to $5.0M, and other revenues dropping 45.9% to $0.7M, though partially offset by higher natural gas prices adding $3.9M. Operating expenses rose 1.2% to $70.8M amid higher SG&A (+12.1%), resulting in an operating loss of $1.3M versus a $5.0M profit in 2024. The company posted a net loss of $1.4M compared to a $4.6M profit YoY.

• ·Revenue declines included $4.9M from reduced rental/service/other due to lower equipment needs and contract conclusions.
• ·Unfavorable customer mix reduced revenues by $0.9M YoY.
• ·Cost of revenues decreased $2.4M from lower LNG volume and $2.2M from reduced rental/service costs (travel/labor).

05-03-2026

For the year ended December 31, 2025, PREFORMED LINE PRODUCTS CO (PLPC) reported net sales of $669.3M, up 13% YoY from $593.7M (+$75.6M), driven by PLP-USA (+17%) and The Americas (+24% excluding currency translation). Gross profit increased 10% to $208.5M, and operating income rose to $55.1M from $50.8M; however, net income attributable to shareholders declined 5% to $35.3M from $37.1M (-$1.8M), with sharp drops in international segments including The Americas (-37%), EMEA (-33%), and Asia-Pacific (-24%). Total assets grew to $653.6M from $573.9M, supported by higher cash ($83.4M) and inventories ($148.7M), though other expenses surged.

• ·Foreign currency translation positively impacted consolidated net sales by $1.4M in FY2025.
• ·Goodwill of $30.7M at Dec 31, 2025, with $17.0M attributable to EMEA reporting unit; no impairment recognized.
• ·Long-term debt increased to $32.9M (less current portion) from $18.4M YoY.
• ·Accumulated other comprehensive loss improved to $(53.4M) from $(82.9M).

05-03-2026

On March 3, 2026, Nuburu Defense, LLC, a wholly-owned subsidiary of Nuburu, Inc., entered into an International Cooperation Agreement with Tekne S.p.A. and Engineering Bureau Beryl LLC to collaborate on the qualification, deployment, and scaling of the Tekne Graelion vehicle in Ukraine, building on their existing Network Contract. The agreement includes a two-year exclusivity period for Beryl and Tekne regarding competing products and Ukraine deployment, with plans to establish a joint representative office in Kyiv and potential capital support from Nuburu Defense. Extensive forward-looking statement risks are disclosed, including development challenges, capital access issues, and prior losses like the patent portfolio foreclosure.

• ·Two-year exclusivity period: Beryl prohibited from representing competing products (except prior contracts); Tekne will not negotiate with other third parties for Ukraine deployment or mission-specific kit.
• ·Joint representative office to be established in Kyiv for operational, industrial, and compliance coordination.

05-03-2026

Sabre Corporation and Constellation Software Inc., a beneficial owner of approximately 12.7% of Sabre's outstanding shares, entered into a strategic governance agreement on March 5, 2026, resulting in the appointment of Damian McKay, CEO of Vela Software Group (a Constellation division), to Sabre's Board of Directors. In connection, Sabre terminated its shareholder rights plan announced on March 1, 2026. Executives expressed optimism about the partnership fostering long-term growth and innovation in the travel technology sector.

• ·Terms of the strategic governance agreement to be filed as an exhibit to Form 8-K.
• ·Sabre terminated its shareholder rights plan announced March 1, 2026.
• ·Damian McKay's prior roles include CEO of Datamine (2012-2020) and General Manager at GE Energy.

05-03-2026

Fidelis Insurance Holdings Ltd reported net income of $225.5M in 2025, up 99% YoY from $113.3M in 2024, driven by underwriting income surging to $117.2M from $8.3M and improved combined ratio of 94.8% versus 99.7%. However, gross premiums written grew modestly 7% YoY to $4.7B, net investment income declined 3% to $184.0M, and net premiums earned were nearly flat at +2% YoY to $2.3B. Operating ROAE improved to 8.5% from 5.6%, while credit ratings remained stable at A (AM Best), A- (S&P), and A3 (Moody's) across key subsidiaries.

• ·Catastrophe and large losses increased slightly to $515.5M in 2025 from $509.0M in 2024.
• ·Financing costs rose to $47.7M in 2025 from $33.8M in 2024.
• ·Weighted average diluted common shares outstanding decreased to 106.7M in 2025 from 115.6M in 2024.
• ·2023 net income included a one-time $1,639.1M net gain on distribution of The Fidelis Partnership.

05-03-2026

Methanex Corp (MEOH) filed its Form 40-F annual report for FY2025 ended December 31, 2025, including IFRS-based disclosures on equity (ordinary and preference shares), property, plant & equipment (buildings, ships, terminals, construction in progress), debt (unsecured notes at 5.125%-6.25%, term loans, limited recourse facilities), leases (ocean vessels, railcars), and share-based compensation (SARs, RSUs, PSUs). The filing details geographic methanol and ammonia operations across China, US, Europe, South America, Korea, Other Asia, Canada, Egypt, New Zealand, Chile, Trinidad, and subsidiaries like Atlas Methanol Company Unlimited and Firewater Natgasoline, with notes on tax losses (2015-2025), derivatives (gas, FX, Egypt supply), and New Zealand CGU sensitivities. No specific revenue, profit, or balance sheet totals provided in XBRL tags; comparisons structured for FY2025 vs FY2024 vs FY2023 across assets, liabilities, and equity.

• ·Unused tax losses disclosed for years 2015 through 2025
• ·Temporary differences in property plant & equipment, right-of-use assets, repatriation, and share-based comp
• ·Derivatives include North American natural gas forwards, Euro FX forwards, Egypt gas supply contract (Level 3 fair value)
• ·Leases: Ocean Vessel 1-Year Term, Ocean Vessel 8-Month Term, Railcar Lease 5-Year Term
• ·Term Loan A with Tranches 1 & 2 maturing June 27, 2025
• ·New Zealand CGU sensitivities to natural gas availability and methanol price forecasts

05-03-2026

Via Renewables, Inc. reported total revenues of $463.5M for FY 2025, up 16% YoY from $398.9M in 2024, driven by 58% higher natural gas volumes, while Adjusted EBITDA rose 23% to $72.3M and Retail Gross Margin increased 6% to $149.8M with strong natural gas segment growth (+27% to $60.8M). However, net income declined 42% to $35.6M from $61.1M amid higher depreciation/amortization and operating expenses, Retail Electricity Gross Margin fell 5% to $88.9M, cash from operations dropped 17% to $42.1M, and RCE attrition worsened to 4.2%.

• ·Electricity volumes sold increased 9.0% YoY in 2025 vs 2024.
• ·Natural gas volumes sold surged 58.4% YoY in 2025 vs 2024.
• ·Customer acquisition costs rose to $10.4M in 2025 from $9.5M in 2024.
• ·Distributions/dividends paid increased to $30.3M in 2025 from $10.7M in 2024.
• ·Non-POR Credit Loss as % of Revenue improved to 0.5% in 2025 from 1.3% in 2024.

05-03-2026

Victory Capital Holdings, Inc. (VCTR) submitted a superior acquisition proposal to Janus Henderson Group plc, offering Janus shareholders a majority in cash plus 38% ownership in the combined company to create a top-tier asset manager targeting $1T AUM. Despite proposals submitted in November 2025 and twice in December 2025, the special committee has not meaningfully engaged, as Janus already agreed to a deal with Trian and General Catalyst. Victory emphasizes strategic complementarity and its track record of eight acquisitions over 12 years with high retention, while noting all options remain open.

• ·Proposals submitted: one in November 2025, two in December 2025
• ·Interview aired on Bloomberg Deals on March 4, 2026
• ·Victory emphasizes non-hostile approach focused on special committee engagement

05-03-2026

Apeiron Acquisition Vehicle I, a Cayman Islands blank check company, filed an S-1/A amendment on March 5, 2026, for a $70M IPO of 7M units at $10 each, consisting of one Class A ordinary share and half a redeemable warrant (exercisable at $11.50 post-business combination). Sponsor Apeiron Sponsor I and Berenberg commit to purchasing 246,350 private placement units for $2.46M simultaneously with the offering. Public shareholders face substantial dilution from low-cost founder shares ($0.009/share) held by sponsor (1,341,667 Class B) and BBG (1,341,666 Class B), plus anti-dilution protections on Class B conversion.

• ·Underwriters have 45-day option for 1,050,000 additional units.
• ·Warrants exercisable 30 days post-initial business combination, expire 5 years later.
• ·15% redemption limit for shareholders holding >15% of shares if shareholder vote (no tender offer).
• ·Founder shares convert 1:1 to Class A post-business combination, with anti-dilution adjustment to maintain ~25% ownership.

05-03-2026

Freshworks Inc. announced the departure of Mika Yamamoto as Chief Integrated Customer Growth Officer, effective March 2, 2026, with her remaining in an advisory capacity until April 2, 2026, and entitled to previously disclosed severance benefits. Concurrently, Ian Tickle was appointed as Chief Revenue Officer effective March 2, 2026, overseeing global sales and support functions previously under Yamamoto. The changes were disclosed on March 5, 2026, with no financial impacts detailed.

• ·Filing signed by Pamela Sergeeff on March 5, 2026
• ·Securities: Class A Common Stock, $0.00001 par value per share, traded as FRSH on Nasdaq

05-03-2026

TaskUs reported service revenue growth of 19.0% YoY to $1.18B for FY 2025, driven by strong performance in AI Services (+58.6%), Trust & Safety (+23.9%), and Rest of World (+36.4%), while Digital Customer Experience grew modestly at 8.2%. Net income surged 123.0% to $102M with operating income up 52.2%, but Free Cash Flow declined to $74M from $100M and Adjusted EBITDA margin was nearly flat at 21.0% versus 21.1%. Headcount expanded to approximately 65,500 from 59,000, and net revenue retention improved to 113% from 102%.

• ·GAAP diluted EPS increased to $1.10 from $0.50; Adjusted EPS to $1.63 from $1.29.
• ·Net revenue retention rate improved to 113% from 102%.
• ·Purchase of property and equipment rose to $63.5M from $39.1M.

05-03-2026

Securitize Holdings, Inc. (SECZ) filed a Form 425 disclosing a March 4, 2026, FINTECH.TV interview with CEO Carlos Domingo discussing the October 27, 2025, Business Combination Agreement with Cantor Equity Partners II, Inc. (Nasdaq: CEPT), expected to close in the first half of 2026 and list Pubco on NYSE or Nasdaq as SECZ. The interview highlights tokenizing equity on blockchain rails alongside traditional DTCC settlement to demonstrate advantages like instant settlement and 24/7 trading, while forward-looking statements note risks including regulatory approvals, shareholder votes, and potential non-completion.

• ·Form S-4 registration statement filed with SEC, including preliminary proxy statement/prospectus.
• ·Additional details in CEPT's Form 8-K filed October 2025.

05-03-2026

PPG Industries' DEF 14A proxy statement details the virtual annual shareholder meeting on April 16, 2026, with proposals to elect 12 directors, approve NEO compensation advisory vote, ratify PricewaterhouseCoopers LLP as 2026 auditors, approve the 2026 Omnibus Incentive Plan, and consider a shareholder proposal for an independent board chair. In 2025, amid a challenging macro environment, PPG reported flat 2% organic sales growth, generated $1.9B in operating cash flow with 5% free cash flow yield, repurchased $790M in stock (3% of shares), and returned $1.4B to shareholders including dividends raised for 54 consecutive years. The board added Leon Topalian of Nucor and Todd M. Schneider of Cintas, and announced a $380M investment in a new Shelby, N.C. facility while opening a Thailand plant.

• ·Record date for shareholder meeting: February 20, 2026
• ·Annual dividend raised for 54 consecutive years; uninterrupted dividends for 126 years
• ·Pre-registration deadline for virtual meeting: 5:00 p.m. ET on April 15, 2026